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Effect of recombinant human erythropoietin (rHUEPO) on the defense
system against red cell oxidation in uremic patients on hemodialysis. R.
Mo!!, A. Miguel Sosa, A. Miguel, M.J. Martin, A. Bernat, f.M.
Escobedo, J. Sánchis, A. Perez, Nephrology and Hematology Services,
General Hospital, Valencia, Spain. A greater susceptibility towards
membrane lipid peroxidation has been described in the red cells of
uremic patients on hemodialysis, which could contribute to the short-
ening of cell mean life in these patients. We studied the effect of
rHUEPO on the defense mechanisms against oxidation and red cell
survival. Eight patients were evaluated (2 males, 6 females), aged 50 to
68 (mean, 60 67) and on hemodialysis for 5 to 54 months (mean, 30
18 months). Hemoglobin (Hb) was under 8 g% (6.91 1.01, range 6.5
to 7.8) under basal conditions. After 20 months of rHEUPO therapy,
Hb was over 10 g% (10.93 1.01, range 10 to 12.5). Parameters studied
were: Hemoglobin (H), ferritin (FR), malonyl dialdehyde acid (MDA;
an intermediate product of membrane fatty acid oxidation, considered
to be a good indirect method for quantifying this oxidative degradation),
reduced glutathion (GSH), giutathion peroxidase (GPX), superoxide
dismutase (SOD) and mean red cell life determined via Cr-Si (ML*).
Hb FR MDA GSH GPX SOD ML*
Pre- 339 534 95 35 3292 17.3
6.9 .5 313 80 15 15 50 1.5
Post- 226 479 89 33 2513 24.7
10.9 1 200 111 19 11 459 5
p <0.001 <0.05 ns ns ns <0.01 <0.01
t-Student evaluation for paired data.
Norma! control values: MDA 475
28 9, SOD 2536 332, ML'
65, GSH 72
27 2. 17, GPX
The results show an increase in cell survival and a normalization of
some the parameters of the defense system against oxidation, whereas
others tend to approach normal values.
Effect of pH, osmolality, temperature and incubation time on erythro-
cyte volume and morphology distribution curves. Their application to the
study of hematuria. A. Miguel Sosa, J. Belda, A. Miguel, f.M.
Escobedo, L. Garces, J. Sanchis, J. Villaro, A. Perez, Hematology and
Nephrology Services, General Hospital, Valencia, Spain. It is currently
possible to establish diagnosis as to the glomerular or non-glomerular
origin of hematuria by non-invasive means, according to the shape of
red blood cells observed by phase contrast microscopy (PCM) or by
means of the red cell volume distribution curves. We have studied the
influence of variations in pH (from 3 to 10), osmolality (200 to 1000
mOsmlkg), temperature (23 to 37°C) and incubation time (30, 90 and 210
mm) on peripheral blood red cell morphology and size, and whether
these variations are similar to those observed in urine erythrocytes of
hematuria patients. In individuals with normal red blood cell parame-
ters and morphology, 5 ml blood was collected and centrifuged at 1500
rpm for 5 mm; 0.1 ml sediment was resuspended in the pH and
osmolality solvents prepared at the different temperatures and incuba-
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tion periods indicated. The samples thus prepared were examined by
PCM and processed by an automatic cell counter (STKR), evaluating
mean corpuscular volume and the width of erythrocyte distribution.
Red cell morphology, as evaluated by PCM, and the erythrocyte
distribution curves provided by the automatic cell counter, were not
affected (results show no significant differences) by variations in pH,
osmolality, temperature and incubation time, which fit to the maximum
changes that may be observed in the urine of hematuria patients.
Effect of recombinant human erythropoietin on platelet function in
anemic hemodialysis patients. M.J. Martin, A. Cerveró, M. Sanchez, R.
Moll, J. Sanchis, J. Villaro, A. Perez, Nephro!ogy and Hematology
Services, General Hospital, Valencia, Spain. Chronic renal failure
(CRF) patients are known to present alterations in hemostasis. The
effect of recombinant human erythropoietin (rHUEPO) on platelet
function has been studied. Seven anemic CRF patients on hemodialysis
were treated with rHUEPO (50 1tlkg/3 times weekly, with 25 Jkg
increments every three weeks until Hb levels of over 10 g% were
reached). Prior to rHUEPO administration, the following parameters
were determined: Hb, hematocrit (Ht), hemorrhage time (HT), platelet
adhesiveness (PA), platelet count (PC), mean platelet volume (MPV),
anisocytosis index (Adpl) and platelet aggregation induced by arachi-
donic acid, ADP, collagen and ristocetin, as well as the liberation of
MDA induced by arachidonic acid. All these parameters were abnormal
under basal conditions, except PC, VDP, Adpl and MDA. After 20
weeks of rHUEPO treatment, the study of platelet function was
repeated, with the following results: significant improvement in Hb (P
<0.001), Ht (P < 0.001), HT (P < 0.01), and PA (P < 0.01). As to
platelet aggregation, there was an individual tendency towards im-
provement, although the differences were not globally significant.
These results suggest that rHUEPO corrects anemia and some of the
platelet function tests in these patients, thus confirming the influence of
hematocrit in platelet function.
Urine erythrocyte morphology and volume distribution curves in the
study of hematuria of glomerular or non-glomerular origin. J.M. Es-
cobedo, J. Belda, A. Miguel Sosa, L. Garces, M.J. Martin, A. Bernat,
A. Perez, Hematology and Nephrology Services, General Hospital,
Valencia, Spain. In 40 hematuria patients we studied the possible
glomerular (G) or non-glomerular (NG) origin of the condition by phase
contrast microscopy (PCM) and by the evaluation of shape and size
alterations in urine erythrocytea. The distribution curves for mean
corpuscular volume (MC) were established using an automatic cell
counter (Coulter STKR). The correlation of these results with the
clinical diagnosis of each patient was also studied. The results obtained
by PCM showed G hematuria in 24 and NG hematuria in 16 cases. The
resultant Coulter curves were of G distribution in 20 patients, NG in 18,
and with a mixed pattern in 2 patients. In establishing correlation with
the clinical diagnosis, the results were found to agree in 23 cases with
PCM (57.5%), and in 32 patients with the cell size distribution curves
(80%). The existence of leukocyturia or preterminal-phase renal failure
gave rise to volume curves that failed to coincide with the etiology of
hematuria in 7 cases. After correction, for the total number of cases
studied, there was 90.6% correlation between clinical diagnosis and the
shape of the corresponding cell distribution curve. These preliminary
results indicate the viability of employing the volume distribution
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curves, a simple, rapid and non-invasive technique to establish the G or
NG origin of hematuria.
Variations in hemodynamic and blood viscosity parameters in hemodi-
alysis patients treated with erythropoietin. L. Garces, M.J. Martin, R.
Mo!!, A. Bernat, M. Labios, F. Ridocci, M.G. Tormo, A. Perez,
Nephology and Cardiology Services, General Hospital, Valencia,
Spain. Eight anemic patients with chronic renal failure (CRF) on
hemodialysis were treated with recombinant human erythopoietin
(rHUEPO) (50 z/kg, 3 times weekly, with increments of 25 zikg every
three weeks until Hb levels of over 10 g% were obtained). A study was
made of factors possibly influencing a presumed increase in arterial
pressure in these patients during rHUEPO treatment. Several parame-
ters were studied before and 20 weeks after rHUEPO administration,
with a stable Hb increase): ECG, cycloergometry and dynamic blood
viscosity (using a cylindrical coaxial viscometer). Throughout the study
there were no global or individual significant differences in terms of
body weight. Arterial blood pressure increased in 4 cases, antihyper-
tensive drugs having to be added or incremented; however, there was
no significant difference between the mean arterial pressure before and
after rHUEPO. Treatment did not induce significant ECG changes.
Cycloergometry showed no significant differences in terms of heart
rate, arterial pressure, double basal and maximun product, on compar-
ing the pre-rHUEPO parameters with those obtained after treatment;
effort capacity improved (P < 0.05). Blood viscosity, initially very low,
increased after 20 weeks (P < 0.001), bearing a good correlation (P <
0.5) to the significant increase in hematocrit (P < 0.001). Thus, in spite
of improving the cardiac factor, the rise in blood viscosity may play a
role in the genesis of arterial hypertension in these patients.
Defense mechanisms against red cell oxidation In uremic patients
subjected to hemodialysis treatment. R. Mo!!, A. Miguel Sosa, M.J.
Martin, A. Bernat, L. Garcés, J. Vi!laro, A. Perez, Services of
Hematology and Nephrology, Valencia General Hospital, Valencia,
Spain. Taking into account the well established greater susceptibility of
red cell membrane lipids to oxidation in uremia patients, we studied the
defense mechanisms against the aggresive oxidation of red cells in 43
patients (24 males, 19 females) aged 30 to 74 (mean, 54 12)undergoing
hemodialysis for 6 to 150 months (mean, 41 24.9 months), and in 40
healthy, non-smoking patient controls. The following parameters were
determined: malonyl dialdehyde acid (MDA), an intermediate product
of membrane fatty acid oxidation (and considered to be a good indirect
method for quantifying this oxidative degradation); reduced glutathion
(GSH); glutathion peroxidase (GPX); superoxide dismutase (SOD).
Results:
Hb GSH GPX SOD MDA
Uremic 7.08 1.5 97.5 25 35.6 15 3032.1 667 534 73
Normal 15 2 72 17 28 9 2536 332 475 65
P <0.001 <0.001 NS <0.001 <0.001
The results confirm the existence of an increase in peroxidation of
membrane lipids, accompanied by an alteration in the defense mecha-
nisms of the red cells against oxidation. The significance of these
changes in the red cells of uremic patients is discussed.
Ultra-short blood purificaiton, 150 minutes, 7 and a half hours a week.
One year experience with the two chambers technique (TCT). J. Botella,
C. Sanz-Moreno, D. Sanz-Guajardo, J. Fernandez-Fernandez, F.
Fernandez-Giron, E. Armada, E. Baamonde, Hospital Puerla de Hi-
erro, Madrid, Spain. One of the fundamental aims of blood purification
is to control the acid-base balance, and in ultra-short dialysis this is
essential to obtain the appropriate cardiovascular stability. With this in
mind the TCT was modified as follows: length of the sessions: 150 mm;Q 350 mI/mm; hemolIltrate volume 12% of body weight; dialysate with
bicarbonate; reinfusion with sodium lactate after the hemofilter. Twelve
patients were treated with this technique for one year, all of them had
previously been treated with the usual TCT and were chosen because of
their poor tolerance of conventional HD. Their characteristics are as
follows: women 9/12; body weight 56.75 7.63; residual renal function
0.43 0.49; age 50.17 15.72; dialytic age (months) 44.17 32.07.
Over the year the clinical tolerance was satisfactory, the average Kt/V
of the group was never under 1.00 and equally the PCR was never below
this figure. The acid-base balance was adequately controlled and the
following results were obtained in 24 sessions: pre, pH 7.38 0.03,
HCO3 18.86 2.33; post, pH 7.48 0.05, HCO3 24.12 2.31 and 60
minutes after the session ended: pH 7.44 0.04 and HCO3 25.01
2.32. The beta-2-microglobulin decreased after 3 months of this treat-
ment, from 43.58 12.60 to 33.13 9.25 (P < 0.01), and stabilized at
36.00 11.08 after 12 months. There was no change in the usual results
of the blood biochemistry over the 12 months, in spite of the reduction
of the purification time to 2 and half hours per session. Conclusion: the
modification of the two chambers technique analyzed in this paper
permits a reduction in the blood purification time to just seven and a half
hours a week, with good tolerance and appropriate clinical and bio-
chemical control of the patients.
Acetate free bioffitration (AFB). A blood purification technique without
buffer in the dialysate. C. Sanz-Moreno, D. Sanz-Guajrado, J. Fernan-
dez-Fernandez, F. Fernandez-Giron, E. Armada, E. Baamonde, J.
Botella, Hospital Puerta de Hierro, Madrid, Spain. Conventional HD
with acetate in the dialysate produces cardiovascular instability. For
this reason bicarbonate is being substituted, although this method
presents technical difficulties: precipitation of calcium salts in the
circuits in the monitors, unstable concentrations of bicarbonate and
sodium in the dialysate, bacterial contamination of the concentrate.
Therefore we have analyzed a method of blood purification which does
not involve any type of buffer in the dialysate and in which the
metabolic acidosis is corrected by carrying out a hemodiafiltration with
post-filter reinfusion of 1/6 molar (166 mEq/liter) bicarbonate solution or
AFB technique. To study the viability of this technique, the following
research was done: Analysis of the acid-base balance of the blood as it
passes throught the dialyzer and the dialysate without buffer. The blood
lost bicarbonate but the subsequent reinfusion not only recovered this
loss but also improved the acid-base balance. The following results
were obtained: HCO3 23.23 1.26 vs. 27.02 2.11 and pH 7.44 0.02
vs. 7.47 0.02 (pre-dialyzer vs. post-dialyzer). The use of different
volumes of reinfusion: The conclusion reached is that the amount of
reinfusion should not be lower than 5.400 ml (900 mEq of HCO3), since
with this volume a satisfactory correction of the acidosis is achieved:
pre-AFB, pH 7.33 0.03and HCO3 15.2 2.23 vs. post-AFB, pH 7.49
0.02 and HCO3 24.28 1.96. In 6 patients the clinical tolerance was
very satisfactory, and with a reinfusion of 1.000 mEq of HCO3 (6 liters)
the following results were obtained in the control of acid-base balance:
pre-AFB, pH 7.38 0.02, HCO3 17.8 1.91; post-AFB, pH 7.51
0.01, HCO3 26.14 1.20. In conclusion, acetate free biofiltration is a
method of treatment of chronic renal insufficiency which is opening new
paths in the era of "short dialysis".
Variation in the efficiency of dialysis techniques during treatment with
erythropoietin. C. Sanz-Moreno, J. Naranjo, D. Sanz-Guajardo, J.
Fernandez-Fernandez, E. Armada, J. Botella, Hospital Puerta de
Hierro, Madrid, Spain. One of the possible disadvantages of treatment
with EPO is the reduction in the efficiency of the dialysis due to an
increase in the erytrocytic cell mass, resulting in a reduction in the
volume of plasma per unit of flood. To study this problem we analyzed
the clearances in 10 patients treated with EPO for 5 months, and these
were divided into two groups: Group 1, 5 patients on short hemodialysis
(150180 min/3 times a week); Group 2, 5 patients on conventional
hemodialysis (240 min/3 time/week). All the patients began the treat-
ment with 40 U/kg/session and the dose was modified according to the
response in order to obtain a stable Htc, between 30 and 35%. The KtJV
was modified slightly in both groups but was kept above the unit in all
cases. In Group 1 the Kt/V went from 1.22 0.18prior to commencing
the treatment (with Htc of 21.6 1.7%) to 1.09 0.11 after 5 months
(with Htc of 30.3 3.1), In group 2 the Kt/V went from 1.10 0.13 at
the outset (with Htc of 18.7 3.6) to 1.10 0.18 after 5 months (Htc
28.4 3.4). The values of BUN, creatinine and phosphorus prior to the
hemodialysis sessions remained stable throughout the study. There
were no significant cases of hyperkaliemia. In conclusion, if kept
between 30 and 35%, the secondary increase of the Htc in the treatment
with EPO does not cause alterations in the efficiency of the dialysis
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significant enough to require modification of the dialysis regime either in
short or conventional hemodialysis.
Correction of hypertriglyceridemia in patients treated with paired
filtration dialysis (PF) and bicarbonate. C. Sanz-Moreno, E. Armada, F.
Fernanedz-Giron, E. Baamonde, J. Fernandez-Fernandez, D. Sanz-
Guajardo, J. Botella, Hospital Puerta de Hierro, Madrid, Spain. The
patients treated with HD often suffer a type IV hyperlipidemia, with
high levels of triglycerides and low HDL-cholesterol. Among the many
factors involved in the etiology of this condition is the acetate of the
dialysate and the middle molecules. We studied the evolution of the
serum levels of the triglycerides in 3 groups of patients: Group I, 12
patients treated with PFD and bicarbonate, 180 min/3 times/week.
Group II, 12 patients treated with the same hemodiafiltration technique,
involving two chambers and bicarbonate, 150 min/3 times/week. An
ultrafiltration of 12% of the body weight was carried out in both groups
in order to increase the clearance of middle molecules; the bicarbonate
dialysate contained 4 mEq/liter of acetate. Prior to this all were on the
same dialysis technique but with acetate, 35 mEq/liter. Group III, 18
patients on another hemodiafiltration technique, with ultrafiltration of 5
to 6 liters/session, 180 min/3 times/week and acetate, 35 mEq/liter. The
triglycerides decreased in the first two groups after 6 months treatment,
the reduction being much greater in Group II (153.0 70.3 mg/dl at the
outset and 140.4 79.2 after 6 months in Group I vs. 163.3 66.5 at the
outset and 107.7 42.3 after 6 months in Group II). In Group III a slight
increase in triglyceride levels was detected after 6 months (169.5 70.9
vs. 177.1 87.9). We conclude from this that acetate may be respon-
sible for the increase in triglycerides in these patients, with more
triglyceridemia in those with the longest exposure to it. This would
explain the high reduction in those patients on 150 mm/session. The
ultrafiltration does not seem to affect this alteration.
Urinary prostaglandins E2, TXB2 and 6-keto-PGF10, monitoring in
human allotransplantation with cyclosporine A (CsA). F. Oppenheimer,
J. Vilardell, M.J. Ricart, G. Hotter, A. Saenz, J. Rosello, E. Ramos, L.
Fernandez-Cruz, P. Carretero, Transplant Unit, Dept. of Surgery,
Hospital Clinic, Barcelona, Spain. It has been suggested that pros-
taglandins (PGs) are important mediators of the immunoresponses.
Also that CsA induced nephrotoxicity may be associated with changes
in renal arachidonic acid metabolism. Aim: To determine the predictive
value, sensitivity and specificity of urinary PGs for diagnosis of allograft
rejection. Material and methods: The urinary PGE2, TXB2, and 6-
keto-PGF1,, (HPCL-RIA) were measured daily until discharge in 17
patients (12 men and 5 women) after renal allotransplantation. CsA (12
to 14 mg/kg/day) was the only immunosuppressive treatment. Rejection
was diagnosed by a decrease urine output, increase in serum creatinine,
fine-needle aspiration, and duplex-doppler echography. An increase in
urinary PGs levels was defined as a >50% increase over the previous
value. Results: Six patients had acute episode of rejection between 2
and 22 days after Tx. A significant increase of TXB2 was observed in all
patients with rejection and in 7 patients in the absence of rejection
(sensitivity 100%, specificity 36%, predictive value 46%). TXB2 levels
were higher 4 days before and 3 days after rejection. A significant
correlation was found between the peak values of TXB2 and PGE2 (r =
0.805, P < 0.001) and among the peak values of TXB2, PGE2 and
6-keto-PGF1,, with the higher values of serum CsA levels (r = 0.59, P <
0.01; r = 0.78, P < 0.001; r = 0.70, P < 0.01, respectively). No
correlation was found among the peak values of TXB2 and PGE2 and
6-keto-PGF1,,. Conclusion: The PGs urinary monitoring is a very
sensitive method for the diagnosis of rejection, but is of limited use in
clinical practice showing low specificity. A high correlation was found
between the peak urine PGs and the higher serum CsA levels.
Nephrotic proteinuria without hypoalbuminemia. M. Praga, A. An-
dres, C. Montoyo, A. Oliet, L.M. Ruilope, J.L. Rodicio, Hospital 12 de
Octubre, Madrid, Spain. We have studied the clinical and biochemical
characteristics of 19 patients with persistent massive proteinuria (>5
g/24 hr) and normal serum albumin (>3.5 g/dl, Group I) in comparison
with 16 patients with similar proteinuria but persistent hypoalbumin-
emia (< 3 g/dl, Group II). We observed clear differences in the
diagnosis of both Groups: the most frequent in Group I was reduction
of renal mass (4 patients), idiopathic and inactive crescentic glomeru-
lonephntis (GN) (4), refiux nephropathy (3), IgA ON (3) and proteinuria
associated with obesity (2). In contrast, in Group II were membranous
ON (10), mesangiocapillary GN (3) and idiopathic focal glomeruloscler-
osis (3). There were no differences in age, sex, range of proteinuria (7.4
1.9 vs. 7.9 2.5 g/24 hr), serum creatinine (2.3 2.1 vs. 2.2 1.5
mg/dl), number of patients with HTA, or duration of proteinuria. We
prospectively investigated differences in the antiproteinuric effect of
captopril: after six months of treatment proteinuria decreased clearly in
Group I (7.1 1.7 to 3.7 1.7 g/24 Hr, P < 0.001) whereas no
significant changes were observed in Group 11(8.1 2.4 to 8.8 4g/24
hr). Finally, since several lines of evidence suggested a role of tubular
protein catabolism in the pathogenesis of nephrotic hypoalbuminemia,
we studied the urinary excretion of NAG and /32-microglobulin and the
presence of renal glycosuria: Group I patients had a significantly lower
excretion of NAG (20.4 4.1 vs. 72.3 35 U/g Cr, P <0.001) and of
132-microglobulin (fractional excretion 0.8 1.6 vs. 9.8 1.6 vs. 9.8
12.9%, P < 0.05) than those of Group II. Renal glycosuria was not
detected in Group I, whereas 58% in Group II showed glycosuria
ranging from 2.5 to 12 g/24 hr. In conclusion, the patients with massive
proteinuria and normal serum albumin have distinctive clinical charac-
teristics; the absence of hypoalbuminemia could be a predictor of the
antiproteinuric response to ACEI. The differences in the excretion of
NAG and /32-microglobulin and the presence of glycosuria suggest that
tubular catabolism of filtered albumin may play a role in the pathogen-
esis of hypoalbuminemia.
Antiproteinuric effect of captopril in nondiabetic glomerular protein.
uria. C. Montoyo, M. Praga, A. Andres, E. Harnandez, V.G. Millet,
J.M. Alcazar, J.L. Rodicio, Hospital 12 de Octubre, Madrid, Spain.
Captopril and other angiotensin-converting enzyme inhibitors (ACEI)
have shown an antiproteinuric effect in some patients with diabetic
nephropathy and other glomerular diseases. We have prospectively
studied the effect of captopril (25 to 100 mg/day for six months) in 23
patients with massive proteinuria (>5 g/day) and several nondiabetic
nephropathies. Sixteen patients (69.5%, Group I) showed a decrease of
proteinuria (initial 7.4 1.7 vs. 3.9 1.7 g/day at six months, P <
0.001) whereas the remaining 7 patients (30%, Group I) did not show
any improvement (7.6 2.7 vs. 9.8 3.9 g/day, P = NS). There were
no differences in age (40.6 14.8 vs. 46.7 14 years), duration of
proteinuria (3.2 2.3 vs. 3.2 3,1 years), captopril doses (65 22 vs.
75 14 mg/day) or number of hypertensive patients (50% vs. 71%)
between both groups. No relationship between normalization of blood
pressure and decrease of proteinuria was observed. Group I had a
serum albumin and creatinine clearance significantly higher than Group
11(3.6 0.6vs. 2.6 0.6g/dl, P <0.01 and 71 34 vs. 48 21 mI/mm,
P < 0.05, respectively). The analysis by diagnosis showed that all the
patients with proteinuria associated with reduction of renal mass (4
patients), idiopathic inactive crescentic glomerulonephritis (3) reflux
nephropathy (2) and IgAGN (2) pertained to Group I. On the contrary,
only 3 out of 7 cases with membranous GN and 1 our of 4 with
idiopathic focal glomerulosclerosis pertained to this group. In conclu-
sion, most (69.5%) of patients with massive nondiabetic proteinuria
treated with captopril have shown a decrease of proteinuria. This
beneficial effect is observed mainly in some clinical conditions, in
patients with normal serum albumin and when the renal function is not
severely reduced.
Duplex-echography for internal arterio-venous fistulas for hemodialy-
sis. G. GarcIa-Erauzkin, L.M. Ruiz, J.I. Vidaur, J.J. Amenabar, P.
GOmez- U/late, I. Lampreabe, Divisions of Nephrology and Radiodiag-
nostic, Cruces Hospital, Vizcaya, Spain. Nine internal arterio-venous
fistulas (IAVF) were studied with duplex-echography (D-Echo: B and
Doppler) in two periods after their surgical construction: I, immediate
postsurgical; II, after 12 to 24 hours. Useful information about their
functional viability with quantifiable parameters such as venous and
arterial diameter, flow or systolic peak was obtained; initial complica-
tions were easily and prompty detected and diagnostic doubts and
mistakes about their functionality were solved. The D-Echo shows
itself as an adequate method, because of its utility and inocuity, for the
study of normal and pathological characteristics of IAVF both after the
surgery and in patients undergoing hemodialysis.
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Plasma interleukin-! (IL-i) levels in patients treated with different
types of membranes in hemodialysis. L.M. Ruiz, G. Garcla-Erauzkin, D.
GarcIa-Masdevall, J.J. Amenabar, P. Gómez-Ullate, I. Lampreabe,
Divisions of Nephro!ogy and Immunology, Cruces Hospital, Vizcaya,
Spain. We studied basal and intradialytic plasma levels (pg/mi) of IL-i
(alfa fraction), determined by enzimoimmunoassay (ELISA), in a group
of 9 patients treated with hemodialysis (HD), comparing with those of
8 healthy individuals (N) and with those of 7 chronic renal failure
without HD (CRF) control groups. The intradialytic changes were
evaluated after sequential weekly periods of treatment with cuph-
rophane (CU) and polyacrilonitrile (PAN). We determined levels at
three moments of the dialysis: initial (I), half (H) and final (F) time. We
did not find significative differences in the comparison of IL-i levels
among N (150.5 78.8), CRF (108.1 48.3) and HD (88.2 11.4)
groups. In our in vivo study the PAN membrane induced a more
significative intradialytic IL-I production (I = 107.4 55.7; H = 138.8
46.2; F = 106.5 53.6) than in the case of the CU membrane (I =
86.1 27.48; H = 104.6 28.84; F = 81.4 20.04). Wilcoxon test: P
<0.05 for the acute increases in the half time moment. In conclusion,
the interaction membrane-monocyte during dialysis with synthetic
membranes like PAN is a prominent inducer of acute IL-I production.
Clinical issues of adult polycystic disease (APKD) with end-stage renal
failure (ESRF). Committee of the Registry of Renal Patients of Cata-
lonia, Spain. A questionnaire was submitted to all nephrology services
and dialysis units of Catalonia in order to ascertain some clinical topics
on the 346 APKD patients alive at December 31, 1988, included in our
Registry. Response rate was 77.7% (269 patients). A total of 43.5% of
patients were known to have familiar history of ESRF. Of these, 4.5%
of patients had suffered a nephrectomy (N) before the onset of dialysis
treatment, 50% of them due to infection. N was performed while on
dialysis in 9.7% of patients, 38.5% of which was due to infection and
23.1% because of neoplasia; 30.1% presented with hypertension during
dialysis treatment. In the last year (1988), 21.6% of hemodialysis
patients had one or more cystic crises, 25.8% requiring hospitalization
from I to 28 days (mean = 8.6 days). Of all patients, 16.7% required
transfusion of Ito 30 units of blood (mean = 3.3 U/patient). Only 35.3%
of patients were submitted to echocardiography (ECO-C), with the
following results: aortic dilatation was present in 1.9% of patients
(5.26% of ECO-C), aortic valvulopathy in 1.5% (4.21% of ECO-C), and
mitral valvulopathy in 1.5% (4.21% of ECO-C). In 10 our of 13 patients
(76.79%) in whom ECO-C showed any of the above mentioned anor-
malities, familiar history of APKD was present (P < 0.05). However,
this was not correlated with nephrectomy in hemodialysis, hyperten-
sion, age, infection nor transfusional requirements. A study on the last
3-year period mortality in the patients of the Registry was performed,
showing 754 deaths, of which 61 were APKD (8.1%). When comparing
APKD and non-APKD populations, significant differences were not
disclosed concerning the causes of death: cardiovascular (47 vs. 43%)
or infective (6.6 vs. 10.2%), but a higher frequency of deaths due to
hepatopathy was found (6.6 vs. 3.3%).
Hypertension, gout, renal insufficiency and lead. C. Bernis, E. Her-
rero, V. Alvarez, J. Hdex Jaras, C. GaCaton, V. Paraiso, B. Rincon,
J.A. Traver, S. Nephrology, Princesa Hospital, S. Biochemistry, La
Paz, Madrid, Spain. Eleven patients with gout, hypertension and renal
insufficiency were studied for possible lead nephropathy by measuring
stimulated urinary lead excretion. Occult lead was assesed using the
Emmerson-Batuman protocol. On the first day, each patient emptied
the bladder and received one g of EDTA. A second dose of 1 g was
given 12 hours later. Three consecutive 24 hr urine collections for
measurement of lead and creatinine were begun simultaneously with the
first injection. Response to the chelating agent was determined as the
sum of urinary lead excretion for the entire 72 hr study penod. A
excretion 600 pb/72 hr was considered positive. All patients had a
possible history of lead exposure, one from illegal alcohol, 8 from
industrial sources, 3 from pottery. Five patients had a positive test.
Two cases with proteinuria> 1 g/24 hr were biopsied, finding 1 case of
IgA with positive test and 1 case of malignant HT with negative test.
The patient with IgA had an improvement of his renal function after
being separated of lead exposure. Conclusions: 1) The test was positive
in the 45%, in association with advanced age, male sex, and uric
clearance low. 2) The history of lead exposure is difficult to evaluate. 3)
The positive test can be associated with other pathology.
Direct calculation of KT/V. Comparation with the conventional
method. M. Garcia Garcia, M. Pocino, P. Arrizabalaga, M. Carrera,
J.M. Pons, L. Revert, Hospital Clinic i Provincial, Universidad de
Barcelona, Barcelona, Spain. The determination of KT/V is becoming
accepted as a standard measurement for monitoring the dosage of
hemodialysis. Current methods for its calculation are limited by inac-
curate knowledge of dialyzer urea clearance (K) and urea volume
distribution (V). Recently it has been introduced a simplified method to
direct calculation of KT/V according to formula: (BUN pre - HD-BUN
post-HD)/BUN mid-HD. The aim of our study has been to compare the
direct calculation of KT/V with conventional method and with the
KT/V by estimate V (60% dry weight) and K according to blood flow.
Twenty patients (13 males, 7 females, mean age 49.4 10.6 years) with
dry weight of 67.8 10.9 kg were studied in one hemodialysis (HD) of
240 minutes (T), blood flow of 250 mi/mm, dialyzer of polyacrylonitrile
membrane (Fitral 16, Hospal) and artificial kidney with direct control of
ultrafiltration. The following were measured: BUN pre-HD, BUN at
midpoint of HD, BUN post-HD. The mean of three K of diffusion with
0 ultrafiltration (30, 60, 90 mm) was done. Also, we measured the
ultrafiltration (K of ultraffitration). The results showed that the direct
calculation of KT/V was higher than conventional method (1.23 0.26
vs. 1.08 0.19; P < 0.001); both were smaller than KT/V by estimate
K and V(l.33 0.22; P <0.001). V by conventional method was higher
than V obtained by formula of direct calculation of KT/V making use of
measured K (46.08 8.16 1 vs. 41.4 8.39 1; P <0.001), significantly
in the first case 67.9% and in the second 60.6% of the dry weight. We
conclude that direct calculation of KT/V is preferable to conventional
method because it is more simple without mistake in K and without
overestimate of V.
Effect of reduction of cyst volume by percutaneous cystic puncture on
the renal function in the polycystic kidney disease (PCKD). M. Garcia
Garcia, C. Bru, J.M. Campistol, C. Piera, A. Torras, E. Ponz, L.
Revert, Hospital Clinic i Provincial, Universidad de Barcelona, Barce-
lona, Spain. The aim of this study has been to examine the reduction of
cyst volume by percutaneous cystic puncture on the renal function in
the PCKD in the short and middle time. In 9 patients with PCKD with
lumbar pain or progressive renal failure the percutaneous aspiration of
cyst fluid was performed with 22 gauge needle under ultrasonography
control. In 6 patients with serum creaatinine of 4.4 3.1 mg/dl the
glomerular filtration rate (GFR) and the renal plasma flow (PFR) were
performed by '251-iothalamate and '311-hippuran 24 hr before and 24 hr
after the reduction of cyst volume. In each patient it was aspirated 5.2
2.5 cysts with a volume of 120 79 ml. Also in 6 patients with renal
failure the 1/serum creatinine slope was assessed before (8—12 months)
and after (6—8 months) the aspirative cystic puncture. The GFR (44.5
53.4 mi/mm) increased 12.1 7.3% (P < 0.05); there wasn't changes in
RPF (237.3 316.9 mi/mm). The 1/serum creatinine slope before and
after the reduction of cyst volume was —0.11 0.01 vs. —0.039 0.04
(NS). In 2 patients with one big cyst it verified at two months with
ultrasonography control that they refilled to same size, diameter of 8
and 9 cm, respectively. Our results suggest that the reduction of cyst
volume improves the GFR in short time but in the following time there
isn't improvement probably because of filling of cysts.
Analysis of cysts in polycystic kidney disease (PCKD). M. Garcia
Garcia, J.M. Campistol, C. Bru, A. Torras, C. Piera, R. Deulofeu, E.
Merola, E. Ponz, L. Revert, Hospital Clinic i Provincial, Universidad
de Barcelona, Spain. Forty-one renal cysts pertaining to 9 patients with
the adult form of PCKD with progressive renal failure or lumbar pain
were studied. The serum creatinine was 4.0 2.8 mg/dl (0.7 to 8.8
mgldl). The cysts were obtained by percutaneous aspirative puncture
with ultrasonography control. The diameter cyst was 2 cm. In each
cyst was determinated Na, K, Cl, creatinine, urea, protein and aspirate
volume. The cysts were classified according to Na cyst/serum into three
groups: proximal or non-gradient: 0.80 to 1.20; distal or gradient: <
0.40; indeterminate: 0.40 to 0.79. Also, the cysts were classified
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according to their aspect: clear or bloody and according to the ratio
creatinine cyst/serum  I or < 1. Our results were:
N
Na K Cl Urea
mg/dl Cr c/s
.
Aspirate
vol mlmEqiliter
Proximal 29 135 6.6 114.1 96.1 6.5 36.9
Indeter. 8 80.2a
19.6
337° 79.1 148.2 21.6
4
41
34.2a 56.5a 45.6a 190.7 10.3 9.7
a p < 0.001
The aspirate volume in the clear cysts (N = 18) was 55.3 57.6 ml and
in the blood cysts (N = 23) was 12.1 9.8 ml (P < 0.001). The cysts
with ratio creatinine cyst/serum < 1 had an aspirate volume of 77,5
70.7 ml and those with ratio 1 were 18.1 17.8 ml (P < 0.001). The
remainder were without changes. Our data suggest that the cyst are
massively enlarged segments of nephrons that when they have blood
into its volume is minor. Also, it seems that the fluid transepitelial
secretion should contribute to increase the growth of the cysts.
Epidemiology of symptomatic hypotension in hemodialysis. Should we
drop the bath temperature? L. Orofino, R. Marcén, C. Quereda, J.J.
Villafruela, M. Naya, M. Rivera, R. Matesanz, J. Ortuno, S. de
Nefrologla, Hospital Ramón y Cajal, 28034, Madrid, Spain. A total of
7742 hemodialysis sessions were performed in 60 patients (39 male and
21 female) during 12 months. The former 6 months, a 37°C bath was
employed and the latter 6 months a 35°C dialysate was used. The mean
age of patients was 51 years (15 to 72), with no difference among male
and female. The time on dialysis was 42 30 months. The women had
a lower body surface area than men (1.5 vs. 1.7 m2, P < 0.01). An
acetate bath and a cuprophan capilar dialyzer of 0.9 to 1.1 m2 was used.
Hypotension was present in a 15.3% of dialysis: more frequent in
women than in men, 28.2 vs. 8.5%, P < 0.001; in patients older than 55
years, than in the younger ones, 21.2 vs. 8.6%, P < 0.001; in those with
a body surface area lower than 1.6 m2, than in the rest, 19 vs 9%, P <
0.05; in those with vascular calcifications than in patients without them,
41 vs. 11%, P < 0.05; in patients not under antihypertensive therapy
than in those treated with them, 16 vs. 9%, P < 0.05; in patients who
presented cardiac insufficience episodes than in those that did not, 30
vs. 11%, P < 0.01. Hypotension frequency was greater during the 37°C
period, 16.4 vs. 14.3% at 35°C, P < 0.001, although the interdialysis
weight gain and the hemodialysis weight loss was greater at 35°C, P <
0.001. Benefits were more remarkable in patients with more than 30%
hypotensive sessions, in men and patients lower than 55 years. An
inverse correlation was seen between post-dialysis blood acetate levels
and body surface area (r —0.56, P < 0.01). Treatment was well tolerated
and no differences were observed in the rest of the symptoms. Conclu-
sions: 1) The drop of bath temperature to 35°C, is beneficial, especially
in patients with a high risk of hypotension. 2) A greater ultrafiltration is
allowed. 3) It is a simple, well tolerated and free cost method.
Hemodynamic changes produced by extracorporeal blood recirculation
and body temperature variation in the dog. L. Orofino, C. Quereda, R.
Marcén, P. Jorge, J.J. Villafruela, J. Sabater, J.A. Herrero, J. Ortuno,
S. de NefrologIa, Hospital Ramón y Cajal, 28034 Madrid, Spain. The
hemodynamic effects of the body temperature variation were studied in
14 mongrel dogs of 21 to 34 kg of weight. Through femoral vessels, a
Swan-Ganz and a Millar catheter were introduced up to pulmonary
artery and left ventricle, respectively. By the contralateral side, an
extracorporeal circuit was established with a 0.9 m2 cuprophan dialyzer
immersed in a water bath kept at either 34 or 42°C, for the cold and the
warm studies, respectively. In 10 sessions, the animal body tempera-
ture was decreased 2°C; in 4 more sessions, temperature was firstly
decreased 2°C and afterwards increased 2°C, and, finally, in 4 sessions
body temperature was increased 2°C and later decreased 2°C. The
animal responses to temperature changes are similar, with indepen-
dence of the order in which increased or decreased temperature was
established. The response to warm produced a 15 1% increase of the
pulse rate, P < 0.001, and a 17 2% of the cardiac index, P <0.05; a
decrease of the systemic vascular resistances of a 14 3% and the dp/dt
max of 1.4 2% was observed. The 2°C body temperature decrease
produced a fall in the pulse rate of a 9 1%, P < 0.01, and in the cardiac
index of a 18 4%, P < 0.01. However, an increase was seen in
systemic vascular resistances (15 3%, P < 0.05), and in dp/dt max (28
4%, P < 0.01). No modification was seen in systolic blood pressure,
systolic index and in pulmonary artery pressure. Conclusion: In this
model, the dog maintains a stable blood pressure at a high or low body
temperature: in the first case because of a cardiac index increase; in the
second one, because of a rise in the systemic vascular resistances.
Isolated ultrafiltration at different temperatures. L. Orofino, C.
Quereda, R. Marcén, J. Sabater, J.J. Villafruela, P. Jorge, J.A.
Herrero, J. Ortuño, S. de NefrologIa, Hospital Ramón y Cajal, 28034,
Madrid, Spain. Hemodynamic changes caused by isolated ultrafiltra-
tion (IU) at two different body temperatures were studied in 5 mongrel
dogs of 26 to 30 kg of weight during 10 sessions. Each animal served as
its own control at upon the basal body temperature. Through
bilateral femoral artery and venothomy, an extracorporeal circuit was
established and a 0.9 m2 capillary dialyzer was inserted and introduced
in a cold or warm bath to reach the desired temperature. By the
contralateral side, a Millar mikrotip and a Swan-Ganz catheter were
introduced up to the left ventricle and pulmonary artery, respectively.
When a stable temperature of upon the basal was achieved, IU at
a rhythm of 0.41 0.004 mI/kg/mm (2.5% of the body weight in 60
minutes), was started. At +2°C, pulse rate increased from 178 21 to
214 34 beats/mm, P < 0.01, and systemic vascular resistances from
1010 139 to 2042 528 dyne. sec cm5, P < 0.001. Cardiac index
decreased from 4.9 0.8 to 2.2 0.4 1/mm/rn2, P < 0.01 and systolic
index from 27 2 to 10.4 3 ml/beat/m2, P < 0.01. Systolic blood
pressure, 94 17 vs. 81 11 mm Hg and dp/dt max, 2243 390 vs.
2180 366mm Hg/sec did not change significantly. At —2°C, pulse rate
increased from 141 8 to 185 16 beats/mm, P < 0.001 but systolic
blood pressure, 90 16 vs. 57 15 mm Hg, P < 0.01, cardiac index,
3.8 .6 vs. 2.4 1 1/mm/rn2, P < 0.05, systolic index, 27 4 vs. 13.3
6 mI/beat/rn2, P < 0.01 and dp/dt max, 1853 293 vs. 1497 329mm
Hglsec, P < 0.05, went down. Systemic vascular resistances did not
suffer changes, 1289 424 vs. 1349 956 dyne. sec . cm5. Conclu-
sion: In healthy dogs, IU is poorly tolerated at a low body temperature.
The cardiac index decreased and a smaller eficacy of the myocardial
contractility was found.
Natural anticoagulants. Effect of urinary losses on the hypercoagulable
state of the nephrotic syndrome (NS). A. Oliver, P. Barceló, J.A.
Ballarin, C. Fernández, 0. Lopez, G. del RIo, Fundacion Puigvert,
Barcelona, Spain. Urinary losses of natural anticoagulants could play a
role in the hypercoagulable state of the NS. We have studied 72 patients
(38 men, 34 women; mean age 36 to 14 years) with glomerular diseases
and nephrotic range proteinuria 3.5 g/24 hr. Plasma and urinary values
of heparin cofacror (HCII; antithrombin (ATIII), protein C (PC) and
protein S (PS) were measured by functional and immunologic methods,
and in 23 NS cases, clearances of albumin, IgG, transferrin and
a2-macroglobulin were done. Blood and urinary samples of 25 healthy
subjects were used as a control.
Plasma level 9'c mean; 5D Urinary excretion (Ag)
ATIH HCII PC PS ATIII HCII PC PS
12 43 25 28 mg/24 hr mg/24 hr g/24 hr g/24 hr
Correlation total proteinuria
rho:
109 94 94 109
11 14 12 25 0.77 0.23 0.77 0.64
<0.001 NS <0.001 NS <0.001 NS <0.001 <0.001
Plasma values of HCII, PC or PS, remained quite similar during the
relapsing phase (Prot 1 g/24 hr) in spite of the decrease of anticoagu-
p 95 105 125 98 108 14 1.31 0.6 94 12 230 12
C
72
c
0
n
25
P
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lant losses. The selectivity of proteinuria does not seem to have a role
in this urinary excretion because all proteins studied have a similar
molecular weight (60 to 80,000 kDa). Our results suggest that the
urinary losses of natural anticoagulants do not participate in thrombosis
phenomena of the NS except for ATIII, a deficiency of which was the
major abnormality detected.
Increased levels of plasmmogen activator inhibitor in nephrotlc syn.
drome. A. Oliver, P. Barcelô, C. Fernández, F. Rousaud, 0. LOpez,
J.A. BallarIn, F. Calero, FundacionPuigvert, Barcelona, Spain. In this
work we investigated several aspects of plasma fibrinolysis in 34
patients with proteinuria (range 3.5 to 11.8 g/24 hr). Plasminogen (PLG),
antiplasmin (AP) and a2-macroglobulin (M) were measured. t-PA
activity (f) (Coaset Kabi), antigen (ag) (Biopool) and PAl activity(Coaset Kabi) were determined before and after venous occlusion.
Twenty-five blood donors were selected as the control group. Baseline
levels oft-PA (f) (0.22 to 4.68 lU/mI) and t-PA (ag) (1.4-13.3 ng/ml) were
with in normal range (0.21 to 1.3 IU/ml and 1.3 to 11.3 ng/ml,
respectively). However, the increase of t-PA (t) by venous occlusion
was poor in 13 patients (38.2%) as compared with controls (mean
increase: patients 4.28 5.98; controls 8.38 8,3; P < 0.001), but not
in the case of t-PA (ag) (mean increase: patients 28.94 30.1; controls
20.07 14.32). Patients' PAl levels were higher (1.9 to 75.4 IU/ml) than
those of controls (2 to 22 IU/ml; P < 0.001, Mann-Whitney's test).
There was a significant positive correlation between PAl levels and
serum triglycerides (r = 0.69, P < 0.001). Four patients had a history of
thrombosis. Two of these patients had the highest levels of PAl (60 and
75 lU/mi). PLG levels (107 + 13%) were higher than in healthy subjects
(98 14%; P < 0.05). AP levels were normal (110 + 20%; control: 104
+ 12%), while M levels (mg/dl) were higher (564 289) than those of
controls (185 35; P < 0.001, Student's t-test). Thus, patients with NS
seem to have low fibrinolytic potential and high PA! levels. These
alterations may contribute to the development of thrombosis.
Deoxiurdine (TsdU) test. Maturative factors' deficit detection in the
anemia of the hemodialyzed patients (HD). A. Oliver, P. BarcelO, C.
Fernández, F. Rousaud, 0. LOpez, F. Calero, T. Donate, M. RodO,
FundaciOn Puigvert, Barcelona, Spain. The anemia in hemodialyzed
patients has a multifactorial origin. The deficits in the maturative factors
can interfere in the erythropoietin anemia response. We study the
incidence of maturative factors in 100 HD with routine blood tests:
complete hemogram, reticulobytes (Rt), serum ferritin (SF) by ELISA,
vit B12 (RIA), and erythrocytary folate (RCF) by RIA and, in 25 of
them, the TSdU test measuring the suppression of the incorporation of
tritiade thymidine to a suspension of the bone marrow nuclear cells to
which deoxiuridine was added, was performed. The test was evaluated
with and without maturative factors: hydroxicobalamine (OH cbl),
methylcobalmine (Mecbl), methyl-tetrahydrofolate (MTHF) and folinic
acid (FTHF). The SF values were: 428 93 g/liter and B12 573 12233
pmol/liter, and were increased, P < 0.001 and P < 0.02 (vs. control)
with RCF diminishing, 797 173 nmol/p. There was a large value bias:
14% had ferropenia, 38% hemosiderosis, 17% macrocytosis and 16%
folates deficit. The TSdU test evidenced that 24% of patients had
alterations that recovered with the incorporation of folates (MeTHF
and FTHF): P < 0.001 and were not modified with B12 (OHCbl:
MeCbl). Seventeen patients with folatopenia were treated with folinic
acid, confirming a significant increase of Hb (P < 0.05) and erythro-
cytary creatinine (P < 0.001) at 6 months after the beginning of the
therapy. Conclusions: 1) The TSdU test accurately detected maturative
deficits; 2) the high incidence of folatopenias that improved with
treatment was detected; 3) the adverse effect of the Fe overload on the
anemia was confirmed; 4) this study evidenced the multifactorial origin
of the anemia in hemodialyzed patients.
Lactate in hemodialysis concentrates: The forgotten buffer. J. Tor-
rente, F. Coronel, M.J. Alvarez, M. Macia, F. Tornero, A. Barrientos,
Servicio de Nefrologia, Hospital Universitario San Carlos, Madrid,
Spain. To our knowledge, lactate has never been used in HD concen-
trates. We studied the possible benefit of this buffer in 14 classically
acetate-intolerant HD patients (hyperacetatemia post-HD > 7 mmol/
liter, bicarbonate decrease during HD > 2 mmol/liter, low body surface
area. We have designed a new concentrate in which a low acetate
concentration is complemented with lactate up to standard quantities of
buffer, with the aim of minimizing the side effects of acetate. Patients
were blindly and randomly assigned to lactate dialysate (LA; Na 138, K
1.5, Ca 1.75, Mg 0.75, glucose 5.55, acetate 17.5 and D.L-lactate 17.5
mmollliter) or the same bath with only acetate (35 mmol/liter) as buffer
(AC). Blood gases, acetate (gas chromatography) and lactate (enzymat-
ic) levels were measured pre- and post-HD. In each HD symptomatic
hypotension, vomiting and headache episodes were recorded. Post-HD
pH showed the same increase with both dialysates. AC caused a
significant decrease in pCO2 (34.3 2.2 vs. 26.05 2.48, P < 0.001)
and bicarbonate (19.82 1.45 vs. 15.34 2.12, P < 0.001). With LA
dialysis, pCO2 showed a lower decrease (35.45 2.25 vs. 31.6 2.0, P
<0.01) and bicarbonate remained unchanged (20.02 1.91 vs. 19.43
1.85, NS). Post-HD acetatemia was lower in LA (9.73 1.6 vs. 3.12
1.6, P < 0.001). Symptoms were less frequent in LA dialysis (hypoten-
sion 64.2% vs. 30.9%, P <0.001; vomiting 15.4% vs. 4.76%, P <0.01;
headache 33.3% vs. 19%, P < 0.01) with similar body weight loss. We
conclude that the use of lactate in HD concentrates is a useful
alternative to standard dialysate in acetate-intolerant patients. It avoids
the serum bicarbonate fall with lower acetate levels and has less
dialysis-induced morbidity.
High efficiency hemodialysis with acetate. J. Martin Garcia, M.A.
Alvarez de Lara, 0. Ortega, I. Ferreras, Hospital Ntra, Sra. de
Alarcos, Ciudad Real, Spain. Sixteen chronic dialysis patients previ-
ously treated with conventional hemodialysis (12 to 15 hr/week), were
transferred to high efficiency HD program. The acetate buffer was used.
The dialyzers were: cuprofan membrane capillaries of 1 m2 and 5 s (9
patients) and AN-69 capillaries of 1.1 and 1.45 m2 (7 patients). Blood
flow was greater than 350 ml/min. Dialysate Na was 138 mEq/liter. We
evaluated this treatment at 5 and 15 months. No significant differences
were observed in biochemical and clinic parameters at 5 months of
treatment, but we needed to modify session mean time previously
established: 191.2 17.9 mm vs. 180 mm (P <0.05), because mid-week
predialysis urea exceeded 200 mg/dI in two patients, and the weight
increases in interdialysis were higher than 4% of body dry weight in
three patients: that doesn't permit a rapid UF. At 15 months this change
in session mean time (20% of the standard HD time) produced a
decrease of the intradialysis hypotensive episodes: 8.5% vs. 16.9% (P <
0.01). No differences were observed in other dialytic symptoms:
Nausea 3.4%, vomiting 5%, muscle cramps 4.2%, headache 0.45%.
Serum creatinine decreased significantly at 15 ionths: 9.8 1.8 vs.
11.5 1.5 mg/dl (P < 0.05). The morbidity was similar at standard HD
group: Hospital admission 1.52 vs. 1.28 patients/year; Hospital perma-
nence 10.5 vs. 10.5 days/pte/year. No one patient developed pericardi-
tis. Mortality was mll. In conclusion our data suggests that high
efficiency HD using acetate buffer doesn't permit adequate dialysis with
a shorter time than 20.5% of the HD standard time, except in selected
patients. The vasodialator power of acetate buffer doesn't permit the
rapid UF of the weight increased interdialysis greater than 3.3% of the
body dry weight.
Tumor markers in chronic renal insufficiency. J. Martin Garcia, N.
Ulecia, 0. Ortega, I. Ferreras, M.A. Alvarez de Lara, Hospital Ntra,
Sra. de Alarcos, Ciudad Real, Spain. We studied the incidence of eight
tumor markers: CEA, SCC-Ag, CA 19-9, CA 72-4, CA 125, CA 15-3,
TPA and thyreoglobulin, measured by RIA, reaction Ag-Ac with
monoclonal antibodies, in three different population samples of renal
patients without malignant disease: 43 patients between the age of 21
and 69 years staying in hemodialysis program (HD), 20 patients
between 25 and 78 years with avanced IR (Cr: 4.6 2 mg/dl; Cr
clearance, 19.4 11 mllmin); and 14 renal transplant patients (Tx)
between the ages of 19 and 59 years who had a slight affection of renal
function (Cr: 1.7 0.9 mg/dl; Cr clearance 63.6 25.3 mI/mm).
Hemodialysis program time was between the month 3 and 264; the
following time of JR was between the month 3 and 84; and the time of
Tx between months 3 and 47. The predominant etiology IR was the
glonierulonephritis in the three groups: 32%, 40% and 36%, respec-
tively. The tissue polypeptide antigen (TPA) was elevated in all cases:
97.6% in HD patients, (x = 202.2 88.1 U/liter); 70% in JR patients (x
= 148.7 59.5); 69.2% in Tx patients (x = 124.6 40.6 U/liter, P <
0.05). In HD patients with residual renal function, we obtained lower
values: 169.8 44.2 vs. 223.6 76.9 (P < 0.05). Squamous cell
carcinoma-associated antigen (SCC-Ag) was elevated in HD and IR
Abstracts 1591
patients: 74.4% (x 4.25 2.5) and 65%, respectively, while only two
Tx patients had slightly increased values. The other tumor markers
studied kept their specificity in the three groups; they were elevated in
a few patients except CEA, which was elevated at 25% in HD group.
We measured each marker pre- and postdialysis in 18 patients using
different membranes; no significant differences were observed. We
conclude that some tumor markers, TPA and SCC-Ag in particular, are
unreliable in monitoring malignant disease in renal patients, because
their metabolism is related to the renal function. The markers CA seem
to maintain their specificity in these patients. The HD session, inde-
pendent of membrane used, doesn't alter the serum levels of the studies
markers.
Influence of erythropoietin treatment on short dialysis. E. Andrés, S.
Gil-Vernet, A.M. Castelao, f.M. Griñó, C. Gonzalez, J. Carreras, C.
DIaz-Gallo, J. Alsina, Hospital de Bellvitge, Hospitalet de Liobregat,
Barcelona, Spain. Dialysis efficiency could be decreased by erythro-
poietin (EPO) treatment. Therefore, this could advise against the
current tendency to prescribe short dialysis schedules. We studied 11
hemodialysis patients (mean age = 44.72 10.56 years) treated with
EPO for 6 months. Dialysis schedule was: 10.5 hr/week, cellulose
acetate 1.7 m2 (2 patients) or 9 hr/week, biofiltration, polysulfone 1 to
1.36 m2 (9 patients). The EPO dose was adjusted to achieve a targeted
Hb = 10-12 g/dl.
preEPO
Months
1 3 6
Hb g/dl 7.2 1 8.2 l.5a 10.3 j,5l 10.4 0.6"
urea mmol/liter 25.6 5.5 25.5 6.3 26.8 5.2 25.8 3.6
P mmol/liter 1.7 0.4 2.16 0.5a 2.5 0.7a 2.17 0.8
K mmol/liter 5.6 0.6 5.6 0.9 5.8 0.6 6 0.8
KTV 1 0.2 1.1 0.1 1 0.1 1 0.2
PCR 1 0.1 1.1 0.2 1.1 0.2 1.1 0.1
preALB mg/dl 28.8 8 28.9 0.2 30 8.1 32.4 9.7
Bodywtkg 58.7±8.1 58.6±7.3
a p < 0.01
b p < 0.001
Dialysis schedule was unchanged during follow-up period. We can
conclude that EPO does not decrease efficiency of short dialysis
regimes, as it is demonstrated by urea kinetics. A rise in urea,
phosphorus and potassium may be explained by increased appetite and
lower dietary compliance.
The role of CAPD in a chronic renal failure regional treatment
program. MA. Gentil, A. Carriazo, M. Rosado, I. Pavón, C. Escan-
don, J.A. Milan, R. Otero, G. Algarra, F. Fernández Montero, Regis-
tro de pacientes renales, Servicio Andaluz de Salud, ConsejerIa de
Salud y SoS. Junta de AndalucIa/Sociedad Andaluza de Nefrolog(a.
We studied 558 patients (pat) treated with CAPD in Andalusia during
the 1983-88 period, based on the regional renal data Registry (100%
centers updated). Results: 1) Frequency of use: The proportion of pat
dialyzed with CAPD has remained constant at about 10%. Of those 22%
included in dialysis for the first time received CAPD at any point in
time. There are great differences in prevalence among the provinces,
that increase in time (1983: 4 to 39 PMP, 1988: Ito 54 PMP). 2) Type of
patients: CAPD pat were significantly different from those treated with
hospital HD, due to greater numbers of: average age at the begining
(49.4 vs. 45.9 years), older than 60 years (45% vs. 29%), diabetes (24%
vs. 4%), cardiovascular co-morbidity (23% vs. 10%). There were very
significant differences in the type of pat treated among the treatment
centers, showing different criteria in the use of the technique. 3)
Results: the 1st, 2nd and 3rd year survivals (SV) were 88%, 70% and
61% (pat SV); 77%, 63% and 52% (technique), and 67%, 44% and 32%
(technique success). Pat SV is related to age (P < 0.0001). Diabetic pat(N = 95) showed 1-year pat and technique SV of 89% (the latter being
significantly better than the one for non-diabetics). Among centers with
more than 50 pat, there were significant differences in pat SV (75% to
95% in I-year, P = 0.025) and in technique SV (52% to 100% in 1-year,P = 0.0000), that can be partially explained by the type of treated pat.
An improvement in SV is shown (technique success by year: 1983, 54%;
1987, 77%; P = 0.047). Conclusions: CAPD plays an important role as
dialysis therapy in our region, but great differences are found among
provinces in the frequency and way of use. It is mostly used in high-risk
pat: older, cardiology pats, and diabetics, The SV results that seem to
improve with time are similar to those reported for other pat groups
(EDTA).
Comparative study of hospital 1W and CAPD in a regional dialysis
program. Results of 1117 patients. M.A. Gentil, I. PavOn, A. Carriazo,
M. Rosado, C. EscandOn, V. Perez Bañasco, M. Ramos DIaz, J.
Lopez, Registro de pacientes renales, Servicio Andaluz de Salud
(Consejerla de Saludy SoS. Junta de AndalucIa)/SociedadAndaluza de
Nefrologla. Based on a regional renal data registry, we studied the
evolution of 845 patients (pat) in hospital HD and 272 pat in CAPD, who
started treatment between 1983 and 1988 in 6 main dialysis units.
Retrospectively, we analyzed the results of survival (SV) with uni and
multivariate procedures (BMDP 1L and 2L). Results: 1) Pat in CAPD
were significantly different because of their greater average age and
higher frequency of diabetes and co-morbidity (cardiovascular, special-
ly). 2) Considering all the pat, CAPD showed worse pat SV (1st, 2nd
year: 91%, 85% vs. 89%, 73%; P = 0.008) and technique SV (89%, 88%
vs. 78%, 62%; P = 0.0000). 3) The comparisons within selected groups
of pat showed:
SV (years)
Ho
N
spital HD
1 2 N
CAPD
1 2 Mantel
Low risk 400 97 93 47 91 91 0,15
>60 yr 170 79 65 107 83 62 0.63
Cardiopathy 90 76 70 54 88 64 0.37
Diabetics 34 75 — 82 91 65 0.27
4) Taking the risk factors as covariates, no significant difference
between the two methods can be shown. Conclusions: Once the
differences between the pat are taken into account, no significant
differences between short-term pat SV on HHD and CAPD are seen.
Nevertheless, the heterogeneity of the groups and the observed trend
during the second year requires further research and study.
Survival analysis of renal transplant from cadaver. Influence of the
patient's and transplant center characteristics. A. Carriazo, M.A. Gentil,
M. Rosado, I. PavOn, G.R. Algarra, F. Tejuca, C. Ascencio, S. Cerezo,
Registro de pacientes renales, Servicio Andaluz de Salad (ConsejerIa
de Saludy SoS. Junta de AndalucIa)/SociedadAndaluza de Nefrologia.
We studied the evolution of 598 renal transplants (RT) from cadavers
that were made between January '84 and June '88, in 7 centers
integrated in a regional program, which used different immunosupres-
sive therapies. Retrospectively, we analyzed the influence on the
patient and graft survival (SV) of different characteristics of the
receptors and of the RT center, with uni- and multivariate analysis
(BMDP IL and 2L). Results: 1) The 1st, 2nd and 3rd year graft SV was
79%, 74% and 69%, and the patient SV was 94%, 93% and 91%,
respectively. The results tended to improve slightly in time: 1986-87
compared to 1984-85: 2nd year patient SV: 95% vs. 91% (P = 0.27);
graft SV: 76% vs. 70% (P = 0.11). 2) Age older than 50 years (2-year SV
84% vs. 95% for the rest), diabetes, HBsAg+, cardiovascular diseases
or previous hepatopathy and long stay in dialysis were associated with
worse patient SV. There were no differences considering sex, other
ethiologic groups or previous dialysis method. Except for diabetes,
none of these factors seemed to significantly influence graft SV. 3)
There are marked differences between centers regarding graft SV (from
68% to 79%, 2-year SV, P = 0.3) and patient SV (from 80% to 99%, P
= 0.002). Although centers with better SV had younger patients, there
were no significant differences in this or other characteristics that could
explain the diversity in the SV results. Conclusions: The patient SV
after transplantation is highly conditionated by his own features regard-
ing age and co-morbidity, but an important center effect also exists (not
significant, though). The graft SV seems to be independent of these
characteristics and a significant difference among centers cannot be
shown either.
Zero net peritoneal ultraffitration (net UF). A desirable aim in CAPD?
Ma C. Miguelez, A. de Paula, A. Rodrigo, A. Molina, SecciOn de
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Nefrologla, Hospital del Rio Hortega, Valladolid, Spain. Net UF can
be manipulated by modifying the volume of infusion, the osmolarity of
the solution or the dwell time, to achieve daily net UFs which permit
the maintenance of patients at a stable dry weight. Moreover, the use of
hyperosmolar solutions has been suggested as one of the factors
potentially implicated in the development of peritoneal membrane
failure. Finally, residual clearance (RCr) seems to remain intact for
longer in CAPD patients. Objective: The maintenance of zero daily net
UF, checking the effect that this produces on diuresis, RCCr, serum
biochemistry and the clinical constants of the patients. MM: 4 patients,
previously stable in CAPD (period A: 5.3 1.2 months) and 4 patients
who started the technique. The dialytic treatment scheme was individ-
ualized for the 8 patients to achieve zero daily net UFs (period B: 4.3
2.1 months). Results:
No. bags
UF Diuresis RCcr
mI/rn
4.25%
month
1.5%
month
2.5%
month
Net
24 hr
Period A
N = 4 30 60 0 —500 800 3.6
Period B
N=8 0 75 15 1400 5.1
Serum biochemistry, weight and TA remained stable after a period of
0.6 months of adjustment to the new scheme. The subjective sensation
of comfort increased as large intraperitoneal volumes were avoided.
Conclusions: 1) By proposing zero daily net UF we obtained a signifi-
cant increase in the volume of diuresis and RCcr. This modification was
maintained over the following months. 2) The reduction of the volume
of hyperosmolar solution in contact with the peritoneum could benefit
its survival as a dialyzing membrane. 3) The clinical and analytical
constants remained stable and the comfort of the patients increased
after the adoption of this therapy. 4) We believe that the application of
the scheme is beneficial to certain patients of CAPD; at the same time
an evolutionary study of RCcr is necessary.
Subcutaneous (SC) treatment of patients with CAPD with recombinant
human erythropoietin (rHu-EPO). Ma C. Miguelez, A. Guerrero, A. de
Paula, A. Rodrigo, A. Molina, Sección de Nefrologla, Hospital del RIo
Hortega, Valladolid, Spain. RHu-EPO has demonstrated its effective-
ness in the treatment of anemia in patients undergoing chronic dialysis.
The fall in the circulant levels of the patient's own hormone gives an
evident physiopathological basis to justify its use. Its administration to
CAPD patients is in the study phase and the optimun dosage, frequency
and form of administration has not yet been determined. Objective:
Administration of rHu-EPO, on a daily basis, to patients with anaemia
in CAPD to evaluate: 1) residual serum erythropoietin levels, modifi-
cation of these levels after exogenous administration of the hormone; 2)
hematocrit level variation; 3) usefulness of SC as a means of adminis-
tration. MM: 10 patients: 6 women and 4 men; average age, 60 were
studied. End-stage renal disease: 7 glomerular and 3 interstitial (3
hemianephric). Residual Ccr: 2.5 nil/mm. RHu-EPO (Eprex® Cilag amp
4000 U) was administered with an insulin syringe through SC at a
weekly dosage of 150 U x kg weight, proportionally distributed every
24 hours. Serum erythropoietin of patients was measured using RIA
before, at 6 and at 12 weeks from the start of treatment. Results: Serum
erythropoietin level: 16 5.2 mU/mI at the start of treatment, 42.1
10.5 mU/mI after 6 weeks (P < 0.001), 34.2 16 mU/mi after 12 weeks
of treatment. Hèmatocrit value: 23.4 1.8% at start; 30.1 3.5 after 6
weeks (P < 0.001), 32.5 2.5% after 12 weeks (3 patients after 4.2 at
50% of dosage. The rest stayed at same dosage; P < 0.01). SC path
complications: none. Conclusions: 1) The residual levels of serum
erythropoietin of the patients with anemia in CAPD were low in relation
to the degree of anemia. After the administration of rHu-EPO through
SC a significant increase of serum levels was noted. After 12 weeks,
independently from a reduction in the rHu-EPO dosage, there was a
significant reduction with respect to previous serum erythropoietin
values. 2) The average increase of hematocrit was approximately 6
points for the first 6 weeks of treatment. This increase initially runs
parallel to the increase in serum erythropoitein level, although it
stabilizes later whilethe latter decreases. 3) SC seems useful and free
from complications for the administration of rHu-EPO in CAPD.
Effect of prednisone withdrawal on red blood cell Na transport and
digoxin-like immunoreactivity in renal allograft receivers. J. Bosch,
Nativadad Hernando, J.J. Plaza, L. Hernando, Santos Casado, f.M.
Lopez-Novoa, Department of Nephrology, FundaciOn Jiménez DIaz-
CSIC, Madrid, Spain. Changes in red blood cells (RBC) Na transport
and endogenous digoxin-like immunoreactivity (EDLI) have been im-
plicated in the adaptations that accompany renal insufficiency and in the
pathogenesis of hypertension (HT). We explored the mechanism of the
increased of Na pump activity after renal allograft. We have studied
the RBC Na transport (Na, K pump activity, cotransport, counter-
transport and passive Na effiux) and plasma levels of EDLI in 10 renal
allograft receiverrs (5 of them HT, creatinine <170 mmol/liter, under-
going treatment with cyclosporine A, prednisone (P), and azathioprine,
and also 30 and 90 days after P withdrawal. A group of 10 controls was
also studied. As compared to controls, P-treated patients showed a
decreased RBC Na concentration and increased Na pump activity
(6.69 vs. 4.99 mi, P < 0.05; and 0.323 vs. 0.571 hr', respectively P <
0.05). They also showed a decrease in the activity of cotransport,
countertransport and passive Na effiux (0.02 vs. 0.005 hr', P < 0.05;
207 vs. 35 zmol/liter, P < 0.05; 0.02 vs. 0.005 hr', respectively P <
0.05). Ninety days after P withdrawal, normotensive and HT patients
showed RBC Na transport system activities and RBC Na concen-
tration similar to those of controls. EDLI was not detected in controls
or in patients. These data suggested that P treatment increased the Na
pump activity, and decreased the RBC Na concentraation, moreover
they induced a decrease in the activity of other RBC Na transport
systems in these patients. Our data do not support the hypothesis that
EDLI modulates the RBC Na pump activity. Neither of these param-
eters seems to be a marker of HT in these patients.
Real possibility for early prediction of prognosis in acute tubular
necrosis (ATN): A contrasted study. F. Liano, A. Gallego, J. Pascual, F.
Garcia Martin, L. Orofino, R. Matesanz, M.T. Naya, J. Ortuflo,
Hospital RamOn y Cajal, Madrid, Spain. The study of prognosis of
ATN has changed over the last decade. Some authors have used two
multiple regression models to evaluate it; however, confirmation of
results with control groups has scarcely been done. In this work we
have prospectively analyzed clinical and demographic characteristics of
228 ATN episodes at the first nephrological evaluation. We used two
multiple regression systems, linear and logistic, which allow an identi-
fication of the effect of the above-mentioned aspects (independent
variables) on mortality (dependent variable). Age, hypotension, as-
sisted respiration, coma, and oliguria showed a statistically significant
influence on mortality. Two equations were obtained to calculate the
probability of death of each patient, and the cut-off point above which
patient's survival was not observed. Furthermore, we confirmed the
value of the equations obtained in two groups of patients: first, 100
consecutive patients with ATN in our hospital (internal validation),
second, 25 patients from another center (external validation). We also
assessed correlation between both methods of multiple regression. This
was excellent (N = 328, r = 0.95, P 0.001), but the use of the linear
method was easier. We have developed and contrasted in two different
control groups an easy punctuation system that allows the statement of
an individual prognosis in ATN patients. We have identified groups of
patients in whom survival prospects are nil.
Analysis of evolution of severity in acute tubular necrosis (ATN) during
11 years using a "severity index". F. Liaño, J. Pascual, A. Gallego, L.
Orte, R. Marcén, C. Quereda, M. Rivera, J. Ortuño, Hospital Ramón
y Cajal, Madrid, Spain. During decades, most of work concerning ATN
has employed a sentence like: "mortality in acute renal failure remains
high probably because of more severe pre-existing disease and agres-
sivity of surgical procedures". However, evolution of severity in ATN
has not been "quantified". During a 11 year period we prospectively
studied 328 ATN patients using a multiple linear regression model
(BMDP). A severity index (SI) was obtained. Correlation between
expected values, outcome or death, and observed ones (r = 0.61, P <
0.001) demonstrated the reliability of this index. Causes of ATN were:
medical 24%, surgical 37%, sepsis 15% and nephrotoxic 24%, with a SI
of 0.61, 0.68, 0.58, and 0.26, respectively. Patients were divided into
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four consecutive periods (A, 65 patients; B, 73; C, 108; D, 82) to
determine if ATN severity was modified by time. Etiological distribu-
tion was similar to the global one in the four periods. SI was 0.52, 0.60,
0.53 and 0.48, respectively, with no statistical differences. When we
redistributed the patients into etiological groups, only nephrotoxic ones
decreased severity, SI significantly decreasing since period C. We
conclude that SI allows a quantification of severity of ATN. Though
global severity during the four studied periods did not change signifi-
cantly, we have appreciated a descendent tendency related to the better
outcome of nephrotoxic ATN.
Comparative study of different methods for measuring blood cyclos-
porin A (CsA) levels in kidney transplantation (TR). J. Sabater, C.Quereda, R. Marcen, L. Orofino, I. Herrera, M.L. Muñoz, J.J.
Villafruela, J. Ortuno, Hospital RamOn y Cajal, Madrid, Spain. Rapid
and accurate measurement of cyclosporin A (CsA) may improve the
efficacy and ameliorate the toxicity of the drug. Our laboratory has
compared the values obtained for whole blood assay of CsA using: a) a
polyclonal antibody-based cyclosporin-RIA kit (PC); b) RIA with two
antisera: specific monoclonal antibody (SM) and nonspecific monoclo-
nal antibody (NSM); and c) the fluorescence polarization immunoassay(FPIA). A total of 500 through blood samples were obtained from
kidney transplant recipients undergoing CsA therapy. Acute tubular
necrosis cases were not considered. We found a good linear correlation
between the results obtained with NSM and FPIA (r = 0.92; P < 0.001)
but correlation was worse when the other techniques were compared.
Correspondence between methods was independent of the evolution
period considered. In the first month, acute rejection was not related to
CsA levels, but CsA nephrotoxicity was strongly associated with CsA
levels over 800 ng/ml using PC or over 1200 ng/ml using FPIA. This
relation was worse when using the other methods. We conclude that
FPIA is an accurate and rapid method for CsA monitoring. CsA levels
are a useful tool for predicting nephrotoxicity but not for diagnosis of
acute rejection in the immediate post-transplant period.
Erythropoietin effect on the physical capacity of hemodialized patients.
J.L. Miguel, F. Ortuño, F. Borrego, J. Muhoz, G. Caparros, B.
Miranda, Nephrology Service, La Paz Hospital, Madrid, Spain. Seven
hemodialyzed patients have been studied regarding their physical
capacity before and after treatment with erythopoietin intravenously
administered after each hemodialysis sesion. Four males and three
females, aged 40.5 15.52 years and under hemodialysis treatment for
118.2 88.41 months were in this study. No one suffered from
miopathy, cardiopathy or severe hypertension. Only 71.4% were mod-
erate hypertensives, but well controlled with medication and remained
well controlled without changing the antihypertensive doses. The study
was performed at the begining (A), and when the Hb reached 10 g% (B).
The effort test was performed 24 to 36 hours after being hemodialized,
following the Bruce protocol in three minute steps without rest between
them, and checking ECU and blood pressure at the last minute in each
step. Effort test checked the behavior in cardiac frequency, blood
pressure and ECG as well as parameters of tolerance and maximum
functional capacity. The test was stopped when intolerance or ECU
alterations was shown. The basal metabolic equivalent (MET) was
defined as 3.5 ml/02/min. In both situations the effort test was well
tolerated except when the Hb and Hto increased (Hb 7.6 0.5 to 10.6
0.62 g% and Hto 23.5 2.09 to 32.5 2.02%, P < 0.001). The results
were significantly better during effort times (4.2 1.6 to 7.17 2.22
mm) as well as the step exercise (1.57 0.53 to 2,71 0.95). Arhythmia
appeared in A in only one patient, and the most frequent reason for
stopping the test was muscular fatigue 57% and dysnea 28% in B. No
was changes in cardiac frequency but the blood pressure increased in B
for the steps II, III and IV (P < 0.05). The 02 burned increased in B:
1141.5 353.5; 1687 487 (P < 0.05). The functional capacity
improved as expressed in aerobic reserve 62.6 18.3 to 87.3 16%, as
well in limit functional capacity, 5.28 1.45, 8.0 2.17 mets (both P <
0.05). All (100%) in A had a very low capacity versus 71% mean
functional capacity in phase B. We have found significant correlations(r = 0.91, P < 0.001) between Hb and the effort tests studied. We
concluded that treatment with EPO very clearly and early improves the
capacity for physical effort in hemodialized patients, and it relates with
the increase in Hb levels, and probably with better tissue oxygenation.
Quality of life improves in LID patients treated with rH-EPO. J.L.
Miguel, F. Borrego, J. Munoz, K.L. Revuelta, A. Sanz, Nephtology
Service, La Paz Hospital, Madrid, Spain. With the advancement of
rH-EPO, new perspectives have been opened to the treatment of
end-stage renal disease. Restoration of anemia determines a better
quality of life as individual and social rehabilitation. There are not many
studies referring treatment consequences on these aspects, and few
about the patients' own feeling. Thirteen patients on HD under iv.
rH-EPO treatment were asked about the following aspects once they
had a Hb value greater than 10.5 g/dl. The evaluated matters were: a)
subjective evaluation of fitness; b) quality of life degree by the Kar-
novsky scale; c) presence of uremic or HD related symptoms; d)
physical exercise capacity and social activity; e) sexual aspects. These
observations are completed with a test to the family with similar
evaluation, asking patients and family about treatment effectiveness.
Results are in general according with clinical evaluation made by the
physician. Of the patients, 60% improved markedly and 92% of the
patients felt much more fit. Of the patients, 46% thought that their
quality of life had improved, arranging a higher step on the used scale,
and 44% of the cases had a more active sexual life and better sexual
relations when compared to before treatment. In general HD is better
tolerated with less hypotension and angoroid episodes. Family ques-
tionairs checked out the same opinions, and referred to patients getting
a more comfortable family and social environment in 20 to 70% of the
cases. It is surprising how 70% of the patients prefer a greater
improvement on the questions evaluated than expected. Families think
that results have been good or very good in 70 and 23% of the cases,
respectively. This study data, using clinical and biochemical parame-
ters, proves the ulility of rH-EPO in ESRD patients.
Treatment of anemia of hemodialysis patients with r-HuEPO. Results
in a non-selected population. F. Borrego, J.L. Miguel, A. Zamorano, J.
Muñoz, J. M-Ara, L. Sanchez Sicilia, S. Nefrologia y S. Bioquimica,
Hospital La Paz, Madrid, Spain. Treatment with r-HuEPO was evalu-
ated in sixteen patients in ESRD, eleven male and five female with an
age range of 21 to 60 years (mean 38.2 14.1), who had been on
hemodialysis treatment (15 patients) or hemofiltration (1 patient) for
77.4 60.9 months, and had a hemoglobin level below 9.0 g/dl and
serum ferritin above 80 ng/ml. Three patients were diabetic and two
anephric. Evidence of clinical and/or biochemichal hyperparathyroid-
ism was present in 37.5% of the group. High blood pressure was present
in fifteen patients needing continuous administration of 1 to 3 drugs to
be controlled. Ten patients had received more than three units of blood
during the last year (4.3 8, range 1 to 11 units in the previous 4 months
of the onset of the treatment), and five were not transfused during the
same period. One single patient with rectal prolapse had recurrent
rectal bleeding. r-HuEPO (50 Jkg body wt) was administered i.v. at the
end of each hemodialysis for a three weeek period, and the initial dose
was increased by 25 j.z/kg every three week period until a hemoglobin
level of 10 to 12 g/dl was reached. Treatment time ranged 2 to 6 months
(mean 2.96 1.43). Weekly controls included Hb, Hct, RBC, WBC and
platelets counts, and every month reticulocyte count, haptoglobin, folic
acid, vitamin B12, serum iron, ferritin, transferrin, urea, creatinine, uric
acid, calcium, phosphate, sodium, potassium, bilirrubin, transami-
nases, glucose, serum protein and albumin. Body temperature and
blood pressure were checked with every dose of r-HuEPO administered
and any side effect noted was properly recorded. Results: All patients
showed improvement of anemia from Hb 7.64 0.76 and Hct 23.9
2.2, to Hb 10.6 1.8 and Hct 32.6 6.04 (P <0.001), with a r-HuEPO
maintenance dose ranging 37.4 to 450 Jkg/week (mean 267.4 110.6).
Five patients developed Hb levels above 12 gIdl at a certain moment of
treatment. Reticulocyte count, reticulocyte count corrected by RBC
count and RBC count gradually increased up to the second treatment
month and then leveled. No change was observed on the WBC or
platelet counts. Serum iron and ferritin decreased and three patients
received oral iron therapy. Non-significant decrease of serum folic acid
and vitamin Bl2 was recorded. Increase of uric acid, potassium and
phosphate almost reaching significance was observed, but no changes in
dialysis therapy were implemented. Fever occurred in three patients
during the first days of r-HuEPO administration. Five patients needed
the antihypertensive therapy to be increased, and one developed
encephalopathy with convulsions, even if r-HuEOP had been discon-
tinued ten days before, and in coincidence with a Hb level of 13.5 g/dl.
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Three more patients complained of myalgias coinciding with the highest
hemoglobin levels. In conclusion, this study can confirm the efficacy of
r-HuEPO in the correction of anemia of ESRD with minimal side
effects. All patients increased hemoglobin to the target level marked by
the study design but with broad differences in the amount of r-HuEPO
needed in each individual patient.
Variation of erythrocytic age-related compounds after treatment with
erythropoietin of hemodialyzed patients. J.L. Miguel, C. Solis, F.
Borrego, R. Selgas, A. Hernanz, M.A. Baio, J. Muñoz, Nephrology
Service and Hemolysis Unit, La Paz Hospital, Madrid, Spain, The
erythrocyte has some components whose concentration decreases as
the cell ages, due to its limited biosynthetic capacity. They are closely
related to the erythrocyte age, because they are higher in young red cell
populations. The present study analyzes the variation of some of these
compounds after treatment with erythropoietin (EPO) of chronically
dialyzed patients. A total of 39 patients were studied, 16 of them under
erythropoietin i.v. therapy during 3 months, with increasing doses until
they had hemoglobin levels (Hb) close to 11 g/dl. Control data was
obtained from 39 age- and sex-matched normals. Routine hematological
data were obtained periodically. Every 2 weeks we measured creatine
(CR), glutamic oxalacetic transaminase (GOT) and hexoquinase (HK)
in the red cells of the treated patients. CR was estimated by our own
colorimetric method, GOT and HK according to Beutler. Before EPO
treatment, the values of reticulocytes (RT), CR, GOT and HK were
significantly higher in the patients than in control group, with P < 0.001
for CR and HK, P < 0.01 for GOT and P < 0.02 for RT. After treatment
of the patients group there was a significant increase of RT, P < 0.05 in
the second week. The elevation persist until the second month. CR
increased significantly, P < 0.05, also in the 2 week, and the elevation
lasted until the third month. The enzymes studied were less sensitive.
GOT increased significantly, P < 0.1, in the 6th week and HK in the 6th
week and third month, being P < 0.01 and 0.05, respectively. We
conclude that the differences between the baseline values of the patients
and the control group are probably due to the mild hemolysis that the
former have. The increase of CR after treatment is as sensitive as the
estimation of RT, being on the other hand more persistent. Both CR and
RT increase before Hb elevation.
Carpal tunnel syndrome (CTS) in CAPD patients: A multicenter study.
K. L-Revuelta, R. Bosch, R. Acebal, U. Blum, M. Casares, F. Coronel,
A. Cruz, H. Dia, A. Fidalgo, C. P-Conde, V. P-Diaz, A. R-Carmona, R.
Selgas, Grupa CAPD, Centro, Spain. CTS is a frequent complication of
HD where the prevalence is related to the duration of treatment.
Amyloid deposits of f3m have been found as responsible in many cases.
The real incidence and implicated pathogenic mechanisms in CAPD are
not defined. We have studied 109 patients exclusively treated with
CAPD for at least 3 years, 33 diabetic excluding those with other
predisposing CTS causes. The diagnosis of CTS was made by EMG in
10. No differences were found in age, duration of treatment, original
disease and plasmatic levels of fm between patients with and without
CTS. We analyzed affected patients, excluding 2 diabetic and I patient
lost. Four new patients were added because of CTS detection in earlier
stages. The final group consisted of 11 patients, aged 66.3 8, on
CAPD 39 19 months. RX examinations of skeleton were evaluated by
2 different observers. Biochemical determinations consisted of urea,
creatinine, Ca, P, PTH, ferritin and uric acid. The indicence of
peritonitis and UF capacity were also researched. CTS appeared at 29
19 months, being first detected in 81% of the patients by EMG; 50%
of them presented symptoms once along the follow-up, never requiring
surgical treatment. Whenever bilateral EMG examination was per-
formed, it disclosed positive features. The moment of appearance was
earlier in asymptomatic than in symptomatic cases (17 vs. 35 months)
and had statistical correlation with the CAPD duration. No relationship
was found between CTS and biochemical parameters, incidence of
peritonitis, diuresis and UF capacity. In 50% of the affected patients
bone cysts mainly in carpus were found, keeping no correlation with
duration of treatment, moment of CTS appearance either with the rest
of parameters studied. In summary, we think that CTS is not rare in
CAPD, it is bilateral and sometimes appears early in the evolution.
Early detection is possible by EMG before the presence of clinical
manifestations. The coexistence of lytic lessions recognized as diagnos-
tic of amyloid arthropathy suggests the same etiology for both pro-
cesses at least in 50% of the cases.
Arterial calcifications in diabetic patients on CAPD. J.C. Rodriguez,
N. Vega, A. Torres, C. Plaza, V. Lorenzo, A. Fernandez, L. Hortal, L.
Palop, Servicio de Nefrologia, Hospital Ntra. Sra. del Pino y Hospital
Universitario de Tenerfe, Las Palmas de G.C., Spain. The etiology of
arterial calcification (AC) in diabetic patients with uremia continues to
be a controversial theme, involving discussions on the various roles
played by age, atheromatosis, diabetic neuropathy, renal osteodystro-
phy, vitamin D treatment and hypomagnesemia. We analyzed the
incidence, progression and regression of AC in 26 diabetic patients
(mean age: 51.5 12.7) and with a mean duration time of diabetes of
17.3 5.4 years. They only had been included in CAPD treatment for
12 to 84 months. They were randomized for 1 alfa calcidiol (0.5 iJday).
All patients had a Rx metabolic bone survey, motor and sensitive nerve
conduction velocities, and bone histomorphometry including aluminon
stain (7/26). Initial studies were made in the month prior to admittance
and the final one in Dec. 88. AC was classified (AC-I: small vessels; II:
medium vessels; HI: large vessels). Initial and after a CAPD period of
34.1 17.2 months were : AC-I: 30.7% to 42.3% (P < 0.001); AC-Il:
34.6% to 53.8% (P < 0.001); AC-Ill: 61.5% to 80.7% (P = NS). AC-Ill
were more frequent in older people (P < 0.01). Motor and sensory
nerve conduction did not have any relation with AC and showed no
evidence of progression with CAPD time, All patients with 2 bone
biopsies had mild forms with Al(—) in their first study. After CAPD
treatment 5 patients remained as mild, 1 developed an osteomalacia and
1 a mixed form, both with Al(+). There was no correlation between AC
and morphometric parameters and treatment with 1 alfa calcidiol. In
conclusion, AC in diabetic patients with ESRD are: a) a frequent
complication after dialysis treatment including CAPD. b) AC-Ill are
exclusively age related. c) AC has not any relationship with secondary
hyperparathyroidism, vitamin D treatment or peripheral neuropathy. d)
Hypomagnesemia? or a consequence of a sumation of various risk
factors?
Characterization of the inflammatory infiltrate in tubulointerstitial
nephritis induced by drugs (TINID). J. Pascual, F. Liaño, F. Mampaso,
C. Bellas, T. Bricio, V. Urena, J. Ortuno, Hospital Ramón y Cajal,
Madrid, Spain. Tubulointerstitial nephritis induced by drugs is being
recognized with increasing frequency associated to an ever-expanding
number of pharmacological agents. While pathogenesis remains contro-
versial, some authors have related this process to cellular immunolog-
ical mechanisms. We have studied 24 patients with TINID, 16 male, age
50 21 years (range 8 to 79). Of them 10 had associated glomerulop-
athy, in 5 previously known, On conventional microscopy all patients
showed diffuse (74%) or focal (26%) infiltrates of lymphocytes and
plasmatic cells, and a number of tubular alterations. Neutrophils (87%),
eosinophils (57%) giant cells (8%), granulomata (8%) or fibrotic areas
(17%) were observed. We characterized interstitial cell infiltrates using
a panel of specific monoclonal antibodies. A quantitative counting
technique was done by determining the percentage of positive labelled
cells in 15 randomly chosen areas of infiltrate. We observed that Pan
T+ cells (total T cells) were, in all cases the most numerous interstitial
cell population (70 to 96, x = 85 9). Analysis of T cell subsets showed
an OKT8+ cell predominance in the majority of cases with a history of
antibiotic administration (62 to 90, x 76 5). In the remaining
patients receiving a heterogeneous treatment (diuretics, anticholin-
ergics, antipiretics, etc.), the predominant T cell subset was Leu3a+
cells (helper T cells). In 16 cases epithelial expression of class II or DR
antigens was demonstrated. Our results support the idea that cell-
mediated immunity may be implicated in TINID imfiammatory reac-
tion.
Hemodynamic effects of erythropoietin treatment. J. Pascual, J.L.
Teruel, M. Jiménez, M. Rivera, F. Liaflo, M.T. Naya, J. Martinez, J.
Ortuño, Nephrology and Cardiology Departments, Hospital Ramón y
Cajal, Madrid, Spain. Patients with renal failure on hemodialysis (HD)
present a hyperdynamic circulatory state with greatly increased cardiac
output attributed to anemia, chronic volume overload and arteriove-
nous fistula. In this work we have assessed contribution of anemia to
cardiac hemodynamics. Cardiac output (CO) was calculated by contin-
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uous wave Doppler echocardiography (CWDE), which has achieved
good reproductibility in our laboratory. We studied 10 patients (aged 17
to 53 years) treated with HD who started treatment with erythropoietin
(EPO; 50 U/kg). CWDE was performed just before treatment (ti) and
after 2 months (t2). Results were compared with those from a control
group of 15 individuals matched for sex and age (C). We have assessed
hematocrit (He), heart rate (HR), integrated flow velocity (IFV),
cross-sectional aortic area (A) and CO:
He HR WV A CO
C — 72 12 0.19 0.24 3.8 0.6 5.39 0.38
P 0.05 0.001 0.001
tl 18.8 2 80 17 0.25 0.05 4.4 1 8.68 1.79
P 0.01 0.01 0.01
t2 29,5 4 76 20 0.20 0.05 4.4 1 6.40 1.22
We conclude that severe anemia is the main cause of elevated CO in
patients on HD. Improvement of anemia with EPO significantly de-
creases CO to levels similar to controls.
Lupus anticoagulant and vascular thrombosis in kidney transplanta-
tion. J. Pascual, R. Marcén, C. Quereda, F. Mampaso, A. Pardo, L.
Orofino, J.L. Teruel, J. Ortuño, Hospital Ramón y Cajal, Madrid,
Spain. Lupus anticoagulant (LA), immunoglobulins IgG, 1gM or mixed,
has been reported in different clinical situations associated to arterial or
venous thrombosis. Previously we have described a 30% incidence of
LA positive (LA+) in our hemodialysis patients. In the last 4 years, 13
of these LA+ patients received a renal allograft (16 transplants). Ten
grafts had good renal function within 6 to 46 months and 6 were lost.
Three patients experienced renal artery thrombosis (RAT) within the
first weeks after transplantation, one of them in two different grafts. In
one living donor recipient RAT was associated with hyperacute rejec-
tion, and another patient developed renal vein thrombosis at 19 months.
Two more patients with RAT in 2 consecutive transplants, who had not
been previously studied for LA, were found to be LA+. Histological
examination of biopsies or nephrectomies showed glomerular thrombo-
sis in 7 out of 12 speciments studied. LA remained positive in the 9
patients with functioning graft tested. RAT was observed in one out of
14 LA negative transplant recipients and in only 5 out of the 290
recipients who completed our series (P < 0.001). Immunosuppression
consisted on azathioprine and prednisone in 5 cases (2 successful) and
cyclosporine (CsA) plus prednisone in 11 cases (8 successful). Our
results suggest that LA constitutes a thrombotic risk factor in renal
transplantation. We do not have definitive data concerning the possible
effects of CsA in these patients. As this is a retrospective study, further
investigations are needed to elucidate clinical significance of LA in
renal transplantation.
When the third drug should be added in kidney transplantation? J.
Pascual, R. Marcén, C. Quereda, L. Orofino, L. One, F. Liano, M.T.
Naya, J. Ortuño, Hospital Ramón y Cajal, Madrid, Spain. Systematic
association of azathiprine to cyclosporin A (CsA) steroids seems to
ameliorate undesirable side effects but is not risk-free. However,
selective addition could be of benefit. Aza was added to 25 out of 128
transplant patients undergoing CsA steroids (19.5%) in 4 different
situations: chronic rejection (N = 10), severe or repeated acute rejec-
tion episodes (N = 5), CsA toxicity (N = 7) or anticonvulsivant therapy(N = 2). Rejection and nephrotoxicity were biopsy-proven in 83% of
cases. Time to initiation of Aza from transplantation was Ito 32 months
(mean 10.3 8.1), mean creatinine was 2.9 0.9 mg/dl and follow-up
was I to 18 months (mean 10.3 6.7). Aza was unsuccessful in 2
patients who returned to dialysis within 2 and 3 months. Three patients
with repeated rejection episodes suffered renal function impairment,
but their grafts were still functioning after 12 months. Renal function
improved in 15 patients (60%) (Cr 2.7 0.6 vs. 2.1 0.6 mg/dl, P <
0.02), CsA dosage could be reduced with Aza addition (4.8 2.3 vs. 3.5
+ 1.6 mg/kg/day). Only one patient had a severe infection episode
during follow-up. Our results support that delayed addition of Aza to
CsA-steroids ameliorates CsA toxicity and chronic rejection without
significant morbidity.
Buffer as a cause of hypoxemia: Effect of the infusion of different
buffers in the interdialytic period. J.A. Herrero, F. Tornero, J. Torrente,
M. Macia, P. Naranjo, P. Olivan, A. Barrientos, Serv. Nefrologia, H.
Universitario San Carlos, Madrid, Spain. The influence of acetate
metabolism in hemodialysis (HD) hypoxemia is controversial. To
obviate HD factors we analyzed the effect of the infusion of different
buffers over gasometric and acid-base values during interHD period. In
8 stable patients we administered sodium acetate (AC), sodium bicar-
bonate (BC), and sodium chloride (SC) (control group), in a I molar
solution. These solutions were administered two hours before the
second dialysis of the week, using the opposite arm of arterio-venous
fistula (AVF). The infusion rate was 60 minutes at the maximun acetate
metabolizing rate (3.5 mmol/kg/hr). We measured pH, PCO2, P02,
HCO3 and acetate level in a blood sample of the AVF taken at 0, 60 and
90 minutes. There was no significant difference between basal values.
The SC solution did not cause any change of these parameters. At 60
mm the AC solution caused a decrease of P02 level (84.4 7.9vs. 67.3
8.8mm Hg, P < 0.01), and an increase of PCO2 (32.8 2.2 vs. 39.1
3.9 mm Hg, P < 0.01), HCO3 (20.6 1.8 vs. 29.5 2.6 mmol/liter,P < 0.001), and pH (7.40 0.02 vs. 7.48 0.03, P < 0.001). These
variations persisted at 90 mm without any significant change. The AC
level at 60 mm increased (0.58 0.21 vs. 1.87 0.44 mmollliter, P <
0.01), and at 90 mm decreased to the basal levels. With BC solution at
60 mm there was a P02 decrease (83.2 9 vs. 66.8 9.3 mm Hg, P <
0.01), and an increase of PCO2 (32.4 2 vs. 37.4 3.7 mm Hg, P <
0.01) HCO3 (20.2 3.1 vs. 30.8 2.9mmHg, P <0.001), and pH (7.39
0.04 vs. 7.52 0.04, P < 0.001). These values persisted at 90 mm.
There was no significant difference between BC and AC at 60 and 90
mm. We conclude that AC solution causes the same degree of hypox-
emia as the BC solution, in spite of its maximum metabolizing rate (Km
of AC 0.7 mmol). Acetate does not seem to be a direct cause of
hypoxemia, taking into account its metabolism.
Urea kinetics in patients on regular dialysis after treatment with
recombinant erythropoietin (EPO). M. Rivera, J.L. Teruel, R. Marcen,
J. Pascual, M.T. Naya, F. Liaño, J. Ontuflo, Hospital Ramón y Cajal,
Madrid, Spain. Treatment of the anemia of patients on regular dialysis
with EPO may result in a state of well-being, with an improved physical
fitness and appetite, with consequently a higher protein intake, so it
may be necessary to increase their dialysis schedule. We studied urea
kinetics in 8 stable patients (2 males and 6 females) with a mean age of
42 12 years (range 23 to 58 years) on regular dialysis for 9 and 134
months. The starting dose of EPO was 50 lU/kg/post-dialysis. Dialysis
schedule was kept constant during the study period. The following
parameters were calculated: mean urea (mgldl), urea generation (mgi
mm), protein catabolic rate (PCR: glday) and KT/V before treatment
with EPO (basal), the first month (T1) and the second month (T2) after
treatment with EPO.
Mean
Hb g/dl urea Gu PCR KT/V
Basal 6.2 0.6 117 18 5.4 1.2 60.1 13.1 0.97 0.17
T1 7.5 0.9 129 19 5.9 1.5 63.9 14.5 0.95 0.25
T2 8.8 1 128 16 6.1 1.2 65 13.2 0.99 0.17
With the exception of KT/V, the rest of the parameters in T1 and T2
were significant with respect to basal time (Student's t-test). Conclu-
sions: Mean urea increases soon after the begining the treatment with
EPO and with minimal increases of hemoglobin. Urea increase is due to
a higher protein intake by the patients since dialysis efficiency does not
change. We think that a reduction of protein intake can be necessary in
selected patients.
Cyclophosphamide (CY) bolus in lupus nephrltis type IV. Results at six
months of treatment. M. Vailés, J.L. Tovar, J. Ordi, J. Bosch, L. Piera,
Nephrology Service, and Internal Medicine Service, Hospital General
Vail d'Hebron, Barcelona, Spain. Eight patients with severe lupus
nephritis type IV (OMS), ( age: 23 yrs, 5 female) treated with monthly
CY bolus and rapid steroid tapering were followed for more than six
months (6 to 18 months). All patients initially received 6 monthly doses
of 0.5-0.7 g/m2 EV. Clinical nephritis began after i: 15.6 months of
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systemic disease. At initial biopsy 100% had extrarenal lupus activity,
3 were hypertensive, 5 were nephrotic syndrome, all had active urinary
sediment. Initial biopsy showed DPLN in all cases. Mean activity index
was 12/24, mean chronicity index (CI) was 2/12. Data at biopsy and at
6 months are:
Proteinuria> 3 g/day
Plasma creatinine > 1.5 mg/dl
Biopsy
5
3
6 month
0
0
All patients were serologically and clinically inactive at 6 months. Side
effects during the first 6 months of treatment included Herpes zoster (2),
significant alopecia (1), transitory menstrual disorders (2), nausea and
vomiting (5). Severe leukopema, infection or hemorrhagic cystitis were
not seen. Improvement of the serological monitoring, reduction of
proteinuria and improvement of the renal function were seen in most
patients. Treatment was well tolerated and virtually free of side effects.
The total prednisone and CY dosages were found lower than when
using oral regimes. These results suggests that CY bolus produces a
rapid improvement in severe lupus nephritis, allowing shorter steroid
treatment times and reducing the total doses of steroid and CY.
First Galician census of dialysis and transplant patients. Analysis of the
population with terminal renal failure disease through substitute treat-
ment. F. Valdes Canedo, L. Gonzalez, D. Sanchez Guisande, A. Otero,
R. Ranero, L. Vidal, R. Criado, V. Arcocha, A. Cimadevila, M. Perez
Fontan, J. Moncalian, Study Group of Terminal Renal Failure and
Nephrology Department, Hospital Juan Canalejo, La Coruña, Spain.
We present the data obtained from the First Galician Census of Dialysis
and Transplant. In 1988, a total of 126 patients were incorporated with
a 47.76 per million incidence rate, showing regional variations from
56.80 for Lugo to 16.30 for Orense. The total number of patients was
858 with a 302.26 per million prevalence rate, and also with provincial
differences such as 346 for Lugo and 266 and 279 for Orense and
Pontevedra, respectively. The mean entry age was 49, in contrast with
the one of the whole of the registered patients, which was 51. At age
intervals, we observed a slight prevalence of patients under 14 (1.28%)
and a shift to groups of advanced years (>60) with 26% of the total and
32% of the new patients. Within the analysis of the basic disease with no
connected nephropathy (16.2%), GNC (19.88%), NIC (19.5%), APKD
(12.9%), Nephroangiosclerosis (11.5%) and Diabetes (5.9%); the in-
crease of incidence of this latter showed up in 1988 with 15.87% of the
total of new patients. By therapeutic specialties, the patients were
distributed as follows: <14 years old, HH 50% and transplant 50%; 15
to 29, HH 50.4%, TR 42.8%, HD 3.8% and CAPD 2.8%; 30 to 44, HH
50.7%, TR 40.7% HD 2.5% and CAPD 6.03%; 45 to 59, HH 70.02%, TR
23.7%, HD 1.6% and CAPD 4.3%; 60 to 74, HH 89.1% TR 4% and
CAPD 6.3%; >75, HH 84% and CAPD 16.%. Initially, the treatment
offered was basically hemodialysis at hospital or at centers, except for
the province of La Coruna with 25% of new patients incorporated with
CAPD, all of them at the hospital Juan Canalejo. A total of 60 cadaveric
transplants and 2 from living donors, have been performed, 41 of them
with CsA and the rest with Pred+Aza. The results for this program of
global transplants are 97% for survival patients and 80% for graft
survival after 12 months. All the removed organs have been trans-
planted within Galicia and none has been received from outside. The
waiting list of transplant was of 347 patients, representing a 52% of all
registered patients. In 1988, the waiting time for transplantation was 5.5
years. There has been no case of hepatitis B among the patients or staff.
There are 25 patients with Antig-HB(+) who are dialyzing separately
and also 6 patients with antibodies VIH without clinical manifestations.
Factors involved in the evolution of chronic renal failure in adult
polycystic kidney disease (APKD). E. Gallego, J.M. Lopez Gomez, R.
Jofre, F. Gomez Campdera, F. AhUado, F. Valderrabano, Hospital
General 'Gre gorio Maranon", Madrid, Spain. APKD accounts for
approximately 10% of patients undergoing dialysis in the last ten years.
To assess the clinical characteristics and the factors involved in the
progression to end-stage renal disease, we studied 73 patients with
APKD. Clinical data, family history, associated cystic abnormalities,
age of dialysis onset and the progression of renal dysfunction as the
reciprocal of plasmatic creatinine concentracion versus time were
studied. The 56.2% of patients were male. Of these cases 87% had
known family antecedents. Hypertension was present in 74.6% without
significant sex differences. Nephrolithiasis, hematuria and urinary tract
infections were present at some stage in 25.4%, 58.2% and 39.4%,
respectively. The prevalence of liver cysts in the group in which
abdominal echography was done was 84.3%. Hemodialysis was re-
quired in 61.6% of the cases. This figure represents the 10.2% of the
total hemodialysis patients number. The mean onset age was 48.5 9.2,
being higher in females than in males (53.0 vs. 45.6 years). The slope of
the renal function lost was 0.0109 dllmg/month, showing no significant
dependence on sex, hypertension, family history or extrarenal involve-
ment. We conclude that the incidence of dialysis onset in patients
suffering APKD has not been modified in the last 20 years. The rate of
renal function lost has not changed according to the studied clinical
data. Females undergo dialysis later than males because of later renal
failure onset and not because of a different severity of the disease.
Acute renal failure after cardiac surgery. E. Gallego, S.G. de Vinuesa,
F. Ahjado, J. Luflo, A. Galan, F. Valderrabano, F. de Diego, R.
Arcas, Hospital General "Gregorio Maranon", Madrid, Spain. Risk
factors and prognostic indicators of acute renal failure in patients
undergoing cardiac surgery were analyzed. There were 497 consecutive
interventions during a year. Types of surgery were: coronary artery
bypass (277 patients), valve replacement (195 patients) or both (3
patients), heart transplantation (8 patients) and others (14 patients).
Twenty-one patients (4.2%) developed ARF. There were no differences
about sex or age between patients who developed ARF and those who
did not. The rejection fractions previous to surgery were inferior in
patients who developed ARF (52.3 13,5 vs. 40.2 17.2, P < 0.05),
and aortic cross-clamp time was superior. Six patients (28,5%) with
ARF had previous mild renal insufficiency, being functional in 4 of
them. All patients with ARF suffered hypotension in the postoperative
period and received vasoactive drugs. Five patients (23.8%) were
diabetic, one with overt nephropathy. Nephrotoxic antibiotics, with
serum levels kept under toxic levels were administered to 8 of them.
The greatest incidence of renal failure appeared in heart transplant
patients (50%), in patients with valve pathology (6.6%, always with
multiple valve replacement or previous cardiac surgery) and only 0.36%
in patients with coronary bypass. Only 48% of ARF required peritoneal
dialysis and 8 died (38%). There were no differences in rejection
fraction or renal function between survivors and nonsurvivors. The
mean incidence of complications per patient (respiratory failure, DIC,
central neurologic damage, bleeding, hemolysis, jaundice, rabdomioly-
sis, hepatic citolysis, bacteriemia, and lung infection) was 7.4 in
nonsurvivors and 3.1 in survivors. Our results suggest that clinical and
hemodynamic situation previous to surgery is the main risk factor of
ARF, which is greater in heart transplantation and valve replacement in
patients with previous abnormal rejection fraction and renal dysfunc-
tion. Long aortic cross-clamp time, diabetes and treatment with neph-
rotoxic antibiotics were also risk factors. This kind of ARF has a greater
mortality than the average, and correlates with the number of postop-
erative complications, independent of the preoperative situation.
Pathogenesis of sodium and water retention in severe nephrotic syn-
drome (NS): Hypovolemia versus intrarenal mechanisms. R. Perez-
Garcia, A. Galan, J.M. Lopez-Gomez, R. Jofre, J. Luño, F. Valderra-
bano, Servicio de Nefrologia, Hospital General Gregorio Maraflon,
Madrid, Spain. In earlier years, sodium and water reabsorption in
patients with NS was considered to be increased because of hypovole-
mia secondary to diminished plasma colloid-osmotic pressure (COP).
Recently, an alternate hypothesis has been advanced, namely, that
renal sodium retention is primary and is the consequence of intrarenal
mechanisms. To evaluate the relative relevance of both hypotheses, 18
patients with severe NS of different etiologies were studied. Ten males
and 8 females, 45 21 (mean SD) years old (age range: 19 to 72),
plasma albumin 1.33 0.62 g/dl, plasma creatinine 1.1 0.37 mg/dl,
proteinuria 15 14 g/day were hospitalized. After 4 days on a diet
containing 40 to 50 inEq of Na, with no treatment, 13 patients gained
weight, 4 lost and I remained stable. A significant correlation was found
between cumulative body weight change (N = 18) and COP r = 0.62,
recumbant plasma renin activity (PRA) r = 0.67, plasma aldosterone
(Aldo) r 0.7, and UNaV r = 0.77. Mean measured COP, 8.4 2.5 mm
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Hg (N = 18), was related to plasma albumin r = 0.9, total protein r =
0.7, and predicted COP (Landis-Papenheimer method) r = 0.97. Pre-
dicted COP overestimated measured COP at very low albumin concen-
trations. There was a significant correlation between basal COP and
PRA r =
—0.76, Aldo r = —0.76, Free water clearance r = 0.75, and
fractional excretion of Na r = 0.69. After 2 hours in the orthostatic
position, PRA and COP increased and blood pressure decreased.
Orthostatic hypotension was present in 10 out of 18 patients those with
a lesser COP level (6.6 0.73, N = 10, vs. 10.7 2, N = 8 mm Hg, P
< 0.001). There was a significant correlation between the degree of
increasing in UNaV secondary to furosemide and basal COP. In 2
patients we followed renal function through prednisone-induced recov-
ery from minimal lesion NS. The increase in natriuresis xlO and GFR
20% and the decrease in protein excretion and PRA were accompanied
by a minimal increase in COP (1.1 mm Hg). Sodium retention of NS can
not be attributed solely to intrarenal mechanisms; our data suggest a
major role of "effective hypovolemia" when COP is lower than 8 mm
Hg.
Normal morphology of urinary erythrocytes in segmental necrotizing
glomerulitis. A. Serra, P. Turguet, E. Abad, F. Milid, J. Bonal, J.
Bonet, R. Lauzurica, J. Teixido, R. Romero, A. Caraips, Hospital de
Badalona "Germans Trias i Pujol", Barcelona, Spain. The study of the
morphology of urinary erythrocytes (E) is a useful method in the
differential diagnosis of the glomerular and non-glomerular origin of
hematuria. Dysmorphic erythrocytes are observed in glomerular dis-
eases, while they are normal in urologic diseases. Preliminary observa-
tions show that in segmental necrotizing glomerulitis, urinary erythro-
cytes can be normal. In a 48-month period the morphology of urinary
erythrocytes was analyzed with light optical microscopy in 3 groups of
patients with glomerulonephritis: segmental necrotizing glomerulitis
(SNG), IgA nephritis (IgA) and other types of glomerulonephritis
(OTHER). Hematuria was more important in the GSN patients than in
the other 2 groups.
Results IgA SNG Others
No patients
Mean age
NormalE
Dismorphic E %
Creat. .unol/liter
1137 9
1/11b52 25
129b
10
60 17
8/10b5 15b
734b
12
44 19
1/12
57 22
151
a p <0.01; b p <0.001
We conclude that the morphology of urinary erythrocytes in SNG,
despite this being a glomerular disease, is normal. This could be due to
severe disruption of the glomerular basement membrane and important
leak of erythrocytes to the urinary space.
Re-evaluation of prognosis of adult polycystic kidney disease (APKD).
Analysis of 107 patients. A. Gonzalo, M. Rivera, C. Quereda, L. One,
J. Ortuno, Servicio de Nefrologla, Hospital Ramón y Cajal, Madrid,
Spain. To appraise the prognosis of APKD, 107 patients (58 male and 49
female) were studied retrospectively. Diagnosis was confirmed by
excretory urography and/or ultrasonography. The mean age at the time
of diagnosis was 45.9 14 years (range 18 to 83 yr). A total of 98
patients had symptomatic APKD. At diagnosis 30 of these patients had
normal renal function (NRF) and 68 presented with chronic renal failure
(CRF, serum Cr> 1.5 mgldl). Nine of the 107 patients were asympto-
matic. Hypertension was present in 51% of the symptomatic patients as
initial manifestation and in 46% of these patients with NRF. Forty of the
107 patients (37%) went into end-stage renal disease (ESRD) at a mean
age of 52.7 9.9 years (range 26 to 75 yr). The probability of either
developing CRF and ESRD (requiring dialysis or transplantation) was
estimated using a time-to-event analysis. All patients had been at risk
for CRF and ESRD since birth. The probability of being alive and not
having ESRD was 74% by age 50, 51% by age 58 and 37% by age 70.
There was no significant difference between the time-to-event curves
for males and females: 75% and 72% respectively by age 50. Neither
was there any significant difference between the time-to-event curves
for hypertensive and normotensive patients: 77% and 67%, respectively
by age 50. The probability of being alive and not having CRF was 46%
by age 50. Thus, the prognosis for patients with APKD is better than
most reports suggested some years ago. The effect of risk factors in this
disease needs further investigation.
Presymptomatic diagnosis of adult polycystic kidney disease (APKD)
with DNA markers. A. Gonzalo, F. Moreno, M. Rivera, C. Quereda, L.
Orofino, J. Ortuño, Servicio de Nefrologla y Unidad de Genética
Molecular, Hospital Ramón y Cajal, Madrid, Spain. APKD is a genetic
disorder transmitted as an autosomal dominant trait and approximately
1 in 1000 people carry the mutant gene. Presymptomatic diagnosis
depends on the ultrasonographic detection of cysts, but exclusion
cannot be achieved by this means: 34% of at-risk patients in the second
decade will go on to developed cysts after a negative diagnosis. Recent
developments have located the adult polycystic kidney disease locus
(PKDI) close to the a-globin cluster on the short arm of chromosome 16
(Reeders et a!, Nature 317:542, 1985) making it possible to detect
carriers before ultrasonographic signs are positive. Two DNA markers,
3'HVR and 24,1 (kindly provided by Dr. Breuning, Leiden, The
Netherlands) were used to study the inheritance of RFLPs (restriction
fragments length polymorphisms) in nine unrelated Spanish families. A
total of 41 individuals were studied: 15 of these were affected, and 17
were at-risk. The disease was diagnosed according to the criteria of
Bear et a!, (1984). The allele in linkage with PKD1 was identified in 8
asymptomatic relatives at-risk (19 to 37 years). Thus, DNA flanking
markers offer an improved method of presymptomatic diagnosis of the
disease.
Antiproteinase activity and membrane dialysis. R. Bustamante, B.
Aguirre, J. Bustamante, Servicio de Nefrologia, Hospital Universi-
tanio, Valladolid, Spain. Nine plasma proteins control the proteolytic
activity in blood and tissues. The alpha1 antitrypsin and the alpha2
macroglobulin are the principal plasma antiproteins which inactivate
proteolytic, cancelling the granulocyte elastase. Plasma levels have
been studied in 25 patients (aged 40 5.6 years) who have used various
dialyzers for 48 13 months throughout hemodialysis. At 0, 15, 30, 120
and 240 minutes of the procedure, 10 patients used cuprophan, 5
polyacrylonitrile (PAN), 5 ethylene-vinyl alcohol (EVAL) and 5 pa-
tients used polysulfone dialyzers. The determination of the granulocyte
elastase was accomplished by enzymoimmunoassay, and that of the
alpha1 antitrypsin and alpha2 macroglobulin by nephelometer. A signif-
icant increase (P < 0.001) of the granulocyte elastase was produced in
the 4 groups in relation to the levels before hemodialysis. The alpha1
antitrypsin was lower in all the groups in relation to the pre-dialysis
levels, but the decrease was significant only in the cuprophan group (P
< 0.05). The alpha2 macroglobulin was lowered in the four groups in
relation to the control levels and the start of the procedure, the decrease
being significant only in the cuprophan group (P < 0.001). During
hemodialysis the granulocyte elastase was not significantly modified
with the polysulfone membrane; however, it was significantly increased(P <0.01) from 30 minutes on in the groups using eval, polyacrylonitrile
and cuprophan dialyzers. The alpha1 antitrypsin and the alpha2 macro-
globulin increase after 30 minutes in all the groups, reaching values
similar to those of the control group, at 240 minutes in the patients
dialyzed with polysulfone, polyacrilonitrile and eval membranes. In the
cuprophan group, at 240 minutes the alpha1 antitrypsin presents a value
of 185 25 mg%, in comparison with the control values of 217 18
mg%, and the alpha2 macroglobulin is 229 30 mg%, against 258 50
mg% in the controls. In conclusion, the decreases in the alpha1
antitrypsin and the alpha2 macroglobulin are more important in the
cuprophan group, where the elevations of the elastase are greatest. The
decrease may be due to the antiprotease effect on the granulocyte
elastase. This phenomenon also occurred in the other three groups, but
with lesser values.
Cytosoiic calcium and intracellular acidosis in vascular smooth muscle
cells (VSMC). R. Peces, M. LaPointe, D.C. Batlle, Northwestern
University Medical School and VA Lakeside Medical Center, Chicago,
Illinois, USA, and Hospital Ntra. Sra. de Covadonga, Oviedo, Spain.
Changes in the intracelular concentration of Ca2, H and Na play a
critical role in the cellular response to a variety of stimulus. This study
examined the effect of changes of intracellular pH (pH1) on intracellular
1598 Abstracts
Ca2 (Ca12) in rat aortic VSMC grown to confluence on glass cover-
slips. Cells were loaded with either Fura-2 or BCECF for continuous
monitoring of Ca12 or pH1, respectively. Intracellular acidification was
induced by the technique of perfusion-removal of 20 mii NH4C1 in
bicarbonate buffer. Acute acidification ( pH1 0.70 0.07) was associ-
ated with a rapid rise in Ca12 (from 163 16 to 191 19 flM, P <
0.001), which was fully reversible as pH1 recovered. In the nominal
absence of extraceilular Ca2, the peak in Ca2 was similar to that seen
in its presence. Removal of extracellular Na to block the pH, recovery
also resulted in an increment in Ca2 (from 149 11 to 196 15 nM,
P < 0.005) but under these conditions the Ca12 recovery was com-
pletely blocked. We conclude that an acute decrease in pH1 increases
Ca2 independent of the presence of extracellular Ca2, suggesting
release from an intracellular store. The inhibition of Na/H exchange
caused by extracellular Na removal, prevents Ca2 recovery possibly
by interfering with a Ca2/H exchange mechanism.
Action of cyclosporin A (CsA) on renal function during compensatory
kidney growth. R. Peces, C. Gutterman, M. LaPointe, D.C. Bathe,
Northwestern University Medical School and VA Lakeside Medical
Center, Chicago, Illinois, USA and Hospital Ntra. Sra. de Covadonga,
Oviedo, Spain. This study was designed to characterize the effect of
CsA on renal function and compensatory kidney growth in a rat model
of uninephrectomy (Ux). The infusion of CsA (12.5 mg/KBW) after
acute Ux resulted in a fall in glomerular filtration rate (GFR) and renal
plasma flow (RPF) and a marked increase in renal vascular resistance.
Three weeks following Ux, GFR was also reduced in chronic CsA-
treated animals as compared to pair-fed controls (0.39 0.03 vs. 0.67
0.06 mllmin/lOO g, P < 0.001), but RPF was not (1.97 0.14 vs. 2.19
0.34 mIIminIIOO g). The reduction in GFR seen in rats treated with CsA
was fully reversible 2 weeks after discontinuation of the drug. Three
weeks after Ux, kidney weight in CsA-treated animals increased to the
level of pair-fed controls (1.50 0.05 vs. 1.57 0.06 g) but renal
cortical RNA (39.4 4.3 vs. 49.3 1.3 rgIm1, P <0.05), DNA (26.4
1.7 vs. 34.7 2.1 g/ml, P <0.01) and protein content (6.4 0,3 vs. 7.8
0.2 mg/dl, P < 0.001) were all markedly reduced. Unilateral renal
denervation in CsA-treated rats resulted in an increase in GFR and RPF
as compared to that of pair-fed sham-denervated animals also treated
with CsA (0.57 0.06 vs. 0.39 0.03 ml/minll00 g, P <0.025 and 2.14
0.14 vs. 1.63 0.20 mlJminJlOO g, P < 0.025, respectively). We
conclude that the reduction in GFR associated with the chronic
administration of CsA in the Ux rats can occur despite unchanged RPF,
is reversible, and is ameliorated by renal denervation. The finding of
reduced cortical RNA, DNA and protein content in Ux rats treated with
CsA indicate that both renal hypertrophy and hyperplasia may be
obliterated with the chronic use of this drug.
Comparison of arterial pressure levels, body mass index, glycohemia,
cholesterol, triglycerides and uric acid, in relation to age, between people
with high and normal blood pressure. F. Roca Marsinyach, J. Soler
Amigo, J. MOdol Gort, A. Garcia Aznar, A. Rodriguez Jornet, Renal
Unit Centre Hospitalari, Unitat Coronaria Manresa, Mutua Manre-
sana Intercomarcal, Spain. It is a well known fact that a series of
clinical and analytical parameters are modified in relation to age. In this
piece of research we assessed the influence that the treatment of arterial
hypertension has in this natural process. We compared systolic pres-
sure, diastolic pressure, the medial pressure, triglycerides, cholesterol,
glycohemia and the body mass index in two groups of people. The first
was made up of 6834 people with normal blood pressure aged from 16
to 75. The second consisted of 755 patients treated for high blood
pressure between 17 and 80 years of age. The significance between the
two groups was examined to assess whether the results would be valid,
and this turned out to be P < 0.001. In the group with normal blood
pressure, the correlation of all the above-mentioned parameters in
relation to age was r < 0.01. In the group with hypertension it was: r <
0.01 in relation to systolic blood pressure, medial pressure, cholesterol
and glycohemia; r < 0,05 in relation to body mass index and diastolic
blood pressure; the triglyceride and uric acid levels did not bear any
correlation or else they showed regression. The averages tended to the
higher in high blood pressure patients, but, on the other hand, the
values were lower in all cases in this group. Conclusions: 1) The "risk"
factors mentioned above increase with age both among people with
normal blood pressure and those with high blood pressure. 2) High
blood pressure patients have a greater prevalence of "risk" factors. 3)
Despite this prevalence, patients with hypertension that undergo treat-
ment halt their natural tendency to increase the "risk" factors, and they
can even reverse this tendency.
Metabolic and hemodynamic effects of oral calcium therapy in essential
hypertension. P. GOmez-FernOndez, R. Perez-M(jares, M. Ramos, B
Benavides, M. Almaraz, J.C. Vargas, A. Castro, Nephrology Service
Hospital General, Jerez de Ia Frontera, Spain. Using a cross, double-
blind study design, we studied the effect of oral calcium on vasoactive
hormones, calcium metabolism and hemodynamics: blood pressure
(BP), cardiac output (CO) and peripheral resistance (PR). CO and PR
were measured by echocardiography. Nine essential hypertensives
were hospitalized. After 7 days on standard diet, oral calcium (2 g per
day) or placebo was given in a randomized way for another week. After
a pause of 7 days, the agent not given previously (placebo or calcium)
was then provided for another week. Systemic hemodynamics were
determined during the last 3 days and analytic measurements were
made in the last day of every period. Oral calcium significantly
decreased systolic BP (170 17 vs. 154 24), dyastolic BP (109 9 vs.
95 13), mean BP(130 9 vs. 114 16) and PR (1746 237 vs. 1580
331 din.). Placebo significantly lowered dyastolic BP and induced
nonsignificant decrease of PR. There were significant differences be-
tween BP and PR of calcium and placebo period. After oral calcium
administration significant increase of urinary calcium was observed
(without changes in urinary sodium, serum Ca2, PTH and cAMP).
Both placebo and calcium caused significant decrease in plasma renin
activity and plasma catecholamines. Conclusions: 1) Admission to
hospital results in decrease of BP and vasoactive agents. 2) Oral
calcium appears to have an additional effect on BP by decreasing
peripheral resistance.
Personal experience on erythropoietin (EPO) treatment in hemodialysis
patients Protocol or art? B. Ramos Frendo, A. Ruiz Fernandez, A.
Va/era Cortes, J. Fernandez-Gal/ego, E. Lopez de Novales, Servicio de
Nefrologia, Hospital Regional de Ma/aga, Malaga 29010, Spain. The
dose regimen and the optimal Hb level in EPO treatment are not well
established. Twenty-two HD patients were treated with EPO during 15
weeks. The initial dose of 50 U/kg i.v. post-HD was changed until a Hb
level of 10 g/dl was reached. The dosing schedule was individualized in
each patient. Blood analysis was done every three weeks. The Hb level
rose from 6.7 to 10.4 g/dl and the hematocrit rose from 21.0 to 33.3%.
Platelet counts did not change. In some patients maintaining the starting
dose, a continuous increase in Hb level was noted during 10 to 12
weeks. The maximum average dose was 72 U/kg and the final mainte-
nance dose was 24 U/kg. All the patients responded and only 3 needed
a maximum dose of 125 U/kg. Transfusions were required by two
patients, one for anemia and another one for a traffic crash. A total of
73% of the patients had an increase in blood pressure. Three patients
clotted their vascular access but in two cases this problem was resolved
by local fibrinolysis. Headaches were reported by 40% of patients. Two
patients died during the treatment of cerebrovascular stroke. Conclu-
sions: 1) EPO treatment is not devoided of side effects. 2) The
individual response is unpredictable. 3) The starting dose must be lower
than 50 U/kg and maintained during 8 to 10 weeks to achieve a slower
increase in Hb level. 4) In high-risk patients, the target Hb level may be
8 to 9 g/dl.
Dietary protein influence on nephrotic syndrome. A randon*zed pro-
spective trial. P. Abaigar, G. Torres, J. Santos Barajas, ML. Carrasco,
S. Pascual, SecciOn de Nefrologia, Hospital "General Yagfle", Bur-
gos, Spain. The present study was undertaken to evaluate the varia-
tions of several factors, clinical and biochemical, in a group of patients
with nephrotic syndrome exposed to two kinds of protein diets: 0.8 g/kg
body wt and 1.6 g/kg body wt. Both having between 35 to 40 Kcl/kg
body wt. Twelve patients, aged 26.9 10.7, with nephrotic syndrome,
underwent a random crossed trial with both diets. Each diet was given
for six months and biochemical and clinical controls were made every
two months. A washed out period of two months, with free diet, was
established between both diets. The patients nutritional state was
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controlled during the trial both anthropometric measurements and
biochemical controls.
Basal 2mo. 4mo. 6mo. P
Diet 0.8 g/kg
Cholest. 382 120 369 108 353 124 357 135 <0.05
mg% (with the
basal one)
Triglyc. 204 78 225 124 191 81 171 63 <0.05
mg% (with the
basal one)
P. Album. 2.3 0.41 2.5 0.58 2.5 0.58 2.6 0.50 <0.01
9% (with the
basal one)
P. Cr. 1.4 0.57 1.5 0.64 1.5 0.72 1.6 0.69 <0.01
mg% (with the
basal one)
Ur. Albu. 5.9 2.4 6.3 3.2 4.6 2.2 5.2 2.0 NS
g/24 hr
Syst. BP 145 11.9 141 10.1 138 12.9 141 13.5 NS
Dyast. BP 92 8.9 88 9.7 87 6.6 88 6.5 NS
Diet 1.6 g/kg
Cholest. 374 133 398 130 404 164 383 131 NS
mg%
Triglyc. 195 113 204 82 227 139 206 109 NS
mg%
P. Album. 2.3 0.44 2.4 0.67 2.5 0.59 2.4 0.58 NS
g%
P. Cr. 1.3 0.48 1.5 0.76 1.6 0.76 1.7 0.95 <0.05
mg% (with the
basal one)
Ur. Albu. 4.7 1.4 6.4 2.1 5.3 2.1 5.2 1.9 <0.01
g124 hr (with the
basal one)
Syst. BP 139 13.7 142 15.7 142 15.5 146 6.7 <0.05
(with the
basal one)
Dyast. BP 89 8.6 87 9.4 91 7.1 87 8.7 NS
There were no meaningful variations in the nutritional state. Comparing
both diets there no significant differences were found among the
different factors above-esposed, although the plasma albumin rose near
the level of significance with the 0.8 g/kg. The plasma albumin increased
significantly with the 0.8 g/kg. There was a significant decrease of
cholesterol and triglycerides in the fourth and sixth months of the diet
of 0.8 glkg; on the contrary they did not suffer modifications with the
diet of 1.6 glkg. The albuminuria did not suffer significant variations in
the 4th and 6th months. The gradual and significant rising of the plasma
creatinine, with both diets, can be connected with the natural evolution
of the disease.
Postinfectious acute glomeruionephritis (PAG). Experience of the
Nephrology Service of Hospital General Vail D'Hebron. M. Galicia, M.
Va//es, L. Piera, Service of Nephrology, Hospital General Vail d'He-
bron, Barcelona, Spain. We have reviewed our experience with PAG.
The diagnostic criteria for inclusion in the study are: compatible
morphological findings in kidney biopsy or compatible clinical features
(infectious illness followed by acute glomerular disease with transient
hypocomplementemia). Other systemic diseases are excluded. Thirty-
nine patients met these criteria: 25 men and 14 women, with an average
age of 17.9 13 years (range 7 to 66). Pharyngeal infection was present
in 25 patients with an average latent period of 16 7.9 (range: 7 to 30).
Clinical features were: gross hematuria (25), hypertension (28), edema
(32) and congestive heart failure (13). Laboratory findings were: micro-
scopic hematuria (all patients), proteinuria (32), renal failure (16) and
hypocomplementemia (33). The average follow-up was 4.6 3.8 years.
After the follow-up five patients had clinical features or laboratory
findings consistent with glomerular disease: proteinuria (3), micro-
scopic hematuria (2), renal failure (3) and hypertension (1). Postinfec-
tious acute glomerulonephritis continues to be a glomerular disease
with a good short and medium term prognosis.
Evaluation of internal arterlo-venous fistula with an angiodinographer
(CDF); a new non-invasive method to study the vascular access in
hemodialysis. L. Horlal, A. FernOndez, M. Casal, N. Vega, J.C.
Rodriguez, C. Plaza, M. Maynar, L. Palop, S. NefroiogIa, S. RX
Vascular, H.N.S. Del Pino, Las Palmas, Spain. We describe a new
method for the study of the vascular access for HD with ultrasound and
a computerized flow-measurement system. We studied 21 patients, with
an age of 50.2 15 years, and a time on HD of 69.9 42.1 months and
a time of AVF of 34.9 36.3 months, by CDF with a transducer of 7.5
NHz and lineal imaging. The usual QB was 200 to 250 mI/mm and
venous resistance 91.6 24mm Hg. Seventeen patients had undergone
in a fistulography whose result wasunknown by the operator the last
three months. Maximal and minimal blood velocity in artery and vein
and minimal diameter of arterialized circuit (Dma) were measured; the
mean and mode of the velocity and the mean flow were obtained with a
computerized system in the CDF. To verify the obtained flow it was
related with the maximum of the HD monitor, increasing up to a
maximum of 400 mI/mm. Arterial mean flow (AMF) was 634 532
mi/mm and venous mean flow (VMF) was 454 405 nil/mm, mean
arterial velocity (MAY) 81.5 42.9 cm/sec and mean venous velocity
(MVV) 42.4 37.5 Dma was 3 1.2 mm. Monitor flow (MF) was 314
80 mI/rn. A significant positive correlation was obtained between the
antiquity of AVF and VMF (P < 0.001), MAF and MVF (P < 0.001),
AMF and VMF (P < 0.001), VMF and VMV (P < 0.05); VMF and Dma(P < 0.001) and VMF and MAF (P < 0.05). Four venous stenosis
proximal and 1 distal to the AVF were found and it was estimated that
there was a good morphological relation of 92% with fistulography.
Conclusion: 1) CDF is a good method to measure arterial flow and to a
lesser degree for venous flow turbulence? 2) the minimal diameter of the
circuit is determinant of mean venous flow. 3) AVF with longer survival
have more venous flow. 4) CDF has a good morphologic relation with
fistulography.
Initial hematologic evaluation of the treatment with recombinant
human erythropoietin (rHuEPO). A. Fernandez, L. Hortal, I. Balda, N.
Vega, J.C. Rodriguez, C. Plaza, L. Palop, S. Nefrologia, S. Hemato-
logia, H.N.S. del Pino, Las Palmas, Spain. rHuEPO has demonstrated
a high efficacy in the treatment of renal anemia, although several factors
have been inplicated in a relative resistance to rHuEPO. We studied the
hematologic response in 16 (10 in HD and 6 in CAPD) with an age of 37
16 and a time in dialysis of 62 43 months treated with rHuEPO
between 3 and 7 months. The dosage was 50 U/kg three times a week
increasing up to 75 U/kg 3 times a week after 3 weeks, depending of the
response. After reaching the target hemoglobin the dosage was reduced
down to two weekly doses, and when the hemoglobin was over 11 g%
the dose was reduced in 25 U/kg. Patients in CAPD received the drug by
the subcutaneous route. A basal hematologic evaluation was per-
formed, including hemogram, reticulocyte count (RC), reticulocyte
production index (RPI), Fe, TiBC, saturation index (SI) and ferritin (F).
All these parameters were evaluated after the first week of treatment
with 50 U/kg, before increasing to 75 U/kg, after 3 weeks of change,
before passing to maintenance dosage, after 3 weeks and after three
months of maintenance. During the first week of treatment, the hemo-
globin was lower than the basal (P < 0.001, 8 vs. 7.3), although there
was an increase in RC (1.2 0.5 vs. 2.1 0.8) and in RPI (0.5 0.2vs.
1.4 1.5, P < 0.05) and a decrease in SI from 64 23.2 down to 37.6
22.3 (P < 0.001). The hemoglobin rose after the first week without
difference between patients on HD and CAPD. Ferritin decreased (P <
0.05) after the third week (1972 854 vs. 1484 702). When
ferrokinetic parameters were analyzed in relation with response we
found a positive correlation between basic SI and response, but this did
not happen with ferritin. Conclusions: 1) rHuEPO is effective by iv.
and s.c. route in HD and CAPD. 2) Up to the moment we have not
found any difference of response between both routes. 3) The S.!. index
is the best ferrokinetic parameter for prediction of response.
Anemia in dialysis, cysts and erythropoietin levels. A. Fernández, L.
Hortal, J.C. Rodriguez, C.R. Hernández, N. Vega, C. Plaza, L. Pa/op.
S. Nefrologia-RX, H. NTRA. SRA, Del Pino, Las Palmas, Spain. The
acquired cystic disease (ACD) has been related to improvement of
anemia in dialysis patients because of erythropoietin (EPO) production
by the cysts. We studied 110 patients (60 in HD and 50 in CAPD) with
age of 44. 14.8, time on dialysis 50.43 41.4 and Cr 12.2 2.25. Of
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these, 36 patients had GN, 24 TIN, 24 CRF of unknown etiology, 14
diabetes and 12 polycystic kidneys. A renal echography was performed
in every patient evaluating renal size, presence and number of the cysts,
and plasmatic levels of EPO (RIA normal value 10 to 30 mU/mi), trying
to relate both with the severity of the anemia in dialysis. Four cystic
patterns are described: I multiplied bilateral cysts 3 to 30 mm; II
multiple bilateral cystic less than 3 mm; III 1 to 3 isolated cysts; IV
polycystic kidney. Hemoglobin in HD was lower (P < 0.05) than in
CAPD (8.7 1.9 vs. 9.6 1.8) and no differences could be found in
EPO levels (19.2 11.1 vs. 16.5 11.1) or in serum ferritin levels
(436.5 528 vs. 459.3 557.7). Hemoglobin and EPO were signifi-
cantly higher in patients with polycystic kidney (11.4 2.2 vs. 28.9
19.2). Patients without cysts had the lowest levels of hemohemoglobin
and EPO (8.55 1.5 and 14.2 6.3), although no statistical significance
was reached with the cystic patterns I, H and 111(9.02 1.7and 17.9
8.7). The serum levels of EPO were statistically correlated with the
hemoglobin (<0.05). Patients with polycystic kidney have higher levels
of EPO and less anemia than the rest of the population on dialysis. The
patients with ACD tend to have higher levels of hemoglobin and EPO
than patients without cysts. The less severe anemia in CAPD is not
related to higher levels of EPO.
Study with echo Doppler of hemodynamic changes induced by the
treatment with rHuEPO. A. Fernández, J. Goicolea, L. Hortal, N.
Vega, J.C. Rodriguez, C. Plaza, L. Palop, S. Nefrologla, S. Cardiolo-
gla, H.N.S. del Pino, Las Palmas, Spain. The use of recombinant
human erythropoietm (rHuEPO) in the treatment of renal anemia can
produce HBP in 15 to 20% of the patients. To study the hemodynamic
changes induced in the medium term after treatment with rHuEPO, we
performed a study with echo Doppler, basal and afater reaching the
targed hemoglobin (10.5 to 12 g/dl) in 11 patients (6 males and 5 women)
with a mean age of 37.5 12.4 years, 6 in HD and 5 in CAPD that
started treatment with rHuEPO in November-December 1988. Out of 8
patients with a normal blood pressure before starting the treatment, 3
developed HBP and out of 3 previously hypertensive patients, two
required an increase of hypotensive medication. Arterial mean pres-
sures (AMP), heart rate (HR), left ventricular diastolic diameter
(LVDD), pulmonary beat advance (PBA), cardiac output index (CI) =
PBA x HR, resistance index (RI) = AMP/Cl.
FC AMP LVDD PBA CI RI HB
Echol 84 16 105 15 51 7 19 3 1616 237 0.06 7.9
P <0.01 NS NS NS <0.001
Echo2 69 11 109 22 54 9 18 5 1265 275 0.09 11
Conclusion: I) Echo Doppler is a valid non-invasive method to charac-
terize the hemodynamic produced after the administration of rHuEPO.
2) The changes consist of a decrease in cardiac output and an increase
in periferic resistance.
Percutaneous transluminal angloplasty In management of renovascular
hypertension. A. Mart Inez-Amenós, X. Sarrias, H. Rama, L. Carreras,
J. Alsina, X. Montanya, Departments of Nephrology and Radiology,
Hospital de Bellvitge "Princeps d'Espanya", L'Hospitalet de Liobre-
gat, Barcelona, Spain. Percutaneous transluminal angioplasty (PTA)
was performed in 74 (39 males) consecutive patients (p) with renovas-
cular hypertension between 1981 to 1-89. Age 47 years (range 14 to
68). Follow up period i was 21.7 months. Stenosis of renal artery was
bilateral in 23. Atheroma was present in 43 p and fibromuscular
dysplasia in 31. Of these, 25 p (33.7%) had plasma creatinine >150
mcmol/liter. Rates of blood pressure benefit: Ii p (14.8%) were cured
(blood pressure <160/95, without medication; 39 p (52.7%) were
improved (blood pressure <160/95 with less medication). No changes
were observed in 16 p (21.6%). In 8 p end follow-up data are not
available. Renal function evolution: 6 p improved with a decrease in
plasma creatinine >30%. No persistent worsening of renal function was
present in any p after PTA. In 9 p a repeat percutaneous angiopiasty
was undergone. In 6 p a double PTA was done in the same sesion, 5 p
with bilateral stenosis and one with a double stenosed renal artery. In 2
cases of bilateral stenosis PTA was performed in two times. Complica-
tions: (1) perirenal hematoma and (2) puncture site hematoma. All cases
were spontaneously resolved. These results in our experience makes
PTA a first therapeutical step in the management of renovascular
hypertension.
Renovascular hypertension treated by autotransplantation. X. Sarrias,
A. MartInez-Amends, H. Rama, L. Carreras, I. Alsina, Serrallach,
Departments of Nephrology and Urology, Hospital de Bellvitge "Prin-
ceps d'Espanya", L'Hospitalet de Liobregat, Barcelona, Spain. In a
series of 170 patients (p) with renovascular hypertension, renal auto-
transplantation (ATR) was performed in 20 p, 6 males and 14 females.
The mean age at the time of operation was 31 years. There was bilateral
stenosis of renal arteries in 7 cases. The etiology was fibromuscular
dyspiasia in 15 p, atherosclerosis in 4 and neurofibromatosis in one.
Decreased renal function (plasma creatinine (>120 mcmol/liter) was
present in 5 p and 4 p had malignant hypertension. Follow-up was 2076
months-patients with a ii period of 103.7 months. At the end of this
period, blood pressure was controlled (<160/95 mm Hg) without
medical treatment in 9 p (45%). Antihypertensive treatment was needed
in 4 p (20%). A satisfactory control was not achieved in 3 p (15%). In4
p end of follow-up data were not available. Two p presented arterial
autotransplant thrombosis immediatly after surgery. This complication
was present at 5 and 6 months from the operation in 2 p. Renal ATR
gives satisfactory results in selected renovascular hypertensive patients
allowing cx vivo reconstruction of the arteries with microsurgical
techniques.
Nonsteroidal anti-inflammatory drugs (NSAID) and nephrotoxlcity: A
wide spectrum of nephrologic syndromes. A.M. Castelao, S. Gil Vernet,
E. Andrés, R. Poveda, J.M. Mauri, J.M. Grino, M. Carrera, M.T.
Gonzalez, C. DIaz, J. Alsina, Hospital Universitario de Bellvitge,
Barcelona, Spain. NSAID are the most widely prescribed drugs in
clinical practice; their renal effects are varied. From 1980 we have
observed nephrotoxicity due to NSAID in 26 patients (15 male, 11
female, main age 62 17 years) due to indomethacin (alone in 9 patients
or associated to aspirine, naproxen or paracetamol in 3), naproxen (3),
diclofenac (7) and piroxicam (4). All the patients presented with acute
renal failure (ARF), which represents 1.8% of the total ARF and 6% of
ARF due to drugs in our hospital. Seven patients (27%) suffered
previous renal failure. Proteinuria was present in 13 patients (50%),
being of nephrotic range in 2. One patient presented with interstitial
nephritis due to indomethacin. In other 2 there were previous lupus and
panarteritis, and rheumatic diseases with amyloidosis in two more.
Three patients suffered a rapidly progressive glomerulonephritis due to
piroxicam (2) and indomethacin (1), with crescents in two cases and
necrotizing vasculitis in the other, being anti-GBM antibodie-positive in
two of them. Oliguria was present in 10 cases (38%). Nine patients
(35%) needed dialysis. Three patients died, 15 recovered renal function
and renal disfunction persisted in 8, four of them requiring chronic
dialysis. In summary the incidence of NSAID nephrotoxicity is not
high, in spite of their generalized use. Nevertheless we recommend
careful monitoring of the renal function in high risk patients—aged,
previous renal failure, cardiac failure, hepatopathy, systemic dis-
eases—in order to avoid an irreversible renal failure.
Pathological differential diagnosis of late failure after renal transplan-
tation (RT). A.M. Castelao, J.M. Griño, D. SerOn, E. Andrés, S.
Gil Vernet, C, DIaz, M. Carrera, R. Sabater, C. Gonzalez, J. Alsina,
Hospital Universitario de Bellvitge, Barcelona, Spain. Between June
1980 and December 1988, 415 RT were performed in our hospital in 399
patients, 269 male, 130 female, aged from 11 to 63 years. Chronic renal
failure was due to glomerulonephritis (GN) in 106 patients (26.3%),
diabetic nephropathy in 13(3.3%) or hereditary nephritis with glomer-
ular involvement in 12 (3%). We observed recurrence of the previous
GN in 10 patients (5 FSGS, 1 IgA, 1 MCGN, 3 HUS), being diagnosed
7 days to 24 months after RT. In other 4 patients (FSG, IgA, policystic
disease) we found "de novo membranous GN" (DNMGN) 15 to 84
months after RT. Two patients loose their grafts 27 and 42 months after
RT. Another patient (MCGN) presented a heavy proteinuria 60 months
after RT, showing FSG. Eight patients developed transplant glomeru-
lopathy (TON). Six of them presented with nephrotic proteinuria,
loosing their grafts 6 to 96 months after RT (x 50 30 months). Renal
histology showed chronic rejection (CR) in 26 patients with different
degrees of proteinuria. Out of them, 18(72%) entered in chronic dialysis
28 12 months after RT. One patient died with a functioning graft and
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plasma creatinine in the remaining 6 ranged from 230 to 600 mol/liter,
after a follow-up period of 38 9 months. Four out of the 42 referred
patients died, 3 of them with a functioning graft. We conclude in
summary that in our experience: 1) recurrence of GN after RT is more
frequent in FSG (3 1%) and HUS (75%), with no recurrence for the
moment of FSGN, Schöenlein H, lupus nephritis or diabetic nephrop-
athy; 2) DNMGN occured only in 0.96% of our patients; 3) TGN and
specially CR are important causes of late graft failure.
Cyclosporin A (CSA)-azathloprine (AZA) overlap in renal transplants
with chronic rejection (CR) or CSA nephrotoxicity. A.M. Castelao, J.M.
Griñó, I. Sabaté, D. Serón, E. Andrés, S. GilVernet, C. DIaz, R.
Sabater, C. Gonzalez, J. Alsina, Hospital Universitario de Bellvitge,
Barcelona, Spain. Two hundred and seventy patients who received a
renal transplant (RT) in our hospital between March 1984 and Decem-
ber 1988 were treated with a CsA-PNS or a CsA-PNS-ALG protocol.
Twenty-five patients presented plasma creatinine above 250 mo1Iliter
in spite of normal CsA blood levels (RIA polyclonal 300 to 800 ng/ml,
RIA specific monoclonal 100 to 250 nglml). Eleven patients (Group I)
had histological evidence of chronic rejection. Fourteen patients
(Group II) were considered to have renal CsA nephrotoxicity. In all of
them we reduced CsA doses and started AZA (1.01 0.18mg/kg body
wt/day), 14 8 months (G I) and 8 7 m (G II) after RT. Evolution of
renal function was as follows:
creatinine before
pjnol/liter
creat 3 m
after
creat 6 m
after
creat 12 m
after
U I 345 89 353 132 383 109 399 157
G II 370 92 260 85 215 48 207 52
P 0.004 0.009 0.001
Two patients in GI maintained stable renal function after overlap (ovl)
and 5 lost their grafts 15 8 months after ovl. The remaining 4 patients
present advanced renal failure. One patient in G 11(7%) lost the graft
due to an acute rejection. The remaining 13 patients have functioning
kidneys. We did not observe opportunistic infections. In conclusion, we
think that CsA-AZA association is a simple alternative that can reduce
CsA nephrotoxicity with minimal risk of rejection, allowing to improve
graft function. This association does not seem to be useful in CR.
Pre-transplant ALG, low dose cyclosporine (CsA) and steroids versus
pre-transplant OKT3, CsA and steroids in kidney cadaveric transplanta-
tion. C. Gonzalez, f.M. Grino, A.M. Castelao, D. Seron, S. Gil- Vernet,
E. Andres, D. Diaz, I. Sabate, J. Bas, J. Alsina, Hospital de Belivilge,
L'Hospitalet de Llobregat, Barcelona, Spain. Prophylactic use of both
ALG and OKT3, associated with CsA and steroids, has been useful in
kidney cadaveric transplantation. The administration of ATG before
transplantation induces allograft acceptance in transplant animal mod-
els. Two groups of first-cadaver transplant recipients (R) were prospec-
tively documented based on the immunosuppression regime used.
Group A (N = 31): horse ALG 15 mg/kg just before transplant (TR)
surgery, ALG 12 mg/kg the first day after TR followed by 4 doses of 10
mg/kg on alternate days; CsA i.v. 2 mg/kg/day until oral route is started
at 8 mg/kg/day; prednisone 0.25 mg/kg/d. Group B (N = 31): OKT3 5mg
just before TR followed by 4 doses of 5 mgld; CsA and prednisone were
administered using the same schedule of the Group I. Results. Inci-
dence of acute rejection during the first 3 months: group A 16%, group
B 13% (NS). Incidence of postransplant renal failure: group A 16%,
group B 22% (NS). There were no statistically significant differences
between the 2 groups in the incidence of infection, cumulative doses of
CsA and steroids, and renal function at 3 and 6 months. Six month
actuarial patient and graft survival: group A 100%, group B 95% (NS).
Spleen cells from the cadaveric donor (D) were frozen and used as
stimulators against the R lymphocytes in unidirectional mixed lympho-
cyte culture (MLC) at 3 and 6 months. A pool (P) of 10 healthy
unrelated subjects was used as control stimulators. The results of MLC
disclosed a donor-specific hyporesponsiveness in both groups. Conclu-
sions: 1) Pre-TR OKT3 followed by a short course of this monoclonal
antibody, associated with CsA and steroids provides similar immuno-
suppression to pre-TR ALG, CsA and steroids in kidney cadaveric
transplantation. 2) Both immunosuppresive regimes induce an in vitro
donor-specific hyporesponsiveness.
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Mannitol solution (MS) versus MS plus allopurinol in kidney preserva-
tion. f.M. Griño, J. Lopez-Costea, E. Gea, D. Seron, M.R. Miravitlles,
A.M. Castelao, E. Franco, R. Sabater, S. Gil-Vernet, E. Andres, J.
Alsina, Hospital de Bellvitge, L'Hospitalet Dell, Barcelona, Spain.
Flush solution containing mannitol, that acts as an hydroxyl radical
scavenger, has been useful in the prevention of postransplant renal
failure (PRF) (Transplant Proc 19:4140, 1987). On the other hand,
allopurinol (AP) blocks the generation of superoxide radicals from
xanthine oxidase. In order to elicit if AP gives an additional benefit to
mannitol in the prevention of PRF, we compare two groups of kidney
cadaveric transplant recipients treated with cyclosporine (8 mg/kg as
initial dose). Group I (N = 20), recipients of allografts perfused with
MS (mannitol 4.19 g/100 ml, osmolality 400 mOsmlkg, electrolyte
composition similar to EuroCollins). Group 2 (N = 21) recipients of
grafts perfused with MS + AP 0.5 mg/mI. The results are summarized
in the table:
Group 1 Group 2 P
Incidence PRF 15% 23.8% NS
Cold ischemia hr 24.5 7.9 25.6 0.4 NS
Donor serum creatinine 114 37 116 36 NS
pnol/liter
Serum creatinine 1st day 625 236 594 189 NS
Urine volume 1st day ml 3504 1929 3633 3142 NS
Serum creatinine 7th day 291 247 355 262 NS
Serum creatinine 30th day 162 58 214 173 NS
Allografts biopsies were taken 30 minutes after blood reperfusion.
Semiquantitative analyses of renal tissue did not disclose significant
differences in the degree of interstitial edema and tubular lesions
between the two groups. In summary: MS is effective in the prevention
of PRF cadaveric renal transplantation, but the addition of AP does not
provide a significant benefit.
Prognostic factors in late renal graft failure. C. DIaz Gallo, D. Serón,
f.M. Griño, R. Sabater, A.M. Castelao, S. Gil-Vernet, C. Gonzalez, E.
Andrés, J. Alsina, Hospital de Bellvilge, Barcelona, Spain. Advances
in immunosupression have reduced the incidence of early graft failure
(EGF). Late graft failure (LGF) is a major problem. Factors influencing
LGF are not well known. We retrospectively studied 337 cadaver
kidney transplants performed during 8 years and treated with 4 immu-
nosuppressive regimes: group A: azathioprine + prednisone (PDN) (N
= 140); group B: cyclosporine (CsA) + PDN (N = 93);group C: CsA (8
mg/kg/day) + prophylactic antilymphocyte globulin + PDN (N = 94)
and group D: prophylactic OKT3 + CsA + PDN (N = 10). The
incidence of EGF (during the first 6 months after transplant) was 21% in
group A, 11% in group B, 3% in group C and 0% in group D (P = 0.006).
The whole incidence of LGF (after 6 months of transplant) was 11.8%
(40 patients). The causes of LGF were: chronic rejection (17), trans-
plant glomerulopathy (7), acute rejection (6), recurrent glomerular
disease (2), "de novo" glomerulonephritis (2) and others (6). We
analyzed the relationship between LGF and each of the following
factors: recipient age, number of pretransplant blood transfusions,
number of acute rejections, post-transplant acute tubular necrosis,
hypertension, vascular and urinary surgical complications and renal
function at 3 and 6 months after transplantation. Risk factors for LGF
were: acute rejection (P = 0.0001), post-transplant acute tubular
necrosis (P = 0.0026), hypertension (P = 0.03) and serum creatinine
levels at 3 (P = 0.0001) and 6 (P = 0.001) months. In 36 of the 40
patients with LGF (90%), transplantectomy was avoided by treatment
with decreasing doses of steroids, and at times, indomethacine. Con-
clusions: 1) The new immunosupressive regimes decrease the incidence
of EGF. 2) Chronic rejection is the main cause of LGF. 3) The presence
of post-transplant acute tubular necrosis, acute rejection and hyperten-
sion is asociated with LGF. 4) Renal function at 3 and 6 months after
transplant correlate with subsequent LGF.
Quantitative and morphologic Langerhans cells alterations in immuno-
supressed renal transplant patients. D. SerOn, C. Diaz-Gallo, 0. Ser-
vitge, M. Carreras, f.M. Grinó, A.M. Castelao, S. Gil-Vernet, E.
Andres, J. Alsina, Hospital de Bellvitge, Barcelona, Spain. Immuno-
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supressed renal transplant patients have a high incidence of both
neoplastic and infective cutaneous diseases. Quantitative and morpho-
logic aspects of epidermal Langerhans cells (LCs) were investigated in
28 renal transplant patients (RTP) and 20 sex-age mached non-immu-
nosupressed controls. RTP were divided in two groups according to
immunosupressive treatment: Group A; prednisone + azathioprine (14
cases, 3 men/Il women, mean age 44 10). Group B: prednisone +
cyclosporine (14 cases, 6 men/8 women, mean age 49 6). Biopsies
were taken from non-exposed skin. Epidermal sheets were obtained by
incubation in EDTA and stained for ATPase activity and with the
monoclonal antibody T6 using the avidin-biotin peroxidase method.
LCs were counted using a calibrated graticule (44)Ox) and expressed as
number of LCs/mm2. The mean LCs area and number of primary and
secondary dendrites were determined with a morphometer adapted to
an Apple II computer. A significative reduction (P = 0.0001) in the
mean number of LCs/nun2 was observed in RTP (ATPase = 417 153;
T6 = 461 171) when compared to controls (ATPase = 417 152; T6
= 695 164). This reduction was higher (P = 0.05) in group A (ATPase
= 494 121; T6 = 402 194) than in group B (ATPase = 494 121;
16 = 402 194). The mean LCs area and number of primary dendrites
(pd) were also higher (P = 0.03) in RTPs (275 65, pd = 3.1 0.3)
than in control group (213 83 2, pd = 2.8 0.3). We conclude that
RTP have a diminished number of LCs and that these cells show
hypertrophic changes. These results suggest that LCs alterations may
play a role in the developement of RTPs skin complications,
Mitomycin C nephrotoxicity: A study of 7 cases. E. Poch, J.M.
Nicolás, J.M. Gonzalez Clemente, E. Ponz, J. Almirall, A. Torras, A.
Darnell, L. Revert, Nephrology Service and Internal Medicine Service,
Hospital Clinic iProvincial, University of Barcelona, Spain. Mitomycin
C (MMC) is used in the treatment of several neoplasms. Nephrotoxicity
is an uncommon finding, with an incidence of 6%. Between Sept87 and
March 89, 7 patients (4 males and 3 females, mean age of 55 years
ranging 23 to 67 yr), affected of gastrointestinal neoplasms (5 colorectal
and 2 gastric) developed MMC related nephrotoxicity. Four received
currently S Fluorouracil and three Ftorafur. Six out of seven patients
developed an hemolytic uremic syndrome (HUS) 3.8 months (range 1 to
9 months) after chemotherapy. Renal biopsy was performed in four
patients and displayed the typical pathologic changes of HUS. Of the 6
patients, two died, one in the acute phase and the other after prolonged
treatment with plasmapheresis and corticosteroids. Another patient,
despite control of acute phase with plasmapheresis developed progres-
sive renal failure, requiring hemodialysis 14 months later. Three pa-
tients are stable with corticosteroids, aspirin and dypiridamol, two with
stable creatinine value of 2.5 mg/dl and the remainder with near normal
renal function. The seventh patient developed a progressive impairment
of renal function 12 months after chemotherapy, neither with throm-
bopenia or hemolysis or hypertension, requiring hemodialysis 10
months later. Renal biopsy in this patient displayed similar histopatho-
logic changes as the others, but less severe. In conclusion, MMC
nephrotoxicity can present with two clinical forms with a similar
histopathologic pattern: one form, of acute onset with the whole clinical
features of a severe HUS; the other, a chronic form, with slow
progression of renal failure without signs of hemolysis. Although the
relative low incidence, it is important to be aware of this complication
in patients treated with MMC.
Usefulness of captopril isotopic renography in renovascular disease.
J.L. Tovar, M. Fraile, J. Castell, M. Vallès, L. Piera, Nephrology and
Nuclear Medicine, Departments, Hospital General Vail d'Hebron,
Barcelona, Spain. Isotopic renography (IR) has not gained full accep-
tance in the management of renovascular disease (RVD) because of its
relatively low diagnostic yield, as it is easily influenced by several
factors sometimes without clinical relevance. On theoretical grounds, it
is possible to enhance IR diagnostic efficacy by means of the pharma-
cologic inhibition of angiotensin converting enzime. Bearing this in
mind, we looked after changes in orthostatic IR evoked by a single oral
dose of 25 mg of captopril given one hour before, the patients not being
on drugs that could inhibit renin secretion. We studied 23 patients (17
men, mean age 50 years) with severe hypertension (DP> 115 mm Hg)
and normal or slightly deteriorated renal function (Cr < 2 mg/dl).
Captopril IR results were compared to renal artery angiographic study.
Results: two patterns of renographic findings were considered positive.
First, slow intrarenal tracer transit and, secondly, lowered kidney
uptake and excretion. With this criteria, we had 7 true positive, 12 true
negative, 0 false negative, and 4 false positive results (one pyelonephri-
tis, and three severe atherosclerotic disease with abnormal renal
function). Of the true positive results, three patients have undergone
vascular repair with good response. Our results suggest improved
sensitivity and specificity of captopril IR in RVD, which might result in
a greater diagnostic efficiency.
Impact of initial nonfunction of the renal allograft (INF) on later renal
function in patients treated with cyclosporine (CsA). F.J. Moncalián, M.
Perez Fontán, J. Saavedra, J. Oliver, C. Fernández Rivera, J. Fernán-
dez Daza, F. Valdés, Hospital Juan Canalejo, A Coruña, Spain. It has
been held that the absence of immediate function alter renal transplan-
tation (Tx) in patients treated with CsA may bear a poorer prognosis for
long-term graft survival. To further assess this point, we have studied
54 renal cadaveric Tx (28 males, age 37 14 years), treated with CsA
(initial dose 14 mg/kg body wt/day) and prednisone (initial dose 0.25
mg/kg body wt/day), and classified as to the presence (Group A, N =
29) or absence (Group B, INF, N = 25) of immediate renal function
after Tx. Initial nonfunction was defined after the need for dialysis
treatment during the first week after Tx. Never functioning grafts were
previously excluded. We monitored: donor and receptor age, cold
ischemia time (CII), peak blood levels of CsA during the first week
post-Tx, acute rejection (ARE) and acute CsA nephrotoxicity (ANE)
episodes, HLA identities, lymphocytotoxic antibodies level (LAL)
before Tx, and renal function at 1, 3, 6, 12 and 24 months post-Tx, as
measured through serum creatinine levels. No significant differences
were found as refers to: age of donor (38 years Group A vs. 36 B) or
receptor 33 vs. 37 years), HLA identities, LAL or peak CsA levels
during the first week (808 362 vs. 804 319 ngr/mL). CIT was more
prolonged in Group B (23 vs. 19 hours, P < 0.05). Group B also had a
higher incidence (62 vs. 33%, P < 0.05) and frequency (0.7 0.7 vs.
0.35 0.5 episodes, P < 0.05) of ANE. The number of ARE was not
significantly different. As refers to renal function:
N +1 m. +3 m. +6 m. +12 m. +24 m. Units
Group 29 1.3 0.3 1.2 0.7 1.2 0.6 1.7 0.6 1.5 1.6 mg/dl
A
Group 25 2.3 1.3 1.5 0.6 1.7 0.3 1.7 0.9 1.5 0.3 mg/dl
<0.005 <0.05 <0.025 NS NS
The absence of immediate function of the renal allograft after Tx does
not seem to bear a particularly poor prognosis for mid-term function of
the graft. A prolonged CIT is a risk factor for INF. Donor or receptor
age, or high CsA blood levels during the first week after Tx are not risk
factors for INF. The association of INF and higher incidence of ANE
further suggests a higher susceptibility to CsA in these patients, also
justifying a poorer renal function during the first six months alter renal
Tx.
Anomalous response of the Gil and LII in chronic renal failure
suggesting a hypothalamic-pituitary change after Gil and TRII adminis-
tration. M.A. Courel, A.J. Perez, R.V.G. Garcia, L. Palomares, A.
Andrade, A. Penalva, F.F. Casanueva, Division of Nephrology and
Endocrinology, Hospital General Vigo and Santiago de Compostela,
Spain. Patients with chronic renal failure (CRF) present different
endocrine abnormalities which can be responsible of some clinic
manifestations, high basal levels of GH and PRL, as soon as there is a
paradogic elevation of GH after TRH administration or oral surcharge
of glucose. With the purpose of evaluating pituitary function in CRF
little studied till now, we proved the answer of GH and PRL adminis-
tration and releasing factors GHRH and TRH in 11 patients, in the
interhemodyalitic period, and 11 controls. GHRH (1 gIkg i.v.) was
administered and we determined GH levels in 0, 15, 30, 45, 60, 90 and
120 minutes. As a group, CRF patients had GH basal levels only slightly
elevated and at a peak of 22.7 5.2ng/ml was not significantly different
to controls. That patients did not show habitual postpeak fast GH fall
till basal values, like in volunteers. Uremic patients showed signifi-
cantly higher PRL levels (11.5 3.0 ng/ml) than normal controls after
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TRH (400 pg i.v) with PRL that rose to 20.6 6.0 at 45 minutes, with
a slight fall in the rest of study. The control group with basal level of 3.8
I had a PRL peak of 26.5 3 followed by a post-peak fall (P < 0.05)
at 60, 90 and 120 minutes. Although this pattern of GH and PRL
response in CRF could be attributed to a defect in the renal catabolism,
however, when the uremic patients were examined individually a
different pattern emerged. CRF patients showed no marked differences
either in net hormonal increase or in the post-peak fall when compared
to controls. On the contrary, hormonal high peaks were dispersed
throughout the 120 minutes period, while in the controls peaks clustered
around 15 to 30 minutes. This peak dispersion creates a false impression
of flattened curves or sustained hypersecretion in uremia. In conclu-
sion, this response of GH and PRL to either GHRH and TRH
administration, individually considered, support the idea of a impaired
hypothalamic-pituitary function in uremia.
Circadian rhythms of cyclosporine and metabolites in renal transplant
patients. I. Sabaté, f.M. GrinO, A.M. Casielao, B. Arranz, C. Gonzá-
lez, E. Guillén, C. DIaz, J. Huguet, S. Gràcia, Pharmacokinetics Unit,
Biochemistry and Nephrology Departments, Hospital Universitario de
Bellvitge, Barcelona, Spain. Preliminary observations in recipients of
hepatic and pancreas allografts suggest the presence of circadian
variations in the clearance of cyclosporine (CsA) and metabolites. To
assess this fact, we evaluated 22 pairs of morning and evening pre-dose
whole blood samples from 22 renal transplant patients (11 hospitalized
and 11 out-patients), taking CsA orally in two equally divided doses
every 12 hours. In the hospitalized patients CsA doses had not been
changed for at least 4 days, and in the out-patients for at least 15 days
prior to the study. All patients had a normal hepatic function and did not
receive any drugs known to interfere with CsA metabolism. Whole
blood was analyzed by RIA (Sandoz), with use of specific and nonspe-
cific monoclonal antibodies to measure CsA parent drug (CsA-P) and
CsA plus metabolites (CsA + M). Results: 16 our of 22 (72%) patients
showed morning pre-dose values higher than those of the evening
pre-dose (P = 0.004 for CsA-P and P 0.01 for CsA + M). When
patients were divided in two groups, 10 out of 11(91%) out-patients
showed morning pre-dose levels higher than those of the evening
pre-dose (P = 0.002 for CsA-P and F = 0.003 for CsA + M), while only
6 out of 11(54%) hospitalized patients showed the same results as above(P = 0.17 for CsA-P and P = 0.3 for CsA + M). Conclusions: Our
findings indicate: 1) diurnal variations on CsA-P and CsA + M
concentrations; 2) these variations were significantly more different in
the out-patients group; 3) because of this, it is essential to standardize
the time of blood sampling for CsA monitoring.
Cyclosporine delays healing of osteodystrophy in renal transplanted
patients. J. Aubia, J. Masramón, S. Serrano, LI. Mariñoso, J. Bosch, I.
Lloveras, Hospital de l'Esperanca, Universitat Autónoma, Barcelona,
Spain. We analyzed the changes of the bone histology of 21 patients at
the time of renal transplantation (RT) and one year later (X: 339 days).
Fourteen patients received cyclosponne (CsA) and low doses of corti-
costeroids and the remaining 7 received azathioprine (Aza) and low
doses of corticosteroids. The global evolution of the histomorphometric
values was towards a clear normalization of the remodeling parameters,
without achieving the complete normalization. A moderate delay of the
mineralization time (Time: 52 days) and slight increases in the osteoid
surface (Sf: 13.2%) among other abnormalities were observed. Before
RT CsA and Aza groups were similar regarding the histology, biochem-
ical values (Ca, P, FAte) and PTHc (2.29 0.6; 1.97 1.1 ng/ml,
respectively). At the time of the second bone biopsy renal function for
both groups was also similar (Cr: 1.6 0.4 and 1.38 0.4 mgldl) as well
as the cummulative prednisone doses (5.75 2.5 g and 6.02 1.2 g,
respectively). The histology of the CsA group was significantly worse
than that of the Aza group that approximated to normality: resorption
surfaces (ES/BS = 2.85 1.2 and 1.99 1.4, respectively), fibrosis(SF/BS = I.! I and 0.3 0.6, respectively) and a higher number of
osteoclasts (7.3 5 mm and 2.69 2 mm, respectively). We conclude
that RT immunossuppressed with CsA have a more prolonged and
intense residual secondary hyperparathyroidism than those treated with
Aza.
Analysis of factors Influencing the loss of bone mass in renal trans-
planted patients. J. Aubia, J. Lloveras, S. Serrano, LI. Mariñoso, J.
Masramón, Hospital de l'Esperanca, Universitat Autónoma, Barce-
lona, Spain. One of the more intensive and universal effects evidenced
in the bone after renal transplantation (RT) is the fast loss of bone mass.
The intensity and the factors influencing this phenomenon have not
been studied extensively. Nineteen uremic patients (15 males, 4 fe-
males) that received a RT (age S: 36.4 yr) were included in a prospective
study of the factors influencing the bone mass loss. Biochemical,
hormonal -PTH- and histomorphometric parameters at the time of
transplantation and one year later were studied. The osteopenia pro-
duced during the first year post-transplantation is correlated with the
quantity of corticosteroids, with the intensity and histologic type of the
osteodystrophy in the previous bone biopsy and with the influence of
the aluminum in this process, by means of lineal and no lineal multiple
correlation. The mean global loss of trabecular bone volume (BV) in
this group was 34% (BV/TV 23.9 9.5 pre; 15.9 6.3 post). Only 4
of the 19 patients maintained a estable bone volume. Surprisingly, we
did not find a significative lineal correlation between the intensity of the
trabecular bone loss and the cumulative doses of corticosteroids.
Contrarily a significative inverse correlation was found with the inten-
sity of the bone remodeling present at the time of RT. Patients with a
greater thickness of osteoid (y 6.21x + 14.67, P < 0.02) and those
presenting a longer bone mineralization time (y = —366.2x + 182, P <
0.002) maintained better their mass. We did not observe influence of
aluminum deposits on the intensity of bone mass loss.
Management of arterial hypertension in patients with chronic renal
failure (CRF). R. MarIn, F. Fdez Vega, L. Sanchez, A. Fueyo, E.
Gómez, J A G, Hospital Covadonga, Division of Nephrology, Oviedo,
Spain. A total of 40 patients with hypertension (HTA) and CRF (serum
creatinine Crs from 1.5 to 5 mg/dl) have been studied retrospectively.
All of them underwent 18 months of treatment: 19 with captopril (C
group) and 21 with other antihypertensive agents (OT group), mainly /3
blockers and vasodilators. Hypertensive nephrosclerosis was the most
frequent cause of CRF. In the begining of the treatment both groups had
similar characteristics related to age (C 49.8 14.4 vs. OT 56.5 8.6),
Crs (2.52 0.8 vs. 2.34 0.5), systolic blood pressure (SBP; 191.8
30 vs. 190.9 19.7), diastolic blood pressure (DBP; 112.6 13.05 vs.
114.2 13.5) and 24-hour proteinuria (1.33 1.5 vs. 1.05 2.1). After
18 months of treatment, a similar and significant drop of DBP and SBP
happened in each group. Crs were raised the same in all but not
significantly (C 2.52 0.8 vs. 2.69 1.2; OT 2.34 0.5vs. 2.50 1.0).
Sixteen patients (8 from C group and 8 from OT) were followed for 4
years. We observed a similar fall of blood pressure (SBP 160.3 12.4
vs. 151,08 8.8; DEP 92.5 6.5 vs. 89.6 6.3). The drop of
proteinuria was slightly higher in the C group (P = 0.1). Crs hardly
changed in this group although it was raised significantly in OT group
(2.28 0.6vs. 3.02 l.21;P = 0.02). Conclusions: 1. Captopril and the
association of 13 blockers and vasodilator have similar effect in the
treatment of HTA and CRF. 2. Captopril is able to delay long-term
impairment of renal function.
Mesangial cell, glomerular and renal vascular responses to endothelin
in the rat kidney are mediated by PAF-acether. A. López-Farré, 1.
Montanés, F. Bernabeu, I. Millás, f.M. López-Novoa, Medical Re-
search Institute, Fundación Jimenez Diaz-Consejo Superior de Inves-
tigaciones Cient(ficas, Avenida Reyes Católicos 2, 28040 Madrid,
Spain. The recently discovered vasoactive peptide endothelin and
PAF-acether share some physiological properties. Thus, the purpose of
the present experiment was to analyze whether a functional relationship
exists between the effect of endothelin on renal function and glomerular
and mesangial cell contraction, and the production of PAF-acether by
the kidney. Endothelin 1 nmol/kg body wt induced a transient decrease
of GFR and RBF and an increase of RVR. Endothelin also induced a
marked reduction of planar cell surface areas of cultured mesangial cells
and of cross sectional areas of isolated glomeruli. BN-52021, a potent
specific inhibitor of PAF-acether receptor, blocked the effects of
endothelin on renal function and isolated glomeruli, and mesangial cell
contraction. Verapamil also blocked these effects. In addition, endo-
thelin induced a significant increase in the production of PAF-acether
by isolated glomeruli. Endothelin also stimulated incorporation of
[3H]acetate into PAF-acether, both in glomeruli and mesangial cells.
These effects were also blocked by BN-5202l and by verapamil. These
results suggest that endothelin effects on renal function and glomerular
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and mesangial cells are mediated, at least in part, by an increase of
PAF-acether synthesis and release.
Influence of long-term cyclosporine (CsA) therapy on chronic liver
disease after renal transplantation (RT). F. Moreno, J.M. Morales, F.
Colina, C. Prieto, A. Andres, J.M. Alcazar, E. Hernandez, J.L.
Rodicio, Nefrology Department, Hospital 12 de Octubre, Madrid,
Spain. The aim of this work was to study the influence of chronic CsA
immunosuppression on chronic liver disease (CLD) in renal transplant
patients. We studied the clinical data of 201 functioning renal trans-
plants, with at least 12 months of follow-up. Seventy-two received
steroids (S) + azathioprine (Aza) and 129 S ÷ CsA. The follow-up
median in Aza group was 60 months and in CsA 30 months. CLD
diagnosis was based on the presence of liver enzyme abnormalities
maintained more than six months, We defined the presence of severe
CLD when prothrobine activity was <70%, unresponsive to K vitamin,
hypoalbuminemia <3 g/Iiter, and coexisting portal hypertension. Time
of development to hepatic complications was evaluated with Kaplan-
Meier estimate, and the comparisons between groups with Mantel-Cox
test. In patients without CLD previous to RT (83%), the probability of
remaining free of CLD at 48 months after RT was higher in CsA patients
(0.81 0.04) than with Aza (0.59 0.07; P < 0.02). Also in 34 patients(17%) who had CLD previous to RT, the probability of remaining
stable, without progression to severe CLD, was a litle bit high in CsA
group (0.91 0.06 vs. 0.63 0.14; P: NS). In this way CsA induced
clinical remission in a patient with active chronic hepatitis before
transplantation (Nephron 51:146, 1989). In conclusion, the probability
of CLD in CsA patients is less than in Aza patients. Our results
reinforce the idea that long-term CsA does not produce chronic
hepatotoxicity. On the contrary, perhaps CsA could be the drug of
election in some patients with CLD undergoing RT.
Long-term use of cyclosporine (C5A) in steroid-dependent nephrotic
syndrome (NS). M. Navarro, Ma José Martinez, C. Sanchez Peinado,
Children's Hospital "La Paz", 28046 Madrid, Spain. The continuous
long-term use of CsA in a boy with steroid-dependent NS lasting 11.25
years, is presented for discussion. The administration of CsA for 2.3
years reverted steroid-dependence and eliminated steroid side effects.
CsA plasma levels were performed by polyclonal antibodies with
radioimmunoassay. Clinical case: B.D. 2-03-73. Boy who presented at
22 months of age with steroid-responsive NS and a renal biopsy of
minimal changes. For the last 11.25 years he has had 33 relapses,
though prednisone treatment has never been stopped. Two cyclophos-
phamide courses (cumulative dose 4.277 mg) and six bolus of 375 mg of
metilprednisolone were given during the follow-up, but the steroid-
dependence could not be modified, neither could the relapses/year be
reduced. From the time he was 3 years old he developed slight
cushingoid features, obesity and progressive loss of height velocity
growth until twelve years old, when he stopped growing. At the age of
13.75 (January 87), CsA treatment was initiated; he is still on it. Results
(mean and SD).
1986 1987 1988 1989
Time with CsA years —1 + 1 +2 +2.3
Relapses years 3 1 0 0
Total protein g/dl 3.9 0.7 6.3 0.6 6.1 0.7 5.8 0.4
Albumin g/dl 1.9 0.4 3.6 1.4 3.9 0.8 3.7 0.3
Cholesterol mg/dl 542 93 363 l54 284 71 220 58
Prednisone mg/month 733 224 370 224 367 166 146 103
CsA mg/kg/day — 3.4 l 5.4 0.? 6.1 0.2
CsA plasma levels — 49 2l 71 ba, 82 3.2
jsg/ml
Cr. mg/dl 0.7 0.5 0.54 0.53
Growth velocity 1 4 7.5 4/Sm
cm/year
a p < 0.05,
Continuous administration of CsA made steroid-dependence fade away
from a CsA dose of 5 mg/kg/day and a plasma CsA level of 71 10 gJml.
Total protein, albumin returned to normal and cholesterol decreased
significantly. Side effects due to long-term steroid therapy were elimi-
nated. He started growing and catch-up growth is possible. CsA
side-effects have been not presented for the time being. Continuous
long-term CsA treatment may be useful in some cases of steroid-
dependent NS in childhood, but side effects must be under close
supervision.
Efficacy of human erythropoietin (EPO) in anemic children with ESRF:
A seven-month experience. M. Navarro, A. Alonso, J.Ma. Avilla. E.
Herrero, E. Martinez, Children's Hospital "La Paz", 28046 Madrid,
Spain. Since October 1988, 25 children were treated with EPO. The
results of 17 cases (9M/8F) with treatment for at least 12 weeks and a
maximum of 28 W (mean 22 W) are presented. Ages ranged from 2
months to 16.6 years (mean 8.6 yr). EPO was given i.v. in progressive
doses (58 15 to 236 59 U/kg/week lx weekly in 10 predialysis
children (EGFR 14.3 6 mI/mi! .73) and in the 4 CAPD, but 3 x weekly
in 3 patients on hemodialysis. Before EPO, 16 out of 17 had received
blood transfusions (11.6 19). Aspirin and dipyridamole were given to
patients with A-V fistula and oral iron supplementation when ferritin
<100 ng/ml. Results (mean and SD)
Hb. g/liter Hto. % Ret. %
Ferritine
ng/ml
Baseline
X 22
weeks
7,5
10.9
l.4a
l.5a
22 3.8
33 5.3
7.5 37
22 lO.8a
604 75?
299 499k
a P < 0.05 for difference vs. Baseline
Increase of Hb. was significant by the 8th week. Blood pressure and
thrombocytes had no significant change, and clinical improvement in
16/17 was excellent. EGFR remained stable in the 10 predialysis (14.3
6 vs. 11.7 4 ml/m/1.73). An increase of the heparin dose was
necessary on hemodialysis (12 to 23% between 4th and 12th week of
treatment). Even though there was a non-significant increase of total Ca
and Ca (T.Ca 10.1 0.86 vs. 11.6 1.06 mg/dl, and Ca 1.28
0.11 vs. 1.52 0.16 mmol/liter), 10 cases developed asymptomatic
hypercalcemia. Aluminum levels (normal 25.6 5.1 pg/liter) showed a
significant increase between 4.4 2.4 and 18 6.7 weeks (62.5 15 vs.
84.4 20 pg/liter). Intact PTH did not decrease significantly (165 27
vs. 80 70 pg/mI), but there was a significant decrease in CO3Ca
suplementation. We conclude that efficacy of EPO has been proven
when given i.v. either 1 or 3x weekly. Maintenance dose was 236 59
U/kg/week. Clinical improvement was remarkable in 94% of patients.
Asymptomatic hypercalcemia may be related to a significant increase of
aluminum levels. Aluminum tissue removal may take places during
EPO treatment as only 2 children were on aluminum hydroxide supple-
mentation throughout the study.
Visceral involvement in amyloid associated hemodialysis. V. Peral, J.
Herrera, P. Menendez, V. Cuesta, M. Alonso, C. Rodriguez, Servicios
de Nefrologia y Anatomia Patologica, Hospital General de Asturias,
Oviedo, Spain. Recent studies have shown the systemic character of
amyloid associated hemodialysis (HD); this type of amyloid is consid-
ered to be rather uncommon, limited in extension and of late onset. To
evaluate visceral amyloid, tissue samples from kidney, liver, bowel,
heart, lung, thyroid, parathyroid, pancreas, adrenal glands, genital and
urinary organs, bone, skin and muscle from 17 necropsies of patients in
HD were stained with Congo Red, and tested for birefringence with
polarized light. All patients had been dialyzed with Cuprophan mem-
branes and their urine volumes were less than 500 mI/day. Mean time in
HD was 4.3 years, ranging from 2 months to 12 years. Other causes of
amyloid were excluded. Amyloid deposition was found in two cases: 1)
A 52-year-old woman with a chronic interstitial nephropathy, who had
been in HD for 3 years. Her kidney, liver, spleen, stomach and muscle
were positive for amyloid. There was also hemosiderosis in spleen,
liver, bowel, heart and lungs. 2) A 66-year-old man with polycystic
kidneys who had been in HD for 7 years had amyloid deposition in
kidneys, liver, spleen, bowel, pancreas and prostate. Of 17 necropsies,
2 cases (11.76%) had visceral amyloid; this shows that visceral amyloid
in HD is neither rare not late, and its extension is not as limited as had
been thought. We remark on the association of amyloid and hemosid-
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erosis in one of the patients that could suggest some etiological
relationship between both entities.
Improvement of primary hemostasis in uremic thrombopathy with
cryoprecipitate. A. Cases, G. Escolar, M. Garrido, T. Feliz, J. Mon-
teagudo, J. Lopez-Pedret, R. Castillo, L. Revert, Nephrology and
Hemostasis Units, Hospital ClInic, University of Barcelona, Barce-
lona, Spain. It has been previously shown that cryoprecipitate (CPT)
shortens the bleeding time in uremic patients, although the mechanisms
of action remain unclear. We have studied the effect of CPT on primary
hemostasis in uremic thrombopathy (UT) and the role of the quantita-
tive increase of plasma levels of von Willebrand factor (vWF) and
Factor VIII in this effect. To 8 hemodialyisys patients with UT (5 men:3
females, aged 51 16 years) blood samples were obtained for perfusion
experiments in vitro. These studies were performed before and after in
vitro addition of CPT (amount equivalent to 1 U/mI of vWF). In vitro
addition of CPT improved the parameters that quantify platelet-suben-
dothelium interaction (percentage of covered surface 21.8 8.5% vs.
13.1 7.1%, P < 0.01; and thrombi 8.4 4.3% vs. 3.2 2.6%, P <
0.01) (mean SD) with respect to control values. In vitro addition of 1
U/mi of vWF or 1 U/mI of vWF plus 1 U/mI of factor VIII did not
improve platelet-subendothelium interaction in vitro. Our results con-
firm that CPT improves primary hemostasis in UT and that this effect is
due to an enhancement of platelet function. This improvement cannot
be ascribed to the quantitative increase of plasma levels of vWF and/or
factor VIII. The combined effect of other adhesive proteins present in
CPT might contribute to the amelioration of UT after CPT.
Tumor markers in chronic renal failure. A. Cases, X. Filella, R.
Molina, A.M. Ballesta, J. López-Pedret, L. Revert, Nephrology and
Biochemistry Services, Hospital Clinic, University of Barcelona, Bar-
celona, Spain. Tumor markers are being increasingly used for the
screening and follow-up of malignancies. However, their correct eval-
uation requires their sensitivity and specificity to be known. It might be
possible that in the presence of renal failure serum levels of these
markers were falsely elevated. The aim of this study was to measure
serum levels and the incidence of increased serum levels of carcinoem-
bryonic antigen (CEA), a-fetoprotein (AFP), CA 12.5, CA 15.3, CA
19.9, CA 50, neuron-specific enolase (NSE), squamous cell carcinoma
antigen (SCC), prostatic acid phosphatase and prostatic specific antigen
in 30 patients with chronic renal failure (CRF) of different degrees and
36 hemodialyzed (HD) patients without clinical evidence of malignancy.
CEA serum levels were increased over reference values in 35% of CRF
patients and 48% of HD patients, CA 50 in 38% and 47%, respectively,
and SCC in 43% and 73%, respectively. Serum levels of CA 12.5 were
found to be increased in 18% of CRF patients and NSE in 28% of HD
patients. The remaining tumor markers evaluated were increased in less
than 10% of patients in both groups. There was a correlation between
serum levels of creatinine and CEA in CRF patients (r = 0.56, P <
0.01). In chronic renal failure several tumor markers (CEA, CA 50,
NSE and SCC) show a high rate of false positive results, while the
others appear to maintain their specificity in this situation. These results
must be taken into account when serum levels of these markers are
evaluated in the presence of renal failure.
Post-mortem evaluation of visceral amyloidosis involvement in patients
on dialysis. J. Fort, M.T. Vidal, A. Olmos, J. Camps, L. Piera,
Nephrology and Pathological Anatomy Departments, General Hospital
VaIl D'Hebron, Barcelona, Spain. Beta 2-microglobulin related amyloi-
dosis is an important known complication of long-term hemodialysis
patients. Although accumulation of amyloid usually takes place at the
osteo-articular structures, several articles have recently highlighted the
incidence of amyloid systemic accumulation. In order to evaluate the
incidence of systemic amyloid involvement, we studied visceral mate-
rial from autopsies of 10 dialysis patients treated with cuprophan
membranes. Patients with primary and secondary forms of amyloidosis
were excluded. Samples of different tissues were stained with Congo
red and examined under conventional light and polarization micros-
copy. The immunohistochemical studies were done with a peroxidase
anti-peroxidase technique with human serum anti-beta 2-microglobulin
(Dako). The lack of reaction against other antisera was used as a
control. The results were statistically treated with non-parametric
methods (Mann Whitney's U-test). We established two group of pa-
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tients: group A with visceral deposits of amyloid on the post-mortem
study, and group B, with no tissue accumulation of amyloid. We found
visceral deposits of beta 2-microglobulin in five of ten post-mortem
studies. The average age of the patients was 8 years and the average
time of hemodialysis was 9.4 years. The amyloid deposits were scarce,
small and segmentary, being predominantly located at the vascular
valls. The heart, bowel and prostate were the most commonly affected
organs. The average age and average time of hemodialysis of group A
patients was higher than that of the group B patients. There was a
statistically significant correlation between the age of the patients and
the accumulation of visceral aniyloid. There was no history of articular
involvement in two patients of group A. We conclude that the incidence
of systemic beta 2-microglobulin amyloid accumulation is high, and that
in our series at least, it seems to correlate with the increasing age of the
patients. The site more commonly affected is the heart, and the deposits
are small and infrequent, which would explain the lack of functional
impairment of the involved organs. Even though most patients with
systemic accumulation have osteo-articular involvement, the lack of
amyloid arthropathy symptoms does not exclude the presence of
systemic involvement.
Organ procurement organization in the Basque autonomous commu-
nity. J. Aranzabal, J. Mi/ares, J. Arri eta, M.T. Neyro, andJ. Montene-
gro, Transplant Coordination, Osakidetza/Basque Health Service, Bil-
bao, Spain. An organ procurement and transplantation program has
been established in the Basque autonomous community. Twelve public
hospitals are engaged in donor detection. Of these, eight hospitals have
been authorized for organ removal operation (Sometimes the donor
must be transported). Only corneal and renal transplantations have
been carried out. The coordination team is made up of two hospital
coordinators and two interhospital coordinators. Continous tracking of
personnel and logistics (patrol cars and helicopters) are guaranteed by
the Coordination Operating Centre (Department of Interior). Results:
During 1987 and 1988, 133 potential donors have been evaluated (31.1
potential donor/PMP/yr) representing 1.1% of hospital deaths. Real
donors were 50% of potential donors, averaging 26 years of age (26.3
years). The causes of rejection of organ donation were medical con-
traindication (32%), detection failure (2%) and family refusal (16%). The
multiorganic donors were 36.4% of the real donors. The rest were
rejected due to medical contraindications (41%), logistical problems
(19.6%) and family refusal (3%).
1987
Removed
organs
—1988
PMP/yr
198
Removed
organs
4—1985
PMP/yr i PMP/yr
Kidneys 132 31 83 19.4 49 11.6
Livers 17 4 2 0.5 15 3.5
Hearts 10 2.4 2 0.5 8 1.9
Eyes 117 27.5 — — — —
Conclusions: Positive aspects: increased number of extraction and
detection hospitals; organ transplantation coordinating team perfor-
mance; medical and surgical teams performance; prompt action of team
(Department of Interior); efficient assistance by the local Police Depart-
ment. Negative aspects: Dependence on outside non-renal removal
teams.
Treatment of high-risk lupus nephritis with i.v. cyclophosphamide.
Preliminary results. A. Alonso, J. Saavedra, J. Fernández Daza, C.
Rivera, M.P. Fontán, F. Valdés, E.V. Martul, Nephrology and Pathol-
ogy Services, Hospital Juan Canalejo, A Corufla, Spain. Six women
with high-risk lupus nephritis (defined by GFR <70 mI/mm, proteinuria
> 3 g/day and an active sediment) were treated with trimestral i.v. bolus
of cyclophosphamide (CP). Renal biopsy disclosed diffuse proliferative
glomerulonephritis (OMS type IV) in all cases, with a mean activity
index of 11/24 (range 10 to 13), and a mean chronicity index of 2/12
(range 0 to 7). No patient had received previous immunosuppresive
therapy. Patients received a mean of 5 i.v. CP bolus (range 3 to 7), at a
dose of 750 mglm2/bolus; prednisone was added at an initial dose of 0.2
to 0.5 mg/kg BWT, and then progressively tapered as clinically toler-
ated. Mean follow-up was 12 months (range 5 to 20). The following
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parameters were monitored before and during treatment: hematocrit,
hemoglobin, ESR, leucocyte and platelet count, serum albumin, urinary
sediment (centered in the intensity of hematuria), C'3, C'4, antinuclear
and anti-DNA antibody titers, and dose of prednisone. Results:
P
Initial Final value
Albumin gIdi 2.43 0.30 3.36 0.40 <0.01
GFR mI/mm 51.5 19.1 93.0 38.5 <0.05
Proteinuria g/day 5.71 1.30 2.05 1.10 <0.001
Sediment eryt./HPF 44 41 2.3 16.9 <0.05
C'3 mg/dl 61.5 14.3 80.3 13.5 <0.05
Prednisone dose mg/day 20.8 9.1 9.6 2.9 <0.05
(The other parameters did not show significant variation)
Treatment was well tolerated. The main complications observed were:
herpes zoster (3 cases), menstrual irregularities (1 case), and slight
allopecia (2 cases). We conclude that, at the doses employed, i.v. CP
ameliorates renal function in patients with severe and active lupus
nephritis, with a clear steroid-sparing effect. Clinical tolerance is
excellent, with few and moderate complications. This notwithstanding,
immunologic remission seems not to be complete, raising doubts as to
the long term prognosis. Additional controlled studies, with a longer
follow-up are warranted to validate these results.
Effects of treatment with a renal inhibitor of the tubular reabsorption
of calcium (WR2721) and with a bisphosphonate (APD) on the hypercal-
cemia and hypercalciuria associated with the Walker 256 tumor. J.
Hurtado, P. Esbrit, A. Rapado, Unidad Metabolica, Fundación
Jimenez Diaz, C.S.I.C., 28040 Madrid, Spain. The Walker 256 carci-
nosarcoma (W256) is an experimental model of humoral hypercalcemia
of malignancy (HHM). Hypercalcemia (HCa) in this tumor appears to
involve an increase in bone resorption (BR) and a stimulated tubular
reabsorption of calcium (TRCa). The relative importance of these
mechanisms is still unknown. To assess the most important mechanism
responsible for hypercalcemia associated with W256, changes in serum
and urine calcium levels have been studied, before and two hours after
the administration of WR2721 [S-2,2-(3-aminopropylamino)-ethylphos-
phorothioic acid] to hypercalcemic tumor bearing rats. This drug is
known to inhibit both parathormone (PTH) secretion and bone resorp-
tion. Moreover, WR2721 has also been shown to decrease TRCa in
another tumor model of HHM. The effects observed with this treatment
has been compared with those obtained with the administration of
3-amino-hydroxypropylidene-1,l-bisphosphonate (APD), a potent in-
hibitor of bone resorption. The results indicate that WR2721 can be
effective in inhibiting the increased TRCa present in W256 bearing rats.
In addition, the efficiency of APD treatment is limited due to the major
importance of the renal mechanism on the development of hypercalce-
mia associated with W256.
Hypoprotem diet and captopril effects on urinary albumin excretion in
type I (insulin dependent) diabetic patients. J.Ma. Mallafre, J.Ma. Pou,
R. So/a, M. Balsells, X.M. Lens, S. Nephrology, H. Creu Roja, S.
Endocrinology, H. Santa Creu i Sant Pau, S. Nephrology, FundaciO
Puigvert, Spain. The microalbuminuria (urinary albumin excretion,
AER) is one of the most important parameter in the early diagnosis of
diabetic nephropaty in type I diabetic (insulin dependent) patients
(IDDM). Different therapies were used to avoid the development from
AER to diabetic nephropathy. Twelve normotensive IDDM patients
(Age: 35 12 yr, diabetes evolution 14 6 yr, HbA1 8.5 1.5%) were
randomized and sequentially treated with hypoproten diet (0.6 g/kg/day)
and captopril (12.5 to 50mg/day) for one month (one month of wash-out
in between). Their AER was 80.4 1.3 g/min (nephelometric method
N < 12 ig/min.). Results: AER was expressed in g/min
Basal status 80.4± 11.3
After hypo. di.
After captop.
31
53.2
12
17
P < 0.01
P <0.05
Conclusions: Decrease of AER was more important with hypoproten
diet than with captopril (P < 0.05). The restriction in protein intake
could be a useful tool in the therapy of AER and the future development
of diabetic nephropathy. We need more experience and duration of
treatment if we want to obtain more definitive conclusions.
Long-term follow-up of serum glucose and cholesterol in essential
hypertension. f.M. Alcázar, A. Oliet, E. Herndndez, F. Moreno, J.L.
Rodicio, L.M. Ruilope, Hypertensive Unit, Department of Nephrology,
12 de Octubre Hospital, Madrid, Spain. It has been amply demon-
strated that long-term diuretic therapy induces biochemical alterations,
mainly related to changes in serum glucose, cholesterol and potassium,
that could be deletereous for the patients. We have followed for a
period of 8 years a group of 211 patients diagnosed as having essential
hypertension. All these patients were divided according to their thera-
peutic needs in 4 groups: A) non-pharmacological therapy (N 39; B)
A + diuretic (N = 96); C) B + beta-blockers (N = 50); D) C +
vasodilator (N = 26). They remained in the same therapeutic regime
during the follow-up. Besides the control of blood pressure (BP) and
body weight, a standard biochemical profile was perfomed at least
every 6 months. During the study BP remained within similarly ade-
quate levels in the four groups of patients. At the end of the follow-up,
serum glucose and cholesterol exhibited similar significant increases (P
<0.01, ANOVA) in those patients who did not receive any medication
and in those receiving a diuretic alone or in association. The statistical
study also disclosed that when the diuretic was employed the increase
of both parameters was already significant after 4 years of treatment,
unlike patients included in group A who exhibited a similar increase
after 8 years of follow-up. Serum potassium behaved in a similar fashion
during the 8 years with significantly (P < 0.01) lower values when the
diuretic was used. These results indicate that long-term diuretic therapy
precipitates the appearance of forthcoming alterations in essential
hypertensive patients.
Persistence of the natriuretic effect of cakium entry blockers. F.
Moreno, f.M. Alcdzar, E. Hernández, A. Andrés, J.L. Rodicio, L.M.
Ruilope, Hypertensive Unit, Department of Nephrology, 12 de Octubre
Hospital, Madrid, Spain. To elucidate whether or not the natriuretic
properties of calcium entry blockers persist during the long-term
administration of the drug, we have investigated the renal capacity to
excrete an intravenous sodium load (2,000 ml of isotonic saline in 4 hr)
in a group of eight mild to moderate essential hypertensive patients,
before and after 1, 8, and 24 weeks of treatment with nitrendipine. The
following parameters were measured before and hourly during saline
infusion: blood pressure, and plasma and urine sodium and potassium.
For 5 days prior to the performance of the test, the patients received a
diet containing 120 mEq of sodium daily. Nitrendipine induced a
significant fall of both systolic and diastolic blood pressure (P < 0.05 to
0.01) that was maintained throughout the study. A significant increase
of the cumulative renal sodium output (Eq/minJhr) was observed after
1, 8 and 24 weeks (P < 0,05 to 0.001) of therapy with the calcium entry
blocker. Meanwhile, plasma sodium and potassium and the kaliuresis
did not change significantly. These results indicate that the natriuretic
effect of calcium entry blockers is still present after long-term treat-
ment.
Diuretic and natriuretic properties of fenoldopain, a DAI agonist in
advanced chronic renal failure (CRF). A. Andres, L. Ruilope, R. Garcia
Rob/es, f.M. Alcazar, J. Tovar, A. Oliet, J. Sancho, J.L. Rodicio,
Department of Nephrology, Hospital 12 Octubre, Department of En-
docrinology, Hospital Ramon y Cajal, Spain. It has been found that a
deficit of dopamine could play a role in the sodium retention of CRF.
We tested the hypothesis that fenoldopam (F), a dopamine Dl receptor
agonist, could have a favorable effect on the renal excretion of sodium
and diuresis in advanced CRF. Therefore, F was infused at doses of
between 0.025 and 0.1 gIkg/min in a group of 12 patients (6 female, 6
male, age: 55.8 8 years) with advanced CRF (creatinine clearance
between 6 and 35 mi/mm), secondary to diabetic nephropathy (6),
nephrosclerosis (3), and chronic interstitial nephropathy (3). F was
infused during 6 hours in 6 patients and 12 hours in the remaining.
Diuresis (D), natriuresis (Nau), kaliuresis (Ku) and creatinine clearance
(Ccr) were determined during an initial period of one hour before to the
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infusion and hourly thereafter. BP was controlled every 15 minutes.
The following results were obtained (X SD).
Basal 1 hour 3 hour 6 hour
12 hour
(N = 6)
D
mi/mm
Nau
p.Eq/min
Ku
i.&Eq/min
Ccr
mi/mm
0.9 0.4
47.7 36
24.8 14
17 11
1.9 1.5 1.4 0.6C
110.9 l27 73.9 29
52.5 55 439 3l
23 18 22 15
1.9 l.5
75.9 31"
47.3 29C
28 l9
1.4 0.3"
70.5 32
32.4 15
15.8 8
a P < 0.05, b P< 0.01, P< 0.001 versus basal.
The levels of systolic and diastolic blood pressure fell significantly and
these changes were perfectly tolerated by the patients. These results
indicate that in the doses used, i.v. F could facilitate the renal excretion
of sodium and water in advanced CRF, while ensuring an adequate
control of BP.
Reduction of protemurla associated with obesity by diet and/or treat-
ment with captopril. E. Hernandez, M. Praga, V. Gutierrez-Millet, J.M.
Morales, Servicio NefroiogIa, Hospital 12 Octubre, Madrid, Spain.
Several cases of proteinuria related to massive obesity have been
reported. The pathogenesis of this proteinuna is unknown, although
some authors have proposed mechanisms of glomerular hyperfiltration.
We have performed a prospective study in obese patients to ascertain
the incidence of proteinuria (>1 g/24 hr). Over 146 patients, 10 (6.8%)
showed proteinuria (1.3-8.4 g/24 hr; mean 3.4 2.3 g/24 hr). In four
cases the proteinuria reached nephrotic range. Their age was 43 10.2
years (range 36 to 70), were two males and eight females. Six patients
had Grade! obesity (>30 kg/rn2) and 4 Grade!! (>40 kg/rn2). The weight
oscillated between 84 and 128 kg (mean 98 12 kg). All the patients had
normal renal function and 7 had arterial hypertension (mild in 3 and
moderate in four). Four patients had a unique functioning kidney
because previous nephrectomy. Renal biopsy was performed in 5 cases.
Minimal glomerular changes (fusion of podocytes) with negative immu-
nofluorescence was observed in 4 cases and the remaining showed a
picture of focal glomerulosclerosis. Four cases (Group I) were treated
with a low caloric diet; at the end of follow-up (18 8.6 months) the
weight had decreased 10% to 15% (mean 11.6%) and the proteinuria had
decreased from 3.2 2.2 g/24 hr to 0.2 0.2 g124 hr (P < 0.05). The
other 4 patients (Group II) were maintained with normal diet and
treated with captopril (50 to 150 mg/day) for 24 1.6 months. The
weight remained stable but proteinuria decreased from 4.4 2.8 g/24 hr
to 0.33 0.14 (P < 0.05). The remaining two patients were treated with
both low caloric diet and captopril (50 to 100 mg/day). Mter 14 and 20
months, respectively, of follow-up, weight had diminished a 9% and the
proteinuria from 1.9 0.3 g/24 hr to 0.07 g/24 hr. There were no
significant changes in blood pressure, renal function, nor serum cho-
lesterol along the follow-up of the 10 patients. Serum triglycerides
showed a significant decrease (195 75 to 145 49 mg/dl, P < 0.05).
!n summary, 6.8% of our obese population showed proteinuria >1 g/24
hr. Our data confirm the proteinuria decrease obtained with marked
weight reduction. Furthermore, the striking decrease of proteinuria
without weight changes observed with captopril treatment in Group II
supports the role of glomerular hyperfiltration in the pathogenesis of
obesity related proteinuria.
Adult renal transplantation with pediatric and elderly donors. C.
Prjeto, E. Rodriguez-Paternina, J. Farias, A. Andres, J.M. Morales, E.
Hernandez, C. Montoyo, J.L. Rodicio, Hospital 12 Octubre, Madrid,
Spain. Between July 82 and December 88 we performed 325 renal
transplants (RT); 54 of them (16.6%) received a cadaver graft from
pediatric donor (PD) aged between 1 and 16 years and 42 of them
(12.9%) received a cadaver graft from elderly donor (ED), aged more
than >50 years. The results of both groups of patients were compared
with control group (CG; N = 52) of RT that received their graft from
donors aged 25 to 40 years. The sex and age in each group were: ED
(SF, 37M, 37.07 10.7 years); PD (23F, 31M, 35.9 11.3); CG (20F,
32M, 37.8 12.3). In the table we show the principal clinical data of the
three groups. There was no difference in acute tubular necrosis (ATN),
acute rejection (AR) nor graft and patient survival rate in the three
groups. There was higher incidence of arterial hypertension after RT in
the groups ED and PD.
HBP
Follow-up
months
Bef,
RT
Al.
RT
I
CsA
S
Aza ATN AR GS PS
ED 25.6 24.3 45% 69% 88% 22% 70% 52.3% 71.4% 95%
PD 30.1 28.4 42% 81%" 44% 56% 71% 70% 66% 98%
CO 38.2 28.2 59% 67% 57% 43% 69% 50% 76% 92%
a p < 0.05 vs. before RT, b p < 0,001 vs. before RT. HBP, high blood
pressure; IS, immunosuppression; OS, graft survival; PS, patient
survival.
In conclusion, in our experience RT with elderly and pediatric donor
did not represent an important risk in the evolution of graft and
recipient.
Reversal of steroid and ATG-resistant acute rejection crises in renal
transplantation with monoclonal antibody (OKT3). C. Prieto, E. Rod-
riguez-Paternina, J.M. Morales, A. Andres, J. Farias, C. Montoyo, T.
Ortuflo, J.L. Rodicio, Hospital 12 Octubre, Madrid, Spain. We report
our experience with ORTHOCLONE OKT3 as rescue therapy for
steroid and ATG-resistant acute rejections in fifteen patients (11 men, 4
women), who failed to reverse rejection with methyiprednisolone
pulses 10 to 15 mg/kg/day for three days and antithymocyte globulin
(ATG) 10 mg/kg/day for seven days in four patients. The mean age was
36.1 years (range 24 to 60 years). All patients received kidneys from
cadaver donors. Maintenance immunosuppression was conventional
therapy in 5 patients and cyclosporine (C5A) or triple therapy in 10
patients. The dose of OKT3 was 5 mg i.v./day for 7 to 14 days, and
during OKT3 therapy CsA doses were reduced. Rejection reversal was
achieved between 4 to 13 days of therapy with OKT3. The first dose of
OKT3 caused fever in 100% of patients and less incidence of chills,
diarrhea, nausea, vomiting and headache. The immunologic monitoring
in eight patients during therapy with OKT3 showed undetectable T3 in
the peripheral blood. Steroid-resistant acute rejection was controlled at
the beginning of treatment in 11 patients (73%) and graft survival was
53.3% in X 8.9 months (range 3 to 18) of follow-up. A second rejection
occurred in 5 cases (33%), 3 of them were controlled with steroids, 1
steroid-resistant was controlled with a second OKT3 cycle. All unre-
sponder OKT3 patients, N = 7, presented late acute rejection at least
one year after transplantation. In these patients interstitial fibrosis was
the predominant histological sign. Ten infection episodes of bacterial or
viral origin were observed, and one patient died because of CMV and
bacterial sepsis four months after OKT3 was stopped. In conclusion,
OKT3 is a very effective drug rescue therapy in high-risk steroid-
resistant rejection crises.
Renal transplantation in older patients treated with low doses of
cyclosporine. J.M. Morales, E. Hernández, E. Rodriguez-Paternina, A.
Andrés, C. Prieto, F. Moreno, M. Praga, T. Ortuno, J.L. Rodicio,
Nephrology Department, Hospital 12 Octubre, Madrid, Spain. In our
hospital from January 1986 to November 1988, 184 cadaveric renal
transplants (RTs) were performed: 55 (29.8%) in RTs over 50 years (37
between 50 and 54, 24 between 54 and 59 and 4 in over 60). The
immunosuppressive protocol was prednisone 0.5 mg/kg/day and cyclos-
porine (CsA) from the 0 day 10 to 14 mg/day. The results of these
patients were compared with those obtained in a group of 90 RTs of low
risk: age <50 years, first RT and no hyperimmunized. Graft actuarial
survival rate (Kaplan-Meier) at 12 and 24 months, was 79% and 69%, in
old patients vs. 86% and 80% in low risk patients (P < 0.05). Patient
actuarial survival rate was similar in both groups (92% vs. 94%). The
incidence of acute rejection and the change to conventional therapy
(because of CsA nephrotoxicity [N]) were a little bit low in older
patients: AR 30% vs. 38%, P = NS and CsAN 23.6% vs. 33.3%, P =
NS. Although the incidence of sepsis was similar (5.4% vs. 4.4%),
infections mainly of urinary origin were more frequent in older patients
(53% vs. 30%, P < 0.05). There were no differences in the presence of
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steroid induced diabetes nor urological complications, such as obstruc-
tive uropathy. In conclusion, in patients over 50 years renal transplan-
tation under steroid and low CsA doses is an excellent therapy. Graft
and patient survival rates are good and there is no more incidence of
important complications than in the younger group.
Influence of LILA-dose II antigens of graft survival in patients with
low-doses of cyclosporine. E. Hernández, E. Paz, J.M. Morales, J.L.
Vjcarjo, C. Prjejo, A. Andres, J.L. Regueiro, A. Arnaiz, J.L. Rodicio,
Nephrology and Immunology, Department, Hospital 12 de Octubre,
Madrid, Spain. The current role of HLA histocompatibility in renal
transplant patients (RTs) treated with cyclosporine (CsA) is controver-
sial. The purpose of this work was to analyze the influence of HLA
antigens, specially of class II in our RTs. Between December 1986 and
November 1988, 123 RTs were performed. Six of them received a
second graft. All patients were treated with prednisone 0.5 mg/kg/day
and CsA 10 mg/kg before surgery, and then the second dose at 24 hours.
CsA was slowly decreased depending on blood levels and side effects.
HLA-typing determining A, B, DR. DRw52/w53 and Dq antigens in
donors and recipients was performed. Graft and patient survival rates
was calculated by Kaplan-Meier method, comparing the different
degrees of compatibility in the 111 RTs that continued the initial
therapeutic protocol at least six months after renal transplantation.
Patient survival rate was 95% and 90% at 12 and 24 months, respec-
tively. Graft survival rate was 85% and 74% at 12 and 24 months. There
were no differences in the graft and patient survival rates between the
RTs with 2 identities versus 0 in the locus A, B, and DR. So, it was
when we consider the identities of a locus isolated or combinated with
the others. Also, the compatibility DR w52/w53, DRI an DR6 antigens
did not show influence on the survival rates. Only the patients with two
identities in locus Dq presented a greater graft survival rate of year than
those with 0 or I identities (86% vs. 81%, P = 0.02, Mantel test). In
conclusion, in patients treated with low-dose of cyclosporine the
compatibility of Dq antigens can improve graft survival rates. However,
we have not showed a beneficial effect of the DR and DRw52/w53
compatibility on graft survival.
Hemodialysis effects on growth hormone (Gil) response to growth
hormone releasing hormone (GH-RIl) in uremic patients. F. Garcia
Martin, S. Donnay, E. Martin Escobar, G. de Arriba, R. Requejo, R.
Martin Hernández, Hospital Virgen de la Luz, Cuenca, Spain. GH
levels are often elevated in renal failure with abnormal response to
several stimuli. The aim of this study was to evaluate the GH response
to GH-RH in uremia and the possible effect of hemodialysis (HD) on it.
An acute OH-RH test (50 sg i.v. bolus) was performed before (8.30
a.m.) and after (12.30 p.m.) HD session (dialysate with glucose 5.5
mmol/liter) in 10 uremic males and in 8 age-matched controls at the
same hours. Blood samples were obtained at —15,0, 15, 30, 45, 60 and
90 minutes after GH-RH administration. The GH blood levels were
determined by RIA. Baseline GH and the peak after GH-RH were
significantly higher (2.6 0.6 and 27.8 5.5 Lg/liter) in uremics before
HD than in controls at 8.30 a.m. (0.68 0.1 and 11.5 4.0 pg/liter) (P
<0.05 and P <0.01 respectively). GH basal level and peak went down
significantly (0.5 0.03and 3.1 1.1 pg/liter; P < 0.01) after HD, while
no descent was observed in controls at 12.30 a.m. The basal glucose and
the levels during the test, before and after HD, was not modified, The
test did not differ when glucose free dialysate was utilized. In summary,
the GH response to GH-RH in uremia is higher than in normal controls,
but this response is lowered by HD. This lowered response is sustained
in spite of no modification in glucose levels and even with the use of
glucose free dialysate. HD probably modified someone modulating
factors of GH response to GH-RH.
Correction of the anemia and bone marrow response in hemodialysis
(LID) patients with recombinant human erythropoietin (EPO-R). F.
Garcia Martin, T. Carrascosa, E. Martin Escobar, J. Va!, R. Martin
Hernández, G. de Arriba, C. Teno, J. Salvatierra, Hospital Virgen de
la Luz, Cuenca, Spain. Several factors may contribute to the pathogen-
esis of uremic anemia, but there is general agreement that inadequate
secretion of erythropoietin is the main cause. The aim of this study was
to evaluate the anemia and bone marrow response to EPO-R in patients
on maintenance HD. Ten anemic hemodialysis patients dependent on
regular blood transfusions with hemoglobin (Hb)  8 g/dl were treated
with EPO-R (50 to 125 U/k three times weekly). Hematological studies
and bone marrow biopsies were performed at the start of the study and
after six months of EPO-R administration, when the anemia was
corrected. The Hb increased from 7.3 0.3 to 12.4 0.3 g/dl (P <
0.01), the hematocrit from 21.5 1.3 to 38.9 0.8% (P <0.01), and the
reticulocyte count from 1.27 0.2 to 3.21 0.4% (P < 0.05). The
serum ferritin levels decreased significantly (215 37 vs. 45 10
pg/liter, P < 0.01). Bone marrow showed normo-hypocellularity with
moderate erythrodysplasia before EPO-R. After six months of treat-
ment iron stores decreased significantly (P < 0.001), and an increase of
cellurarity and improvement of cellular dysplasia were found. In
summary, the EPO-R is a very effective treatment of anemia in patients
maintained on HD, and the need for transfusions was completely
eliminated. Bone marrow showed decrease of iron stores with increased
cellularity and improvement in the erythrodysplasia; this finding could
be due to shortened time passage for hematopoietic progenitors across
bone marrow with improvement of their maturative process.
Improvement in the bleeding time (BT) in chronic hemodialysis (LID)
patients after treatment with recombinant human erythropoletin (EPO-
R). F. Garcia Martin, T. Carrascosa, E. Martin Escobar, R. Martin
Hernández, J. Va!, G. de Arriba, Hospital Virgen de Ia Luz, Cuenca,
Spain. Uremic patients have a defect of primary hemostasis manifested
as increasing bleeding and lengthening of the BT. The aim of this study
was to evaluate the BT in uremic patients on maintenance HD treated
with EPO-R for six months. EPO-R was administered (50 to 125 is/k
three times weekly) in 10 uremic patients on HD, aged 32.6 13 years
old. All patients required regular blood transfusions. The BT was
measured in the forearm by a template method (Simplate II, General
Diagnostics) before and after six months with EPO-R treatment. Values
are expressed as mean standard error.
Basal 6 months P
Hb g/dl 7.23 0.2 12.38 0.3 <0.01
Ht % 21.55 1.2 38.96 0.8 <0.01
Red cell 106/ml 2.42 0.1 4.34 0.1 <0.01
VCMfl 93.26 1.9 91.97 2.7 NS
Platelet 103/ml 233 12 274 17 NS
BT mm 27.10 1.6 8.41 0.8 <0.001
A significant correlation (r = —0.9049) was found between hematocrit
and BT. Furthermore, in four patients with hemorrhagic diathesis
before EOP-R treatment, these symptoms disappeared. We conclude
that correction of anemia in uremic patients with EPO-R improved the
BT. The increase of hematocrit might favor thrombus formation and
might improve the hemostatic abnormalities of uremia. A significant
negative correlation was found between hematocrit and BT.
Clinical implications of unexpected high glomerular filtration rate
(HGFR) after renal transplantation. G. Hernandez Poblete, A. Andres,
J.M. Morales, C. Prieto, E. Hernandez, T. Ortuno, J. Farias, E.R.
Paternina, V. Gutierez Millet, C. Montoya, J.L. Rodicio, Nephrology
Department, Hospital 12 Octubre, Madrid, Spain. The aim of the study
was to investigate from a clinical point of view the significance of
HGFR that can appear in some renal transplants (RT). We revised the
clinical data of 234 functioning RT: 122 on cyclosporine (CsA) and 112
on azathioprine (Aza). Forty RT (17%), 20 CsA 20 Aza, showed HGFR
defined as a creatinine clearance (Car) more than 120 ml/min/1.73 m2 in
at least three consecutive clinical revisions in some moment of the
evolution. We compared these patients with a group of 40 RT, 20 CsA
and 20 Aza, with C between 80 and 100 mI/mm/i .73 m2 in the same
circunstances. There were no differences in donor and receptor age,
sex, first RT, cold ischemia time, HLA-DR matching, acute tubular
necrosis, acute rejection nor the increase of body weight nor urine urea
excretion in both groups. Only HGFR patients showed higher C. at the
first posttransplant month (73.3 24 vs. 62.2 23.5, P < 0.05). These
patients developped HGFR 4.3 3.9 months later. Remarkably, HGFR
CsA patients showed a shorter renal function recovery time after
transplantation (13.5 6.6 vs. 21 10.1 days, P < 0.05) without other
differences. The presence of HGFR was maintained at least more than
one year and only four lost HGFR, but nobody presented proteinuria
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nor renal failure. In conclusion, RT patients could have HGFR, even on
CsA therapy. This finding could mean that RT have a potential renal
reserve that can be evident if immunologically well tolerated and early
CsA nephrotoxicity is avoided. At the moment, long-term conse-
quences of chronic HGFR are unknown.
HD strategy and recombinant human erythropoietin (EPO). Is it
neccesary to modify it? G. Barn!, C. Bernis, J. Hdz-Jaras, V. Alvarez,
V. Paraiso, c.Ga-Canton, B. Rincon, J.A. Traver, S. NefrologIa,
Universidad Autónoma, Hospital de La Princesa, Madrid, Spain. The
consequence of the schemes of HD can originate from the amount of the
values of Hct, Hb and platelets. We've analyzed in 18 patients (IOM-8F)
in treatment with EPO for 5 months these parameters: BUN, creatinine,
total proteins, albumin, Na, K, kinetics of urea (G, PCR, TAC, KTV),
transfusions, dry weight, heparine dose/session, flux of the fistulae and
interview about quality of the life. The results of the levels of the BUN,
creatinine, Na and K showed no significant difference in 2 cases with
symptomatic hyperkalia in relation with the increment of the diet. Also
we didn't find differences in the levels of G, PCR and TAC, nor in the
dry weight. But the KTV decreased significantly (P < 0.05), but to an
aceptable limit (1.121 0.22/1.06 0.25). In 11 patients it was necesary
to increase the dose of heparin during the study, but the differences
(0.67/0.8/mg/kg/sesion) were not significant. We've not founded
changes in the flux obtained from the fistulas and had no problems of
coagulation. The needs of transfusions disappeared in all cases, reduc-
ing to levels of 2.4 units patient/S months to 0. In the patient interviews
all had better physical conditions, more permission to be active except
in 1 case. The valuation of the beginning of improvement was variable,
and had similar appetites, oscilating in some by days and others in the
first two months. No one had secondary effects except 1 case of
temperature of 37.2°C during the first month that ceased with adminis-
tration of Paracetamol. Conclusions: 1) EPO use don't look like it
requires important variations in the scheme of the HD. 2) Transfusion
needs disappeared in all the cases. 3) We haven't found problems in the
fistulas and the bigger needs of heparin were not significant. 4) The
quality of life got better subjetively and objectively in all the patients. 5)
It is necessary to study the changes of the different parameters further
to validate our results.
Treatment of the anemia in ND with recombinant human erythropoi-
etin (EPO). J.A. Traver, G. Barn!, J. Hdz-Jaras, C. Bernis, V. Alvarez,
A. Diaz, V. Paraiso, C. Ga-Canton, B. Rincon, S. Nefrologia, S.
Bioqulmica, UniversidadAutónoma, Hospital de La Princesa, Madrid,
Spain. Eighteen patients (IOM-8F) were studied who had an average of
52.02 years (17 to 74), time in HD 38.94 months (8 to 141), with an Hb
lower than 8.4 g during 5 months (6 to 4). Previously we've asked for
authorization of our patients. The initial dose of EPO was 50 U/
kg/sesion i.v. at the end of HD, which we've modified depending upon
patient response. Hct, Hb and platelets were determined weekly, and
monthly retriculocytes, iron, ferritin, transferin, saturation and the
habitual controls. In 10 patients basal EPO by RIA was determined. In
the begining and ending, PTH, aluminium and osteocalcine were
measured. Significant elevations (P < 0.001) of the Het (22.8 +
2.24/32.36 + 4.49), Hb (7.74 + 0.67/10.36 + 1.56), platelets (169 +
45/220.5 + 58) and reticulocytes (12.9 + 7.7/29 + 12.25) were found. In
the 10 patients studied the average basal EPO was 11.8 + 1.4 and
correlated negatively and significantly with the increasing Hct in 8 first
week patients (P < 0.05). In 6 patients the dose of EPO was reduced.
The average of TA did not have significant variations. Of the 18 patients
II don't have HTA; 4 have been controlled by diet and 3 with
medication. Two of them have presented symptomatic elevation that
has required medication. There haven't been significant variations in
the K, but 2 patients presented symptomatic elevation of the K in
relation with dietetic transgression. We haven't found complications in
AVF. Eleven cases have needed increased heparin even though the
difference wasn't significant, One patient had fever 37.3°C, which was
controlled with Paracetamol. We've not found hepatic disorders, as-
teoarticular signs or convulsions. One patient with epilepsy was
treated. All needed transfusions, the average early in 5 months was of
2.4 units/patients. Significant decreases in the levels of aluminium and
alkaline phosphatase (P < 0.05) were found, without changing the rest
of the parameters. Conclusion: EPO is an efficient corrector of the
anemia in HD with minimal secondary effects in our experience.
Microalbuminuria in autosomal dominant polycystic kidney disease.
M.D. Jarillo, M. Sanchez, J. Nieto, L. Lozano, A. Lopez-Castejon, J.
Mayor, J. Arenas, Department of Nephrology, Hospital General Uni-
versitario, Guadalajara, Spain. Microalbuminuria has been considered
as the first stage of renal disease for a long time. In adult polycystic
disease, severe proteinuria is not frequent, and some degree of protein-
uria is often associated with certain renal function impairment. We have
studied the excretion rate of urinary albumin (UA) in fifteen patients
affected of ADPKD without clinical proteinuria, who were measured by
usual techniques. Renal function was normal and the arterial blood
pressure was normal or drug controlled (BP <160/90). We also deter-
mined the UA in eleven ADPKD relatives, without clinical manifesta-
tions or renal cysts found in the ultrasonography, as well as in eight
control patients. We determined the UA excretion rate through two
different techniques: a) qualitative albuminuna measurements, by
means of reactive tablets (microbumin test); and b) quantitative UA
measurement using immunonephelometry (ranged normoalbuminuria: 0
to 25 mg/24 hours; microalbuminuria: 26 to 250 mg/24 hours). The mean
age in the group of ADPKD patients was 53.06 17.73 years; 66% of
them were affected by HBP and 33% suffering other associated dis-
eases. We detected microalbuminuria in 66.7% of the studied patients (
= 60 58.5 mg/24 hr). We didn't find any significant correlation
between microalbuminuria, and age, sex, blood pressure, or other
associated diseases. The mean age in the group of the ADPKD patient's
relatives was 17.57 12.68 years. Forty-four percent of them presented
with microalbuminuria ( = 49 29.6 mg/24 hr), in contrast the control
group (mean age: 28.3 10.2 years) who showed an albumin excretion
rate of 11.18 10.3 (P < 0.05). We conclude that: 1) ADPKD patients
showed a high UA excretion rate, not related with the HBP, their
clinical value and etiopathogenesis remains unclear. 2) ADPKD pa-
tient's relatives also presented with microalbuminuria to a lesser
degree, without clinical disease. This can be a useful early sign to detect
the patient who is going to develop the disease.
Proteinuria in patients with solitary functioning kidney. M. Sanchez,
L. Lozano, J. Nieto, J. Mayor, M.D. Jarillo, J. Arenas, Hospital
General Universitario, Guadalajara, Spain. In this study we analyzed
the evidence of proteinuria and microalbuminuria in 56 single kidney
patients (urine-albumin excretion rate measurements in 24-hour col-
lected urine), using immunonephelometry (microalburninuria = 26 to
250 mg/day). We studied the influence of associated diseases (HBP,
renal stones) and the eventual action of drug treatment in the existence
of renal failure. We used the following statistical methods: Student's
t-test, chi square test and ANOVA (one two factors). Results: the mean
age found was 59.14 + 13.65 years. We found the following etiology:
renal stones in nineteen cases, kidney tuberculosis in 14, chronic
pyelonephritis in 6, hydronephrosis in 4, renal malignancies in 2 and
renal traumatic injury in 1 case. The nephrectomy was performed
237.16 + 150.27 months before the study. We also included 6 hypoplas-
tic kidneys and 5 unilateral renal agenesis. Associated disease was
present in 32 patients (56%). We detected proteinuria in 15 patients
(26.78%) (it = 1.75 + 1.57 g/day). The albumin excretion rate was
measured in 22 patients with no proteinuria, normal renal function,
normal glycemia, and blood pressure < 160/90 mm Hg. We found
microalbuminuria in 91% of cases (it = 99.2 + 53.3 mg/day). We found
no related the proteinuria and microalbuminuria and age, sex, BP, size
and location of isolated kidney nor standard analytic measurements. In
the same way associated disease was not related. The proteinuria
showed a relationship with the time from nephrectomy (n = 0.39; P <
0.05), likewise, proteinuria was often found in agenesia and kidney
hypoplasia (P < 0.01). Proteinuria was also often found in those
patients with renal failure (26%, P < 0.01). Referring to microalbumin-
uria, it was only related with the time from nephrectomy (r = 0.60, P <
0.01). We conclude that in our patients, proteinuria and microalbumin-
uria was related with the time from nephrectomy in patients with renal
mass reduction. It seems to be an association between proteinuria and
agenesialhypoplasia as an etiological factor, and it should be a mani-
festation of the longer follow-up from clinical onset or implied previous
renal damage.
Hypertension and proteinuria in diabetic patients. Long-term effect of
captopril. J. Nieto, M. Sanchez, L. Lozano, S. Ortiz, A. Lopez, M.D.
Jan/b, S. Nefrologia, Hospital Universitario de Guadalajara, Univer-
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sidad de Alcala de Henares, Guadalajara, Spain. We studied the effect
of captopril in thirty patients (10 male and 20 female), aged 34 to 80
years (x = 63.4 yrs.). All of them had diabetes and mild-moderate
hypertension, with normal renal function. There were five patients
(16.6%) with type I diabetes. The follow-up period was 24 months.
Captopnl was prescribed (25 to 100 mg/24 hr b.i.d.) and hydrchlorothi-
azide (50 mg/24 hr) only if there was no control of hypertension.
Systolic and diastolic blood pressure and weight were determined every
six months. Measurements of glucose, cholesterol, triglycerides, creat-
mine, uric acid, calcium, phosphorus, sodium, potassium, proteinuria
and urine sodium and potassium were made at the start and the end of
the following period. SBP and DBP decreased since sixth month (178.5
+ 19.8mm Hg vs. 157.2 + 19.1 mm Hg, P < 0.001, and 103.5 + 8.9 vs.
89.8 + 10, P < 0.001) with the same significance at two years. We also
observed a significant reduction in proteinuria values (0.33 + 0.6 g/24 hr
vs. 0.13 + 0.4 g/24 hr, P < 0.05) and plasma creatinine (1.25 + 0.4 mg/dl
vs. 1.11 + 0.4 mg/dl; P < 0.05); there were no correlations between the
decrease of both and the other studied parameters. We did not find any
significant modification in the other measurements. We conclude that
long-term treatment with captopril reduces blood pressure in diabetic
and hypertensive patients. In our patients, decrease of creatinme and
proteinuria values are not dependant on blood pressure reduction.
Thus, other mechanisms must be invoked and it is possible that
long-term effect of captopril would be involved.
Microhematuria as consultation symptom. S. Ortiz, A. Lopez Caste-
jon, J. Nieto, L. Lozano, J. Mayor, M.D. Jarillo, M. Sanchez, S.
Nefrologia, Hospital Universitario de Guadalajara, Universidad de
Alcala de Henares, Spain. The incidence of Microhematuria (MH) is
higher (10%) that in other series. We have studied the possible reasons
in a Nephrology Consult attending patients referred from Primary
Medical Care and Urology Service. We chose 30 patients (P), 9 males
(30%) and 21 females (70%) aged from 3 to 87 years (x 41 + 21.05).
Afterwards, we separated patients in two groups: Group I (<41 years),
14 P, and Group II (>41 years), 16 P. We found no significant
differences between both groups in the presence or absence of lithiasis,
recurrent urinary tract infections or MH. However, Group I presented
significantly more hypertension (P < 0.01) than Group II. In both
groups a familiar renal lithiasis background existed in 20% and familiar
macroscopic hematuria in 10%. Patients had previous reports of lumbar
pain in 60%, microhematuria in 43% and mictional symptoms in a 46%.
A significative correlation (P <0.05) existed between previous episodes
of lulmbar pain and persistent microhematuria. The clinical onset of
microhematuria was mictional syndrome in 46.6%, lumbar pain in
46.6%, gross hematuria in 36.4%, expulsive lithiasis in 23.3%, casual
finding in 43.3%, fever in 13.3%, physical effort in 6.6%. The final
diagnosis of MH was: 40% microlithiasis (13.3% hypercalciuria, 20%
hyperuricosuria), 26% kidney stones, 20% urinary tract infection, 13%
pyelonephritis, 26% glomerular nephropathy (8 IgA and 1 membranous
nephropathy), 3% renal tubular acidosis, 19% urological problems
(tumors were excluded). Sixteen percent of patients had an associated
systemic disease (TB, diabetes, hypertension, hematological abnor-
malities). Conclusions: 1) The incidence of MH is very high in our
region, probably related to elevated frequency of microlithiasis. 2) An
elevated proportion of females suffer from MH, not related to any
specific pathology (infections, lithiasis). 3) An important number of
glomerular nephropathies can be detected in primary medical care in a
base of MH.
Cyclosporin A in high-risk idiopathic membranous nephropathy. J.M.
Lopez Gomez, R. Jofre, E. Gallego, R. Perez Garcia, C. Albarracin, F.
Valderrábano, Hospital General "Gregorio Marañon", Madrid, Spain.
About fifty per cent of idiopathic membranous nephropathy (IMN)
progress to ESRD in 10 to 15 years. Immunosuppressor treatment has
shown a better evolution in some cases of IMN. Cyclosporin A (CsA)
has been proposed as treatment in some cases of nephrotic syndrome.
Five patients (3 M, 2 F) with IMN have been treated with CsA. Their
ages ranged from 31 to 60 years (mean, 44.2 13.3 yr). All of them had
severe nephrotic syndrome, with a mean evolution time of 26.0 19.2
months. Three of them were previously treated with prednisone but
without response. Three had had thromboembolic complications. One
of them had an acute renal failure. Three showed refractory severe
edema. Previous proteinuria was 11.3 2.2 g/day and serum albumin
was 2.4 0.5 g/dl. All cases but one (Se. 3.0 mg/dl) had normal renal
function. Mean dosage at onset was 4.2 mg/kg/day and was decreased
progressively over 6 months to 2.5 mg/kg/day with mean serum levels of
28.2 3.2 g/ml (polyclonal antibodies, RIA) at the end of this period.
Simultaneously, all patients received 10 mg/day of prednisone. At the
third month of treatment proteinuria had decreased in all cases (mean
3.1 1.7 g/day) disappearing the nephrotic syndrome. Only two
patients completed the treatment after 9 and 10 months. One of them is
in complete remission after 6 months and the remaining patient is in
partial remission at 9 months alter therapy withdrawal. Serum creati-
nine rose and proteinuria disappeared in the patient with decreased
renal function. Then, CsA was discontinued and S decreased to
pre-therapy levels and minimal proteinuria newly appeared. Other side
effects were minimal and well tolerated. These preliminary results
suggest that low dosage of CsA could be effective in high risk IMN, but
its long-term effect must be evaluated. CsA should not be used
indiscriminately in patients with IMN.
Cyclosporin A in Idiopathic nephrotic syndrome of adult patients with
bad response to steroid. R. Jofré, f.M. Lopez GOmez, E. Gallego, R.
Perez Garcia, A. GalOn, F. Valderrábano, Hospital General "Gregorio
Maranon", Madrid, Spain. Cyclosporin A (CsA) can be effective in
some cases of resistent or relapsing nephrotic syndrome. In this study,
we evaluated the effect of CsA in 6 adult patients (3M, 3 F). Their mean
age was 21.5 6.4 years. Four patients were steroid-resistant and one
was steroid-dependent. Four of them had received chlorambucil previ-
ously. The last one was not treated with steroids before. Renal biopsy
showed focal glomeruloscierosis (FGS) in 3 cases, added to tubulo-
interstitial lesions in two. Two patients had diffuse mesangial prolifer-
ation with 1gM deposits in one, and other patient had minimal change
nephropathy (MCN). CsA was started at 4 to 5 mg/kg/day and was
decreased to a mean dosage of 3.5 1.1 mg/kg/day at 6 months of
treatment, with mean serum level of 59.7 39.3 g/ml (polyclonal
antibodies, RIA). Treatment was discontinued at 9 months in 4 cases.
Pre-treatment proteinuria (9.5 5.5 g/day, mean SD) disappeared
after 2 to 3 months of treatment in all cases. One patient with FGS had
a complete remission at 2 months of treatment, but he relapsed during
treatment in the same dosage of CsA. Two other patients with FGS
relapsed at 0.5 and 7 months of discontinuation of therapy. All cases
had normal renal function (RF) at the onset of treatment and none had
RF impairment. After 3 months on treatment mean serum albumin
increased from 2.3 0.7 to 3.9 0.7 g/dl. Side effects were minimal and
reversible. Our results suggest that patients with adult steroid-resistent
or steroid-dependent nephrotic syndrome can benefit from CsA treat-
ment. Long-term low doses of CsA must be considered in cases of FGS
with poor response to steroids.
Cardiovascular instability in short-dialysis: Hemodialiltration and he-
modialysis. F. Valderrabano, J. Luño, E. Junco, M. Rengel, R. Perez
Garcia, F. Ahjado, E. Gallego, C. Albarracin, Hospital General
Gregorio Maraflon, Madrid, Spain. Four different short-dialysis sched-
ules have been comparatively evaluated. Two were hemodiaffitration
techniques: 1) biofiltration (BF) with An-69 1.2 sq m dialyzer (N = 11);
2) PFD with polysulphone (PS), 0.4 to 0.5 sq m + hemophan, 1.1 to 1.4
sq m, (N = 4). Two others were hemodialysis: 3) high efficiency
hemodialysis (HEHD) using a polysulfone 1.9 sq m dialyzer, (N = 13);
and 4) Short hemodialysis with cuprophane (CHD) 1.8 sq m dialyzer, (N
= 13). Dialysate with Na = 138 mmollliter and acetate = 35 mmol/liter
(BF, PFD) or bicarbonate = 39 mmollliter (HEHD, CHD) as buffer was
used. Blood flow ranged 350 to 500 mI/mm and dialysis time oscillated
from 120 mm in HEHD to 150 to 180 mm in BF, PFD and CHD. KTIV
= 1 was achieved in all techniques. Clearance of /32-microglobulin was
37 to 81 mI/mm when high permeability membranes were used (BF,
PFD, HEHD) but it was 0 mllmin with cuprophan (CHD). There was no
significant difference in the incidence of dialysis-related symptoms
among the four schedules of dialysis studied, hypotension being,
however, more frequent in BF. Changes at the end of dialysis in whole
Na, plasmatic Na, K, Ca, total proteins, albumina, P°2, BUN, osmo-
lality, plasmatic volume and colloid osmotic pressure were not also
different. No correlation between hypotension and increase of heart
rate with ultrafiltration volume or the remaining parameter previously
cited could be seen. We measured Valsalva ratio (VR) as an index of
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aut000mic dysfunction at onset, one hour and at the end of a session in
each patient. Pre-dialysis values were lower than in normal controls,
and moreover, it decreased during dialysis time when dialysis patients
were considered together. YR was not correlated with changes in
plasmatic volume, colloid osmotic pressure and dialysis related symp-
toms. We conclude that cardiovascular instability is not different in
hemodiafiltration or short-dialysis techniques and that it appears not to
be correlated with changes in osmolality, colloid osmotic pressure,
plasrnatic volume and autonomic dysfunction according to valsalva
ratio.
Aluminium (Al) uptake and transport: Relationship with Al and iron
(Fe) metabolism in dialysis patients. I. Olaizola, M.J. Virgós, J. Fernán-
dez Garcia, L. Sanchez, P. Ruiz de AlegrIa, J. Guerediaga, C.
Caramelo, J.B. Cannata, Bone and Mineral Research Unit, Hospital
General de Asturias, Hospital Nira. Sra. de Covadonga, Cruz Roja,
Oviedo; and Hospital San AgustIn, Avilés, and Fundación Jiménez
DIaz, Madrid, Spain, Al gastrointestinal (G-I) absorption (abs) is a
recognized route of Al incorporation. Al and Fe are carried by trans-
femn, thus it is reasonable to postulate a relationship between Fe and
Al G-I abs and its blood transport. The aim of this study was: a) to
evaluate the serum (sr) Al transport and its relationship with the Fe
transport capacity; and b) to evaluate the likely Al(OH)3 abs as a
function of Fe and Al metabolism. We studied 66 patients (pts) with
chronic renal failure (CRF) undergoing hemodialysis (HD) divided into
two phases: Phase I (Aim a): In all of them we measured basal sr Al and
hematologic parameters (hematocrit, hemoglobin, mean corpuscular
volume, serum iron, transferrin, ferritin, total iron bound capacity, %
transferrin saturation), establishing a multiple correlation study among
them. We found only a significant negative relationship between basal
sr Al and sr Fe and transferrin saturation, showing: the lower the basal
sr Fe and transferrin saturation the greater the sr Al (P < 0.025). Phase
2 (Aim b): We performed an A1(OH)3 abs test measuring sr Al
increments (pg/liter) before (basal) and after (2, 6, 12 and 24 hr) a single
oral dose of Al(OH)3 (30 mg/kg wt). In phase 2 we also found a negative
relationship between sr Al increments and sr Fe levels (r =
—0.88;P <
0.05) (the lower the sr Fe and sr Al the greater the Al abs) (P < 0.01).
Only those pts with low sr Al (x = 24.4 sg/liter) increased their sr Al
after the abs test (Abs area + 19.69 g/1iter/hr); by contrast the high sr
Al pts (x = 90.2 gll) did not increase their sr Al, and they showed a
negative abs area (—28.08 sg/liter/hr). These results suggest an inverse
relationship between sr Fe and/or sr Al levels and the capacity for Al
uptake, indicating the lower the saturation of transferrin with Fe and/or
Al, the higher its capacity to transport and to incorporate either Fe or
Al, suggesting that in pts with iron deficiencies the risk of Al intoxica-
tion would be increased.
Treatment of aluminium (Al) intoxication: Preliminary study with a
new drug which is active orally. I. Olaizola, J.L. Fernandez Martin, B.
DIaz Lopez, G. Kontoghiorghes, J.B. Cannata, Bone and Mineral
Research Unit, Hospital General de Asturias, Oviedo, Spain; and
Department of Haematology, Royal Free Hospital, London, United
Kingdom. Desferrioxamine (DFO) has shown to be an effective chelat-
ing agent to remove Al from Al-overloaded patients. However, DFO is
not active orally. Recent papers have claimed that 1-2 dimetil 3
hidroxipiride-4-ona (LI) is effective via oral in removing Fe from
thalassemic patients and also from experimentally Fe-overloaded rats.
Therefore, the aim of this preliminary study was to evaluate the
Al-removal effect of LI. We investigated 15 Wistar adult rats divided
into three groups: Group I: Controls with normal renal function (NRF).
Group II: Al-intraperitoneal (ip) intoxicated (intox) rats with NRF (12
months of exposure, AIC13, 2 mg 5 days/week). Group III: Al-intox rats
with chronic renal failure (CRF) (6 months of exposure, AId3, 2 mg 5
days/week). Groups II and III (Al intox) showed a significant increase
in serum and urinary Al (P < 0.001) throughout the exposure (12 and 6
months) and also a significant Al increase (P < 0.001) in tissues (bone,
liver, etc.). At the end of the Al intox, all groups received sequentially,
Li ip, Ll oral and DFO i.p. as shown in the scheme. After the Li and
DFO administration we measured serum Al changes (times 0, 6, 12, 24
hr), 24-hr urinary Al excretion, Al/Cr urinary index and creatinine (Cr)
and Al clearance.
Basal Li ip Basal Li oral Basal DFO ip
Both DFO and Li (oral and ip) were able to remove Al significantly
(P < 0.001) without showing significant differences between LI i.p.
and oral. The increments obtained using LI orally are shown in the
table.
Control NRF+Al CRF+Al
Urinary Al tg/24 hr 0.55 0.45 204 75 132 47
Al clearance sl/min 0.90 0.8 151 59 56 29
Urinary Al/Cr index 0.05 0.01 21.4 9 14 6
jig/mg
These preliminary results show that in short-term basis, Li is able to
remove a great amount of Al from Al-intox animals with and without
renal failure. Further studies should be done to determine its long-term
efficacy and safety in this field.
Aluminium (Al) body burden with normal renal function (NRF): Risk
of oral intoxication. J.L. Fernández Martin, C. GOmez Alonso, 1.
Olaizola, M.L. Naves, J.B. Cannata, Bone and Mineral Research,
Hospital General de Asturias, Oviedo, Spain. Aluminium hydroxide
[AI(OH)3] has become one of the most important sources of Al in renal
patients. However, this compound is widely used as antacid in patients
with NRF without taking into account the likely risk of Al intoxication.
We consider that more than 90% of Al would be protein-bound and it
should have a limited renal clearance. The aim of this study has been to
evaluate the long-term risk of aluminium accumulation in animals with
NRF having intraperitoneal (i.p.) and oral aluminium exposure. During
16 months, 6 rats were exposed to MCI3 (10 mg/week, Group I), 6 rats
received 40 mg/day of Al(OH)3 through gastroesophageal catheter
(Proportional to patient's dose; Group II), other 6 animals had no Al
exposure (Group III). During this experiment serum and urinary
aluminium was measured, and at the end after sacrifice we measured Al
in tissues. Tissues were dissolved in high-pressure teflon reactors with
concentrated nitric acid. The liquid sample and also serum and urine
were determined by Graphite Furnace Atomic Absorption Spectrome-
try with Zeeman Background Correction. For this technique the detec-
tion limit is I sg/liter. As we expected, those rats receiving A1CI3 i.p.
showed the greatest increase of aluminium in serum, urine and tissues
(bone, liver and heart) (P < 0.001). The most striking results were
that rats exposed to oral Al(OH)3 showed important increases of
aluminium in comparison with the controls (despite their NRF). Urine
(g/24 hr) 6.3 5 vs. 0.4 0.3 (P < 0.01); bone (/Lg/g) 9.6 12 vs. 1.1
0.3 (P < 0.01), being higher but not significant in serum (16.5 11.1
vs. 6.5 4) and in liver (4.4 3.5 vs. 0.5 0.2). These results draw the
attention about the real risk of oral Al toxicity even in patients with
NRF.
Aluminium (Al) intoxication and cardiac conductivity in rats with
normal renal function and chronic renal failure. M.J. VirgOs, I. Fdez
Soto, M. Sanchez, C. GOmez Alonso, J,B. Cannata, Bone and Mineral
Research Unit, Hospital General de Asturias, Facultad de Medicina,
Oviedo, Spain. It has been suggested that Al might induce cardiac
abnormalities. The aim of this study was to evaluate the effect of
chronic renal failure (CRF) and Al overload in the ECG pattern. We
studied 30 male Wistar rats divided into three groups (0). Gl NRF
(Normal renal function) (Serum creatinine (SCr mg/dl 0.36 0.26). G2
CRF + intraperitoneal (i.p.) saline (sal) [Sc,.: 0.99 0.3, 0.1 ml of
acified sal, pH = 3.6, 5 days/week (wk), 14 wk], G3 CRF + i.p. Al
overload (Scr: 0.97 0.2, 2 mg C13A1 in 0.1 ml of sal, pH = 3.6, 5
days/wk, 14 wk). After 14 wk of sal or i.p. Al infusion, ECG was
recorded in 6 derivations (measuring: rate, duration of P wave, QRS,
QT and PR segments, and displacement of J point). We also measured
calcium and potassium in serum. After killing the rats we investigated
the heart Al concentration. As the table shows, the only sign ECG
change was the increase in QT segment in CRF (G 2 and 3), being more
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marked in i.p. sal than in i.p. Al infused animals. This QT increase
could be due to the variations observed in CRF due to changes in K.
NRF (Gi)
CRF + sal
(G2)
CRF + Al
(G3)
Serum Al pg/I 4.3 3.1 7.7 6.5 245 127"
Cardiac Al sg/g 0.97 0.8 1,55 1 1.66 0.7
Serum K mmol/liter 4.6 0.5 5.5 1.1 6.3 0.8
Cardiac rate liter/mm 408 48 405 42 407 47
PR interval mseg 47 10 54 9.6 52 11
Pwavemseg 18±3.3 18.5±41 18±7.1
QRS complex mseg 23 5 19.5 4.3 22 7.5
QT interval mseg 50 15 84 8.9" 71 16
Point J displacement mm 0.52 0.63 0.97 0.53 0.9 0.77
a p < 0.02; b p < 0.001
These results suggest that chronic Al overload did not significantly
increase the heart Al concentration, and also did not induce important
changes in conductivity.
Iron (Fe) gastrointestinal (G-I) absorption (abs) in aluminium (Al)
overload. I. Fernández Soto, C. Gómez Alonso, M.T. Allende, B. Diaz
Lopez, J.B. Cannata, Bone and Mineral Research Unit, Hospital
General de Asturias, Oviedo, Spain. Recent studies have demonstrated
that the degree of Fe stores might modulate Al G-I abs; in the same
way, Al overload could also have some influence on Fe G-I abs.
Therefore, the aim of this experimental work was to evaluate the effect
of chronic Al exposure (exp) on erythropoiesis and Fe G-I abs in rats
with normal renal function (NRF) and chronic renal failure (CRF). The
study was performed in two experimental phases: Phase 1 (NRF): 16
Wistar rats were divided into three groups (0): 0.1: Control (no Al exp)
(N = 5); 0.2: oral Al exp (40 mg Al(OH)3/daily through gastroesaph-
ageal catheter, N = 6); 0.3: intraperitoneal (i.p.) Al exp (2 mg AICI3, 5
days/week, N = 5). Phase 2 (CRF): 15 Wistar rats were divided into
three groups: 0.1: control (NRF, no Al exp, N = 5); G.2: CRF + i.p.
CINa (9%) 5 days/week (N = 4), G.3: CRF + i.p. AlCl3 5 days/week (N
= 6). After 13 months (Phase 1) and 3-½ months (Phase 2) of Al exp,
hematologic (hem) parameters (param), TIBC (pg/dl), serum (s) Fe
(pg/dl), transferrin saturation (%), MCV (p3), serum (zg/liter), urinary
and tissue Al (bone, liver and heart), and Fe59 0-I abs were measured.
In Phase 2, the study was completed investigating the residual Fe59
radioactivity in duodenum, jejunum and ileum. The table summarizes
the more important results in Phase I in control and in i.p. Al exp,
observing in the latter a microcytic anemia, with hem param resembling
an Fe deficient anemia. Despite this pattern, Al exp rats showed
reduced Fe G-I abs likely due to the competitive-inhibitory effect of
high Al on Fe abs (P < 0.05). In Phase 2 (CRF) we obtained similar
results. Those rats receiving A1CI3 showed the most important alter-
ations in hem param (Ms = 244.4 126, TIBC = 386 83, % sat = 20.1
10.5, Fes = 74.8 30.5) and Fe59 abs was almost undetectable
(<2%). The residual radioactivity in intestine was negligible (lower than
iQ—% of the dose of Fe59 administrated). Al in tissues showed a
significant increase in Al exp rats (P < 0.01).
%
s Al hto TIBC % sat sFe MCV Fe abs
Control 4.9 47 504 55.4 277.6 70 19
Ali.p. 256 43 600 37 218.4 63 7
exp 6a 1a 8a 1a 6j6a 2a
These findings demonstrate that chronic Al exp may lead to tissue Al
overload and anemia (even with NRF). In addition, the paradoxical
reduction in Fe abs observed in Al intoxicaation might maintain and
even increase the anemia observed in Al intoxication.
Iron (Fe) deficiency: A risk for aluminium (Al) gastrointestinal (G-I)
hyperabsorption. M.J. Fernández, I. Fernández Soto, D. Halls, J.L.
Fernández, J. Brock, J.B. Cannata, Bone and Mineral Research Unit,
Hospital General de Asturias, Oviedo, Spain, and Royal and Western
Infirmary, Glasgow, Scotland, United Kingdom. Previous clinical
studies have suggested that Fe stores might modulate Al gastrointesti-
nal (0-I) absorption (abs). The aim of this experimental in vivo and in
vitro work was to evaluate if Fe metabolism could be implicated in Al
G-I abs. In vivo: 38 Wistar rats with normal renal function (NRF) and
27 rats with chronic renal failure (CRF) were studied. Both groups
(NRF and CRF) were divided into three subgroups (0): G. I: Fe
overload (intraperitoneal (i.p.) Fe dextran 5 mg/48 hours during 1
month); 0.2: controls; 0.3: Fe depleted (2 to 3 bleedings and low Fe
diet, 1 month). All groups were exposed during 30 days to 40mg of oral
A1(OH)3 daily, measuring the concentration of Al in serum (s), and
urine throughout the experience and Al in brain after sacrifice the
animals. As the table shows, at the beginning of the study the micro-
hematocrit (ht) showed significant differences between the three
groups (P < 0.01). The changes in serum, urinary Al (P < 0.01) and
brain Al (P < 0.025) throughout the study suggested the lower degree of
Fe stores, the higher abs of Al (Table).
Hcto
Un nary Al ng/24 hr Brain Al
pg/gDay 0 Day 15 Day 30
Fe over- 53.8 670 1380 1620 0.73
load l.7 280 1140 1300 0.41"
Controls 49.3
3.0
860
640
1420
1080
1450
1420
1.42
0.96
Fe deplete 42.9
4.la
1590
700a
3160
134O
4500
208k
1.93
0.67"
In vitro we evaluated the Al uptake in intestinal epithelial cell line
(RIEI) previously prepared and divided into three groups: 0.1: Fe
overloaded cells (addition of Fe Nitriloacetate to the RPMI-1640
medium); G.2: normal cells (RPMI-l640 medium); 0.3: Fe depleted
cells (addition of DFO to the RPML-l640 medium). After the prepara-
tion we investigated the cell Al uptake throughout 24 hours adding
AlCl3 to the medium (34 g/ml). The results are expressed as ng/ml of
Al incorporated per ng of DNA.
Fe
overload Normals Fe deplete
0.81 0.09 0.83 0.1 2.3 0.3k
a P < 0.001
These experimental findings strongly support the concept that the
degree of Fe stores might be an important factor in the regulation of Al
abs. In addition they suggest that in iron deficiencies we could have a
higher risk of Al abs.
Pregnancy in renal transplantation. P. Errasti, M. Jurado, L. Bol-
años, 0. Vaz, F. Maduell, N. Esparza, R. DIaz-Tejeiro, A. Purroy,
Division of Nephrology, D. ofObstetrics and Gynecology, University
Clinic of Navarra, Pamplona, Spain. Since 1975, 9 pregnancies have
been observed following cadaver renal transplantation (7 with classical
immunosuppressiön and 2 with CsA therapy). Eight patients had 10
actual births, 8 singlet and one twin birth. No spontaneous abortion
occurred in our patient group. The age of the transplanted patients was
27 3 years (mean saM). The interval from transplantation to
pregnancy was 25.4 6 months (range 6 to 56).The mean gestational
age was 35.4 1 weeks (range 27 to 38). Seven children were born from
vaginal delivery and two from cesarean section (due to obstetrical
indication), all alive and free from malformations. The mean weight of
the children (7 males and 3 females) was 2525 194 g (range 1550 to
3320). Pregnancy complications included one case of deterioration of renal
function, two cases of hypertension and four cases of urinary infections
(two of these were related to vasico-ureteral reflux into the graft). Chronic
rejection in one patient with pre-pregnancy creatinine level of 1.8 mg% led
to graft loss 38 months after delivery. She died two months later (40 from
delivery) from brain stroke. Another patient died 21 months after delivery
of disseminatedvaricela infection transmitted from her son (necropsy). At
present time seven patients have normal renal function and the 10 infants
are alive and have developed normally, without any malformation. We
conclude that pregnancy after renal transplantation presents many medical
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and ethical problems, but in our experience is safe and has had a normal
outcome, even in the case of twin pregnancy.
Prospective randomized trial of double versus triple drug therapy with
cyclosporm A (CsA) after renal transplantation (ART). F. Maduell, P.
Errastj, L. Bolanos, 0. Vaz, N. Esparza, R. DIaz-Tejeiro, A. Purroy,
Division of Nephrology, University Clinic of Navarra, Pamplona,
Spain. Thirty consecutive patients who received a cadaveric renal trans-
plant entered into the trial and were randomly selected to receive CsA in
double or triple drug therapy (protocol A: Predn. 30 mg/day, CsA 15
mg/kg/day initial dose. Protocol B: Predn, 20 mg/day, CsA 10 mg/kg/day
and Aza 1.5 mg/kg/day). Both groups of patients were comparable with
respect to the age, time on dialysis, number of transfusions, HLA
identities, etc. The distribution of the classical high-risk factors (N = 16
patients, 52%, corresponding to 7 retransplants, 7 patients older than 50
years, 3 ID diabetes and 3 hyperimmunized patients) were also similar in
both groups. There were significant differences between both protocols in
the dose and levels of CsA at 3.6 and 12 months ART, but not in the
creatinine values, number of acute rejection episodes, number of ATN,
CsA side-effects or medical complications. Four patients in protocol A
were converted to triple drug therapy for prolonged acute tubular necrosis
associated with acute rejection. With a mean follow-up of 19.7 1.6
months (mean sEM), the actual results are:
Prot. A Prot. B P
Follow-up months 19 1.7 17 1.3 NS
CsA dose mg/kg/day 3.5 0.2 2.7 0.2 0.01
CsA levels (J125) 159 21 96 5 0.05
Creatinina mg% 1.5 0.1 1.6 0.2 NS
Graft survival N = 30 100% 100% NS
In conclusion, CsA has been as effective in double that in triple drug
therapy in 30 consecutive patients, of which 16 (53%) were of high risk.
The triple therapy reduces the duration of ATh, decreases the acumula-
tive dose of steroids and makes the postoperative follow-up ART easier.
Carpal tunnel syndrome (CTS) in CAPD patients: A multicenter study.
K. L-Revuelta, R. Bosch, R. Acebal, G. Blum, M. Casares, F. Coronel,
A. Cruz, H. Dia, A. Fidalgo, C. P-Conde, V. P-Diaz, A. R-Carmona, R.
Selgas, Grupo CAPD-Centro, Spain. CTS is a frequent complication of
HD which has a prevalence related to the duration of treatment.
Amyloid deposits of /32M have been found as being responsible in many
cases. The real incidence and implicated pathogenic mechanisms in
CA.PD are not defined. We have studied 109 patients exclusively treated
with CAPD for at least 3 years, 33 diabetics, excluding those with other
predisposing CTS causes. The diagnosis of CTS was made by EMG in
10. No differences were found in age, duration of treatment, original
disease and plasmatic levels of 132M between patients with and without
CTS. We analyzed affected patients, excluding 2 diabetic and 1 patient
lost. Four new patients were added because of CTS detection in earlier
stages. The final group consisted of 11 patients, aged 66.3 8, on
CAPD 39 19 months. X-ray examinations of skeleton were evaluated
by 2 different observers. Biochemical determinations consisted of urea,
creatinine, Ca, P, PTH, ferritine and uric acid. The incidence of
peritonitis and UF capacity were also researched. CTS appeared at 29
19 months, being first detected in 81% of the patients by EMG; 50%
of them presented symptoms once along the follow-up, never requiring
surgical treatment. Whenever bilateral EMG examination was per-
formed, it disclosed positive features. The moment of appearance was
earlier in asymptomatic than in symptomatic cases (17 vs. 35 months)
and had statistical correlation with the CAPD duration. No relationship
was found between CTS and biochemical parameters, incidence of
peritonitis, diuresis and UF capacity. In 50% of the affected patients
bone cysts mainly in carpus were found, keeping no correlation with
duration of treatment, moment of CTS appearance or with the rest of
parameters studied. In summary, we think that CTS is not rare in
CAPD, it is bilateral and sometimes appears early in the evolution.
Early detection is possible by EMG before the presence of clinical
manifestations. The coexistence of lytic lessions recognized as diagnos-
tic of amyloid arthropathy suggests the same ethiology for both pro-
cesses at least in the 50% of the cases.
Ciprofloxaclne as a treatment for peritoneal catheter-related skin
infections. F. Moreno, B. Miranda, K. Lopez Revuelta, G. Caparros, R.
Selgas, Hospital La Paz, Madrid, Spain. Peritoneal catheter-related
skin infection is one of the most important causes of morbidity in
peritoneal dialysis, because of catheter changes and catheter-dependent
peritonitis. These infections represent a bioincompatibility phenome-
non and show great difficulty to heal with the treatments used until now
(in our hands the rate of failure is around 70%). Ciprofioxacine is a new
quionleine which reaches high levels in some tissues, among them skin,
and that allows ambulatory treatment (p.o.); on the other hand, its
bacterial sensitivity includes S. Aureus, the most frequent germ in-
volved in these infections. The aim of this study was to evaluate the
results with Ciprofloxacine (750 mg/l2 h.p.o. during 21-28 days) for 14
episodes of peritoneal catheter exit-site and tunnel infection in 13
CAPD patients. Among the episodes, some resistant to Vancomycin +
Rifampicine were also included. Results:
Germ
Prey-
ious
failure
Improve-
ment
interval
Antibiotic
associated
Toler- Usefull-
ance ness Relapse
S. Aureus 3 2-14 1 (Rifam) 2 bad 5 total 1
(7 epi.) days 4 good 1 partial
1 non-use.
Gram + 2 2-15 2 (Venco) 1 bad 2 total 2
(5 epi.) 4 good 2 partial
1 non-use.
Proteus
mirabil. 1 10 — 1 bad 1 total —
(I epi.)
P. Aeruginosa
(1 epi.) 1 12 — 1 bad 1 total —
(Two patients required two cycles). Slight gastric discomfort was
referred to by several patients. For the second cycle, if required,
Vaneomycin association seems to be appropriate. We conclude that
Ciprofioxacine treatment has been useful for eradicating the peritoneal
catheter exit-site and/or tunnel infection in 64% of episodes, a 50%
decrease in the previous failure rate. Peritoneal catheter survival figures
have consequently increased.
Gemfibrozil as a hypolipemiant agent in CAPD patients. B. Miranda,
R. Selgas, C. Felipe, J. Munoz, A. Zapata, F. Moreno, J.L. Miguel,
Hospital La Paz, Madrid, Spain. Cardiovascular diseases are the main
cause of mortality in ESRD patients under dialysis treatment. Arthe-
riosclerosis has been definitely related to abnormal levels of choles-
terol. Gemfibrozil is an hypolipemiant agent whose beneficial effects on
coronary disease-induced mortality have been demonstrated (Hel-
sinki's study). The aim of this study has been to know the effects of
gemfibrozil on plasma lipid levels in a group of patients under CAPD
treatment, who presented with hypercholesterolemia unresponsive to
appropriate diet and data of high coronary disease risk. Twelve patients
(5 diabetics), 5 males and 7 females, aged 29 to 72 years (54 13), under
CAPD for 12 to 103 months (32 25) were used. None presented an
overweight index higher than 30%. The treatment protocol consisted of
an oral gemfibrozil at an initial dose of 300 mg/48 hr, which was increased
to 300 mg/day if an appropraite response was not reached. Period of
treatment was at least 12 months. Nutritional parameters, muscle en-
zymes, plasma lipids and usual analytic controls and biliary ultrasonogra-
phy were monitored. Both nutritional and hepatic control parameters did
not show changes. Only one patient presented clinical and biochemical
data of muscle necrosis, which disappeared after reduction of the dose.
One patient showed microgallstones after one year. No other colateral
effects were detected.
Total
Chol. HDL-Chol. LDL-Chol.
Tryglicer.
mg/dl
Basal 326 50 43 12 167 82 206 58
6 months 256 30 53 9.7 153 42 156 53
12 months 223 37 48.7 7 158 29 140 50
ANOVA P < 0.01 NS NS P < 0.1
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We conclude that genfibrozil is an appropriate, accurate and useful
hypolipemiant agent for CAPD patients. Its dose should be reduced in
renal patients to avoid toxicity. Possible colateral effects should be
monitored as in other patients under this treatment. Long-term effects
on lipid profile and coronary disease related morbidity and mortality are
being investigated.
Measurement of peritoneal platelet activity through effluent beta
thromboglobulin (BTG) levels in CAPD patients. R. Se/gas, B. Miranda,
M.V. Cuesta, F. Moreno, G. Caparros, J.L. Miguel, Hospital La Paz,
Madrid, Spain. Platelet activity is closely related to endothelium and
could release factors able to influence capillary wall and surrounding
tissues. BTG is a protein included in platelet vesicles and a measure of
its activation. Some alterations of peritoneum could be partially related
to platelet activity. BTG peritoneal transport from blood is weight
limited (36000) and consequently, high levels in effluent should repre-
sent local production. The aim of this study has been to characterize
peritoneal effluent BTG. Twelve patients, on CAPD 27 15 months,
and 5 diabetics were studied. Previous peritonitis was 0.3 0.4 e/year.
Determinations performed: plasma (P) (BTG, T. protein, albumin,
platelet count, Hct and fibrinogen) and effluent (EF) (BTG, T. protein,
fibrinopeptide A, FDP, fibrinolytic act., fibrinogen, plasminogen and
mitogenic induced capacity on Swiss 3T3 mice fibroblasts). To evaluate
peritoneal function we used mass transfer coefficients (MTC) and net
UF. Results. BTG levels: P 118 14 EF 34 14 ng/ml P/EF(%) 31
13 (6 to 54%). Regression analysis: P BTG did not show a significant
relationship with any of the studied parameters. EF BTG showed direct
significant correlation (P < 0.05) with creatinine-MTC (r: 0.81) and EF
fibrinogen (0.68), and was in limited significance with EF T. prot. (0.57)
and EF mitogenicity (0.26). P/EF BTG showed significant correlation
with creatinine-MTC (0.77). The analysis of these values, by grouning
patients showed: diabetes has no influence on BTG values, hyperten-
sive patients show higher PIEF BTG values than normotensive (39 9
vs. 23 11%, P < 0.05) and no influence of peritonitis or CAPD period
was found. Our results suggest a double origin for peritoneal BTG
according our knowledge about transference of similar proteins, that
diffused from plasma and that produced locally, suggesting different
degrees of platelet activation. Its relationship with diffusion permits
speculation about interrelationships between platelet activation and
pentoneal transport.
Effects of h.r-erythropoietin (EPO) through two different routes on
CAPD patients. B. Miranda, R. Selgas, A. Fernandez Zamorano, F.
Moreno, F. Borrego, L. Sanchez, Sicilia, Hospital La Paz, Madrid,
Spain. Intravenous EPO represents a great improvement in the man-
agement of hemodialysis patients. CAPD is an hospital treatment which
needs alternative routes for the administration of this drug, such as
intraperitoneal (i.p.) or subcutaneous (s.c.). The appropriate dosage by
these routes in these patients remains to be established. Ten CAPD
patients with severe anemia, 19 to 65 years, 8 to 91 months on CAPD
were included in two alternative protocols: i.p. (4000 U in 100 cc of
1.5% dialysate, maintained 2 hours in peritomeum during bed rest, 3
days/week) and s.c. (21 jilkg/day). These doses were adjusted according
to the response to anemia. Results: Hemoglobin rose from 6.5 0.8 to
10.5 2.5 gldl at 3rd, and to 10.8 2.3 at 6th month of treatment (P <
0.01). The values of corpuscular volumes, haptoglobin, billirubin,
transferrine, serum ferrum, Bl2 vitamin, and folic acid, leucocytes and
platelets did not show changes, whereas ferritin levels decreased. EPO
doses decreased from 10498 2310 to 4410 2540 U/week and to 2825
1940 (P < 0.01) at the same periods. Modifications of potassium,
weight, blood pressure, hypotension agent requirements, peritoneal
function and dialysis and nutritional parameters were not observed.
One patient showed exogenous hyperpotasemia and other arterial
hypertension, which was controlled by reducing the EPO dose. The i.p.
group required a higher EPO dose than s.c. group: 12000 vs. 7172
1368 U/week, P < 0.05). Furthermore, its response to treatment was
slightly worse at 2nd month: Hb 8.1 1.3 vs. 10.1 1.1 gIdl, P <0.05)
and three episodes of peritonitis caused by Staphlococcus were regis-
tered. Because of this reason, i.p. patients were subsequently trans-
ferred to s.c. We conclude that h-r-EPO through subcutaneous route at
relatively small daily doses results in useful!, cheap and accurate
treatment for severe anemia in CAPD patients. Intraperitoneal route
diluting the drug in small quantities of dialysate is also useful route, but
in respect to s.c. is more expensive and favors peritoneal contamina-
tion.
Treatment with converting enzyme inhibitors (CEI) can contribute to
anemia in CAPD patients. B. Miranda, R. Selgas, A. Oliet, C. Felipe, F.
Moreno, L. Sanchez Sicilia, Hospital La Paz, Madrid, Spain. There is
evidence that CEI treatment can increase anemia in predialytic ESRD
patients. We evaluated the effect of CEI treatment on hematological
parameters in patients with CRF under CAPD therapy. Sixteen patients
of our CAPD program were evluated (7 males and 9 females). Mean age
was 52 13 years and mean time on CAPD was 36 26months. All of
them have received captopril (50 to 75 mg/day) or enalapril (10 to 40
mg/day) at least for one year in doses large enough to achieve a good
control of blood pressure. Hct values fell from 31.6 4.1 to 26.2
3.5% (P < 0.01) as well as hemoglobin values, 10.7 1.5 to 8.2 0.9
g/dl, after 12 months of treatment. Plasma levels of ferritin, vitamin Bl2
and folate did not show any modification. A progressive recovery of
those hematological values was observed in two patients after the drug
withdrawal. Peritoneal functional parameters, residual renal function,
dialytic index and nutritional data did not change during the treatment
period. We conclude that the treatment with converting enzyme inhib-
itors can contribute to anemia in CAPD patients and that this phenom-
enon can be reversible after the drug withdrawal.
Peritoneal resting and heparinization as an effective treatment for
ultrafiltration failure in CAPD patients. B. Miranda, R. Selgas, J.
Munoz, J.L. lvtiguel, L. Sanchez Sicilia, Hospital La Paz, Madrid,
Spain. Peritoneal hyperpermeability in CAPD patients expressed as an
ultrafiltration failure (UFF) limits the adequate extracellular volume
control. Its anatomic basis is the peritoneal demesothelization, which
can favor fibrin formation, fibroblast activation and finally sclerosing
peritonitis. Until now, no effective medical measures have neen de-
scribed, M. and M.: 7 CAPD patients (4 males) (2 diabetics) showing
UFF secondary to peritoneal hyperpermeability (high transport diffu-
sion capacity according to mass transfer coefficient values or MTC5)
were included in the protocol: 1) during 4 weeks were treated with
hemodialysis. 2) In this period peritoneal care consisted of: 35 mg
heparin diluted in 100 cc dialysate 1.5% were infused every 3 to 4 days
to avoid fibrin formation. Epidemiological characteristics: age 46 17
yr. Time on CAPD when UFF occurred was 56 18 months. Peritoneal
background: fast resolution peritonitis (0 to 5 e.), slow resolution
peritonitis 2 cases, severe hemoperitoneum and laparotomy 1 case.
Causes of UFF: Abdominal surgery and hemoperitoneum (1), acute
severe peritonitis (2), acute light peritonitis (1), multiple concentrated
light peritonitis (2), and unknown (1) case. UFF was defined as a clear
decrease in their UF capacity: 4 to 25% of previous values (1564 306
to 585 337 cc/day, ANOVA P < 0.01). UF was measured in a
standard manner. Results: 5 out of 7 patients fairly recovered their
pre-failure UF capacity (mean 80%). The overall group increased their
values from 585 337 to 1057 531 cc/day. ANOVA showed a
significant increase in UF capacity, and maintained six months for the
4 patients who reached this observation period. MTC values suffered
the appropriate decrease, probably reflecting the recovery of previous
peritoneal structures and consequently the normal permeability. In
conclusion, we propose the peritoneal rest and intermittent heparmniza-
tion as an effective treatment for CAPD patients who present ultrafil-
tration failure secondary to hyperpermeabilization.
Cyclosporin A (CsA): Is it the treatment of choice for maintenance
therapy in cadaver renal transplant? M. Gonzalez-Molina, M. Cabello,
A. Va/era, M.A. Frutos, E. Lopez de Novales, Servicio de Nefrologia,
Hospital Regional de Mdlaga, Spain. Because of its nephrotoxicity
CsA is not unanimously acceptable for long-term therapy in CRT. CsA
therapy was evaluated by studying the evolution of renal function and
transplant survival in 313 CRT patients receiving one of 3 different
immunosuppressive protocols: 86 with azathioprine (Az) and 227 with
CsA. The latter were divided into two groups: 192 received CsA
indefinitely (mean age 36.7 12.3 years), the other 35 (mean age 32.1
11 years) formed part of a prospective study, and 17 (mean age 30.4
12 years) had the CsA substituted by Az (Csa-Az) after the third month,
and 18 (mean age 33.8 11) continued with CsA (control group). These
two groups differed only in the number of transfusions received (9.6
3 and 7.1 5, P < 0.05). Group CsA with acute rejection (AR) had
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serum creatinine (Sr) greater than those without rejection (30 months,
3 1.6against 1.6 0.6, P < 0.01). Comparative analysis of the Sc,. of
the CsA and Az groups revealed no differences in: 1) evolution (36
months 2 1.1 against 1.8 1.3, P NS); 2) actuarial graft survival (CsA
87.2 at 12 months, 82.1 at 24 months); and 3) patients survival, 99.6 and
99.5, respectively. For the Az group the figures were 67 and 60, 87 and
84, respectively. The CsA-Az group and the control group at 36 months
gave a S. of2.2 1.5 against 1.6 0.3 P = NS and at 42 months 2.5
1.5 against 1.6 0.8 P = NS. The actuarial graft survival at 12
months 93 against 95, at 24 months 79 against 84, and at 36 months 70.4
against 89. Conclusions. The data show that chronic nephtotoxicity
produced by CsA is not clear, but rather that the AR is determined by
the degree of renal function, and that the change from CsA to Az led, in
the long-term, to greater loss of grafts.
A new perspective on dialysis treatment: Rapid high efficiency hemo-
dialysis. J. Luño, F. AhOado, S.G. de Vinuesa, E. Junco, R. Perez, F.
Valderrabano, M. T. Martinez, M. Rengel, Hospital General Gregorio
Marañon, Madrid, Spain. Eighteen chronic hemodialysis patients who
had been on conventional hemodialysis during a period of 73 45
months (mean age of 54 14 years) were prospectively started on a
high flux dialysis schedule using a 1.9 sgm polysuiphone dialyzer, over
a period of 20 months. All patients received a diet with a least I g/kg of
protein and were monitored using kinetic modeling at a blood flow rate
of 400 to 500 mI/mm with volumetrically-controlled dialysis monitors.
Dialysate Na was 138 mEq/liter and the buffer used was acetate in 4
cases and bicarbonate in 14. At the end of the follow-up period, 13
patients remained in the protocol, one died due to a myocardial
infarction, 3 were transplanted and the other was transferred to
peritoneal dialysis for a gastric bleeding. All 13 patients ended the study
with buffer bicarbonate. The mean dialysis time was 135 15 mm (120
to 150); the mean TAC: 50 7 mg/dl, mean PCR: 0.92 0.17g/kg/day
and mean KT/V: 1.02 19. The biochemical and clinical parameters
were not different from control values. Mean bicarbonate predialysis
level was 23 2 mEq/liter. Plasma lipid decreased significantly at the
end of the study and there were a tendency to decrease beta-2-
microglobulin levels. The frequency of dialysis symptoms, maen arte-
rial pressure, weight and nutritional status ot the patients were similar
than control values. The mean inter-dialytic weight gain was 1.7 0.4
kg. No changes in the osteodystrophy parameters, cardiothoracic index
and nerve conduction velocity were detected. We conclude that high
flux dialysis with a large surface area, polysulphone membrane, permits
to reduce dialysis time approaching two hours, with good dialysis
efficiency as shown by kinetic modeling, clinical, bichemical evaluation
and self assesment by the patients.
Clinical and genetic study of a family with autosomal dominant
polycystic kidney disease (ADPKD). G. de Arriba, F. Garcia-Martin, R.
MartIn-Hernández, E. MartIn-Escobar, B. Peral, C. Hernández, J.L.
San-Milldn, Nephrology Unit, H. Virgen de la Luz, Cuenca, Molecular
Genetics Department, H. Ramón y Cajal, Madrid, Spain. We studied
sixteen members of three generations of an affected kindred with
ADPKD. Our aim was to evaluate alterations in kidney function and to
detect asymptomatic carriers. Excluding the propositus (a 64-year-old
woman on hemodialysis), 7 were women and 9 men (age 24.1 14.9,
range 9 to 51). Renal function and urinary osmolality after dehidration
were analyzed in all and abdominal ultrasound was performed in
subjects older than 20. Furthermore a genetical study with based in the
analysis of restriction fragment lenght polymorphisms (RFLPs) with
DNA probes (3' HVR and 24/1) was done. We found RFLPs associated
with ADPKD in seven patients. We did not find significant differences
in renal function between carriers and healthy subjects, either globally
or in two groups (younger, N = 8, or older than 20, N = 8). In subjects
older than 20, we found a good correlation between the genetic study
and the existence of multiple renal cysts. We conclude that in ADPKD
renal function test are not very useful in the diagnosis of the disease;
however, genetic studies with DNA probes have allowed early diagno-
sis of asymtomatic carriers and are correlated with the existence of
polycystic kidneys in older patients.
Glomerular diseases after kidney transplant. J.M. Campistol, J.
Almirall, F. Oppenheimer, M.J. Ricart, J. Vilardell, J. Andreu. Renal
Transplant Unit, Hospital Clinic, Barcelona, Spain. We studied retro-
spectively the incidence and characteristics of glomerular diseases after
kidney transplant (transplant glomerulopathy, de novo glomerulone-
phritis, and recurrent glomerulonephritis), in a group of 594 renal
grafted patients (490 cadaver; 104 related donor) performed between
January 80 and December 88. Renal biopsy was practiced if proteinuna
(1 g/24 hr) and/or hematuria was present. Thirty-seven glomerular
diseases were observed (6.2%), being: transplant glomerulopathy in 12
patients; Ig A nephropathy in 5 cases; membranous glomerulonephritis
in 7 cases; mesangio-capillar glomerulonephritis in 5 cases; focal and
segmental glomerulosclerosis in 6 patients; uremic-hemolitic syndrome
in 2 patients; and one case of minimal change nephropathy and 1gM
mesangial. The clinical manifestations were proteinuria, impaired of
renal function, hematuria and hypertension. The glomerular diseases
was considered de novo in 15 cases (membranous glomerulonephritis
and focal segmental glomerulosclerosis) and recurrent glomerulonephri-
tis in 10 cases (IgA nephropathy and mesangio-capillar glomenilone-
phritis). Follow-up was in general bad, leading to chronic renal failure
and graft loss, specialty transplant glomerulopathy, mesangio-capilar
glomerulonephritis and focal segmental glomenilosclerosis. IgA
nephropathy and membranous glomerulonephritis had better evolution.
Usefulness of pulsed Doppler (PD) in diagnosis and follow-up post-
kidney transplant (KT) acute tubular necrosis (ATN) and comparation
with isotopic studies. J.M. Campistol, R. Gilabert, P. Lomena, C. BrU,
A. Catafau, F. Oppenheimer, M.J. Ricart, J. Andreu, Renal Transplant
Unit, Radiology and Nuclear Medicine Service, Hospital Clinic, Bar-
celona, Spain. We studied 19 recipients (11 males, 8 females) who
developed an ATN post-KT in our unit during 1988, to evaluate the
usefulness of PD in diagnosis and follow-up of ATN post-KT. ATN was
diagnosed by isotopic and FNAB studies. All patients had a baseline
(48-hr post-KT) and sequential PD and isotopic studies after grafting
and when fever or graft dysfunction were present. PD spectrum (3.75
MHz transducer) was obtained at main, segmental, interlobar and
arduate arteries being quantified by the Pourcelot Index (P1). PD studies
obtained in 19 KT patients with normal renal function were used as a
control group (P1 0.7). Isotopic studies were performed with 37 MBq (1
mCi) of MAG-3 using conventional technique. One patient with ATN
and preserved diuresis had normal PD study (P1 7). Oligoanuric ATN
(18 patients) coursed with abnormal PD (P1 = I),which severity ranged
from lack of telediastolic blood flow to abscess of diastolic flow and
finally early reverse of diastolic blood flow. Recovering from ATN
coursed with the normalization of PD. Eleven patients developed an
acute graft rejection, which was diagnosed by PD in all cases and only
in 7 by isotopic studies. In conclusion, PD represents a useful tool in
diagnosis and follow-up of post-KT ATN, pointing the worsening of PD
study to the diagnosis of acute graft rejection.
Results of renal transplantation (RT) for dialysis arthropathy. J.M.
Campistol, J. Munoz-Gomez, M. Sole, F. Oppenheimer, M.J. Ricart, J.
Vilardell, J. Andreu, Renal Transplant Unit, Hospital Clinic i Provin-
cial, University of Barcelona, Barcelona, Spain. Dialysis-amyloidosis
(D-Am) has emerged as a new osteo-articular complication in patients
with chronic renal failure on HD after 7 to 8 years. For the moment no
effective treatment was described, although HD with biocompatibles
membranes, specially polyacrylonitrile, would defer the development
of dialysis arthropathy. During a period of two years we studied 7
patients (6 males, one female) with severe D-Am for cadaveric RT
(mean age 51 years; mean time on HD 13.4 years, range 8 to 16). All
patients suffered from severe D-Am in the form of carpal tunnel
syndrome and chronic and relapsing swelling of the shoulders and/or
knees. Cyclosporin A alone was the initial immunosuppressive therapy,
and when acute graft rejection was present pulsed Metil-Prednisolone (1
g x 3) was introduced. Immediately after RT all the patients had
improvement of articular symptoms, pain and stiffness, including the
patient treated with cyclosporin A alone. Afterward and during the
follow-up (mean: II months) articular manifestations disappeared pro-
gressively and no new complaints developed. Only one patient, with
large lytic bone lesions at femoral neck, developed a pathological
fracture 4 months after RT. Serum /32-microglobulin fell to normal
range in all patients (mean: 4.2 mglliter) after transplant. In conclusion
and at the moment, RT represents the only reasonable treatment for
D-Am; articular complaints improve after transplantation.
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Treatment of peritonitis by gram-positive (G+) organisms in D.P.C.A.
with ciprofloxacin (Cp). M. Perez Fontán, M. Rosales, F. Fernández, J.
Moncalián, C.F. Rivera, M. Cao, J. Saavedra, F. Valdés, Hospital
Juan Canalejo, A Coruña, Spain. Quinolones possess certain charac-
teristics which, a prior, make them a good choice for treatment of
peritonitis in D.P.C.A. However, its efficacy against G+ has been
questioned. For a full year we have been treating peritonitis in DPCA
with Cp, administered i.p. (200 mg initial dose + 100 mg/bag) for five
days, and orally (500 mg/12 hr) for ten more days. During the afore-
mentioned period 19 peritonitis by G+ episodes were observed, not
primarily associated with tunnel infection (7 S. aureus, 5 coagulase-
negative staphylococci, 5 S. viridians, 1 pneumococcus, and I mi-
croaerophilous 0+ coccus). Fifteen cases (79%) responded adequately
(immediate clinical improvement, culture negativization from 2nd day
and cytological normalization after 1 to 4 days), with no relapse or
reinfection. In two cases (S. aureus), the culture became negative
starting the 2nd day and the clinical improvement was rapid, but
cytology took more than 7 days to normalize. In one case (S. aureus)
the culture became negative on the 3rd day and relapse occurred,
having observed an inadvertent infection of tunnel after removing the
catheter. Only one case (S. aureus) did not present remission of
infection until removal of catheter. Minimal inhibitory concentrations
for Cp varied between 0.06 and 0.50 pg/mI, and minimal bactericidal
concentrations were between 0.25 and 1.0 pg/ml. No significant differ-
ences were observed between different 0+; therefore, plasma levels
and i.p. obtained at administered doses were effective. No significant
side effects were noted in treatment with Cp; of note was only slight
gastrointestinal discomfort after oral Cp in 4 cases. Cp constitutes a
valid form for treating peritonitis by 0+ in DPCA. S. aureus presents
complications due to its virulence and/or inadvertent tunnel infection.
However, these are no greater than those present in other antibiotics,
including vancomycin. In essence, all of these factors, as well as its
proven efficacy against gram-negatives, low toxicity and administration
versatility, make Cp the method of choice for treatment of peritonitis in
DPCA.
Hyperparathyroldism after aluminum depletion in patients on hemodi-
alysis (lID) treatment. J. Almirall, J.M. Campistol, A. Torras, J.
López-Pedret, L.L. Revert, Nephrology Service, Hospital ClInic, Uni-
versitat de Barcelona, Spain. We have studied the use of CO3Ca in 18
patients with chronic renal failure on HD treatment during 12 months.
Patients were divided in two groups: (A) patients with aluminum (Al)
intoxication (basal Al > 80 ng/ml and after DFO test> 160 ng/ml), 5
females and 2 males, with a mean age of 56 years and a mean time on
HD of 12 3.7 years; (B) patients without Al intoxication (basal Al <
80 ng/ml), 5 females and 6 males, with a mean age of 48 years, and a
mean time on HD of 3.4 2.6 years (P < 0.01). In all patients OHAI
was substituted for CO3Ca, and in patients of group A DFO was
introduced (1.5 to 3 g/week). During the study the levels of serum
calcium and phosphorus remained normal, without differences between
both groups and the baseline values. Al leves showed a great decrease
in both groups: (A) basal: 232 39 ng/ml—.-final: 31 20 ng/ml (P <
0,0001); and (B) basal: 62 28 ng/ml—.final: 27 20 ng/ml (P < 0.01).
Five out of the 6 patients in group A developed a hyperparathyroidism,
PTH-N basal: 21 4 ng/liter, at 6 months: 49 25 (P < 0.007)—final:
62 26ng/liter (P < 0.008). In patients of group B only two developed
a hyperparathyroidism clearly related with hypocalcemia, and it was
reversible after reintroduction of vitamin D, PTH-N basal: 22 9 at 6
months 30 21—final: 26 14 (P = NS). In conclusion, patients with
Al intoxication could develop hyperparathyroidism after Al depletion,
probably related with desappearance of aluminum inhibition over the
PTH gland.
Familial hypophosphatemic rickets (FHR) in children. Response to
1,25(011)31)3 and 100111)3 therapy. M. Vázquez Martul, J.L. Ecija,
M.E. Martinez, J. Merino, C. Serna, S. NefrologIa H. Niño Jesás, S.
Bioqulmica, H. La Paz, Madrid, Spain. The present study was under-
taken to examine the effects of I ,25(OH)2D3 of 1 aOHD3 in FHR. Three
girls aged 3, 3.8 and 10 years, with a well documented FHR, have been
treated with 1 ,25(OH)2D3 or 1 aOHD3, for 4, 1.5 and 2.5 years,
respectively. All cases had initially normal PTH levels; serum
l,25(OH)2D3 was 19.7 and 20 pg/mI (nl 20 to 40) in the first and third
patients, respectively. The first girl received 1 ,25(OH)2D3 to a dose of
457 ng/kg/day, but due to patient's incompliance she was switched to
1aOHD3, increasing the dose to 405 ng/kg/day. The other two cases
have started with 1aOHD3, to maximum tolerated dose of 192 and 600
mg/kg/day, respectively. All patients have received phosphorus at
doses of 160, 96 and 60 mgfkd/day. At the end of follow-up period PTH
levels were 2, 14 and 31 pg/mI (nl 10 to 50 mol intacta) in the three
patients. The transient decrease of P'FH in the first patient was due to
iatrogenic 1aOHD3 hypercalciuria. Serum alkaline phosphate activity
was normalized and rickets have been cured in all patients. Bone
deformities persisted in first and third girl. Only the 2nd case caught up
on her growth. Plasma phosphorus (Pp) and maximal tubular phosphate
reabsortion (Tmp/GRF) remained low. Conclusions: Vitamin 1) metab-
olites did not normalize Pp or Tmp/GRF, even after very high doses.
Early treatment did not always achieve a normal growth and avoid bone
deformities. The evolution of these cases showed familial hy-
pophosphemic rickets as a disease with a broad spectrum response to
vitamin D metabolites.
Cyclosporine (CsA) treatment in childhood idiopathic nephrotic syn-
drome (INS). M. Vázquez Martul, J. Vara, J.L. Ecja Peiró, R. Muley
Alonso, M.S. Peinado, 0. Mur, NefrologIa Infantil H. Nino Jesds, H.
Dcoe de Octubre, S. de BioquImica H. La Paz, Madrid, Spain. CsA
treatment in 10 children with INS, between 3.0 and 11.5 years of age,
has been evaluated. The study was performed during a 2.25 year period.
The mean duration of treatment was 7.3 months (range 4 to 12). The oral
dose used was 5 to 6 mg/kg/day, with CsA blood levels monitored
monthly by RIA (polyclonal antibodies). All patients had received
steroids and immunosuppressive drugs (prednisone and chiorambucil or
cyclophosphamide). Three children become steroid dependent (SD) and
the other 7 steroid resistant (SR). Histopathological studies were
undertaken in 8 and showed 3 focal segmental glomerulosclerosis and 5
minimal changes. Among the 7 SR there was no response in 5, complete
remission in I, that is, still present nine months after CsA supression,
and a partial remission in the other. In the 3 SD, CsA resulted in long
lasting remission, even if one relapsed 2 months after CsA was
discontinued; the other 2 are still on remission seven months without
CsA. Side effects were: one patient with transient renal insufficiency, 9
with hirsutism; tremor and mammary hyperplasia being found less
frequently. Conclusions: CsA could be very effective in INS steroid
dependent and resistant patients, although we found better results in the
former. No major side effects were found.
Reduction the hyperlipidemia in diabetic patients on dialysis with
pantethine as hypolipidemic agent. F. Coronel, J. Perez, J. Torrente, P.
Naranjo, P. De Oleo, F. Tornero, A. Barrientos, Nephrology Depart-
ment, University Hospital S. Carlos, Madrid, Spain. In the diabetic
patient on dialysis, both diabetes mellitus and chronic renal failure are
associated with the development of hyperlipidemia. Dietary restriction
is common in both diseases and make very difficult to maintain a
lowering lipid diet at the same time. The drugs commonly used to
improve the lipid disorder have important toxicity or side effects. We
have treated 22 diabetic patients on dialysis with hyperlipidemia (class
Ha, lIb, IV; 2, 14 6 of Fredrickson's classification, respectively) with a
physiological substance, pantethine, a coenzyme A precursor, in oral
doses of 900 mg/day, without changes in diet. The effect on total
cholesterol (T-chol), LDL, HDL, VLDL, T chol/HDL quotient, triglyc-
erides (TR), uric acid, SOOT, SGPT, blood glucose and HbAl was
studied after two months of treatment. Results: with oral administration
of pantethine a reduction on T-chol (275 72 vs. 231 54 mg/dl, P <
0.001), VLDL (66 36vs. 46 18 mg/dl, P < 0.01) and TR (332 182
vs. 227 90 mg/dl, P < 0.01) was obtained. There was no change on
HDL-chol, but the T-chol/HDL quotient decreased significantly (P <
0.05). The uric acid, SGOT, SGPT, blood glucose and HbAl did not
show any change. Two patients suffered gastric pyrosis and one
presented pruritus as side effect, but no one withdrew the treatment.
Conclusions. 1) The results seem to demonstrate that pantethine at least
in short-term treatment is a very effective hypolipidemic agent in the
different classes of hyperlipidemia of the diabetic patient on dialysis,
with minimal secondary effects. 2) The reduciton of cholesterol and
T-cholIHDL quotient could contribute to the diminishment of cardio-
vascular risk of these patients.
